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ABSTRACT 
Some studies on Plasmodium falciparum, the cause of human malaria, have shown a 
strong association between both mefloquine and quinine resistance and overexpression 
of the pfmdrl gene (Plasmodium falciparum multi-drug resistance 1). However, other 
field studies and genetic crossing work have found no evident correlation between this 
gene and drug resistance. In order to clarify the role of mdrl and other genes in 
mefloquine resistance, a stable mefloquine-resistant clone of the rodent malaria 
Plasmodium chabaudi, AS (15MF), has been selected from a chloroquine resistant, but 
mefloquine-sensitive clone AS (15CQ) in this laboratory, prior to the start of this study. 
Pulsed-Field Gel Electrophoresis (PFGE) analysis of AS (1 5MF) revealed differences in 
karyotypes, and Southern blot analysis showed that these were due to duplication and 
subsequent translocation of the P. chabaudi mdrl homologue. Northern hybridisation 
showed that the gene was being overexpressed in AS (15MF). In order to determine 
whether pcmdrl duplication is an essential requirement for the mefloquine resistance 
phenotype, we performed two genetic crosses between AS (1 5MF) and a drug sensitive 
clone (AJ) that differ in a number of genetic markers. Sixteen independent progeny 
recombinants were produced which were tested for their mefloquine-response to 
determine whether co-segregation of mefloquine resistance with pcmdrl amplification 
occurred. There appeared to be a strong correlation between mefloquine resistance and 
duplication of this gene, but there were four exceptions, pointing to the involvement of 
other genetic events other than pcmdrl duplication. Progeny clones were also tested for 
their quinine-response, since the mefloquine resistant parent of the cross, AS (15MF), 
presented some degree of quinine resistance. Surprisingly, a negative correlation was 
found between quinine resistance and pcmdrl duplication in the great majority of the 
cloned progeny, in contrast to earlier studies made in P. falciparum. The chloroquine 
response of the progeny clones was assessed, but there appeared to be no correlation 
between chioroquine resistance and pcmdrl amplification. 
1 
The cloned progeny of the crosses presented various degrees of sensitivity to the drugs 
under study, indicating that resistance to these drugs has arisen as the result of mutations 
at more than one genetic locus. 
To investigate whether point mutations in the pcmdrl could be responsible for 
mefloquine, chioroquine or quinine resistance, the gene was cloned and sequenced. No 
genetic polymorphisms were found between drug-sensitive P. chabaudi clones, AJ, and 
AS (sens), and drug-resistant ones, AS (3CQ), AS (15CQ), AS (30CQ), and AS (15MF), 
indicating that point mutations in the pcmdrl gene are not required for resistance to the 
drugs under study. 
Quinine selection was attempted from two drug-sensitive P. chabaudi clones, AJ and AS 
(sens), and one chioroquine-resistant clone, AS (15CQ). These experiments proved to be 




The parasite Plasmodium falciparum, the cause of the most severe of the human 
malarias, is becoming resistant to most drugs presently used, such as chloroquine, 
pyrimethamine and mefloquine. The genetic basis of this resistance is at present under 
urgent examination. This thesis reports work which is contributing to the understanding 
of the origins, genetic basis and relationship between resistance to chioroquine, 
mefloquine and quinine, by using the rodent malaria species Plasmodium chabaudi as a 
model for P. falciparum. 
The main aims of this work are: 
• To establish patterns of parasite resistance to the drugs chloroquine, quinine and 
mefloquine, using the rodent malaria P. chabaudi. 
• To clarify the role of the P. chabaudi multidrug-resistance gene 1 (pcmdrl) in 
resistance to chioroquine, quinine and mefloquine. 
• To identify or map other genes involved in resistance to these drugs. 
In the introduction to my thesis I will attempt to provide the essential background 
information underlying my work. 
The first section entitled "The malaria problem - a general view" is a summary of the 
global impact of malaria, focused mainly on the repercussions of the disease, the 
strategies used in its control, and the problems faced by these measures, with special 
relevance to drug resistance. This is followed by "Drug-resistance - its emergence and 
spread" that aims at explaining the conditions under which resistance to the drugs 
investigated in this work arose and spread in natural parasite populations, as this may 
help understand the genetic mechanisms underlying resistance. The example of 
pyrimethamine resistance is also presented here, since this is the only drug for which the 
mechanism and origins of resistance have been well characterised. A brief summary on 
the "Genetics of Plasmodium" follows, as it is important to understand the genetic 
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organisation of malaria parasites before trying to understand how genes responsible for 
drug resistance can be identified in natural parasites populations or through experimental 
in vivo studies. "Identifying genes involved in drug resistance" ensues, consisting of an 
explanation of the major laboratory methods that have been adopted to study genes 
determining drug resistance. This will also present notions such as "selection for drug 
resistance" and "genetic cross" which will help to understand the methods used in work 
that has already been done on the genetics of resistance to some of the most important 
anti-malarial drugs. 
It is also important to understand how anti-malarials work, since this will almost 
certainly relate to the genetics of drug resistance. Consequently, the next sections are 
focused on "The modes of action and mechanisms of resistance of some of the most 
important anti-malarial drugs". Once more, the example of pyrimethamine is given, 
since this is the only drug for which the mechanism of action and resistance are well 
understood. "Theories on the mode of action of chloroquine, mefloquine and quinine" 
are then presented, as well as the present theories on the mechanism of resistance to 
these drugs. Special emphasis is given to "The MDR theory of drug resistance". The 
evidence for the involvement of the multi-drug resistance gene 1 (mdrl) in resistance to 
chloroquine, mefloquine and quinine in P. falciparum will be described. 
I also present background data associated with work that has been done on the "Genetics 
of chloroquine, mefloquine and quinine resistance in rodent malaria models", since my 
studies involve work on the rodent model P. chabaudi. This section will also review 
some of the work that has already been done in this laboratory, since some of these 
studies are the basis of my project. This is followed by a description of the parasite 
starting material for this project in a section where I describe the "History of the lines 
and clones of P. chabaudi used in this study". 
Finally, I will present a detailed "Outline of the proposed work", where I describe the 
main parts of this study and the structure of the thesis. 
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1.1 The malaria problem- a general view 
Malaria parasites are transmitted by mosquitoes of the genus Anopheles, there being four 
species infective to humans: Plasmodiumfalciparum, P. vivax, P.malariae and P. ovale. 
P. falciparum is the most severe of the four species, since it can cause severe anaemia, 
and a condition known as cerebral malaria which can kill in a few hours, if not detected 
and treated in time. 
Malaria is one of the major causes of mortality and morbidity in the tropical and sub-
tropical areas of the globe, where approximately 500 million people are at constant risk 
of suffering from the acute form of the disease (WHO, 2000). Estimates of mortality 
indicate that malaria claims between 0.5 and 2.5 million lives every year (White et al., 
1999). Most of these deaths occur in children under 5 years of age and the World Health 
Organisation (WHO) estimates that a child dies of malaria every 30 seconds (WHO, 
2000). 
It might be thought that 100 years after the discovery of the malaria life-cycle (reviewed 
in Bynum, 1999) the disease would have been eradicated, but in fact it appears that the 
situation is deteriorating, with malaria mortality rates on the rise, especially in Africa 
(WHO, 2000). The WHO has recently put in practice the Roll Back Malaria program 
(RBM), which aims at reducing the impact of the disease by 50% before the year 2010, 
but these expectations may prove to be over-optimistic. 
The control of P. falciparum malaria could be based, ultimately, on a cheap and highly 
effective vaccine, that would reduce global parasite prevalence to insignificant levels. 
Several anti-malarial vaccines have been produced and tested in the past and efforts to 
synthesise new and better vaccines are currently underway (Ballou etal., 1999; Brown, 
1999). However, thus far, efforts aimed at producing the ideal vaccine have encountered 
only limited success, mainly due to the difficulty in characterising the immune response, 
identifying protective epitopes, and the extensive antigenic variation displayed by 
malaria parasites. Nevertheless, the Walter Reed Army Institute of Research (WRAIR) 
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has recently synthesised and tested a vaccine directed against multiple protective 
epitopes of P. falciparum, with encouraging results (Stoute et al., 1997). 
In the meantime, the control of malaria has been relying on more traditional methods 
such as those directed at the anopheline mosquitoes, aiming at preventing contact 
between humans and the malaria vectors. The majority of efforts are aimed at killing 
adult mosquitoes by the use of insecticide-impregnated bed nets and curtains, as well as 
insecticide residual house spraying. 
In the 1940's, the discovery of DDT insecticide gave hope for global eradication, as huts 
and houses world-wide were sprayed. This program saw initial success, as malaria was 
eliminated or reduced in 77 countries (Malaria Foundation Fact Sheet). However, soon 
the number of reported cases recovered and then quickly exceeded previous levels 
(Shell, 1997). There is no single explanation for our inability to eliminate the disease, 
but many point to political and social barriers which constrained this eradication 
program. It is probable that sub optimal use of DDT increased the selection of 
insecticide resistant mosquitoes. Nevertheless, in most cases insecticide-based 
approaches are relatively cheap and still very effective in reducing the impact of malaria 
in highly endemic areas (Diallo et al., 1999; White, 1999). 
Chemotherapy stands as the most efficient approach for malaria control. Many of the 
available anti-malarial drugs such as chioroquine and pyrimethamine are effective, 
cheap and easy to distribute, but in recent years, parasites resistant to most drugs have 
emerged and are now widespread (reviewed in Newbold, 1990; Peters, 1987). This poses 
a serious obstacle to the control of malaria, and it is therefore critical to understand the 
mechanisms that the parasite employs to avoid the toxic effects of drugs. This may allow 
rational approaches in new drug design and re-structuring of older drugs. Furthermore 
this knowledge can be applied in the monitoring and control of the spread of drug 
resistance in natural parasite populations. 
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In the next section, I describe how resistance to some of the most important anti-
malarial drugs has arisen and spread in natural parasite populations, since this may 
provide vital clues as to which mechanisms underlie these phenomena. 
1.2 The emergence and spread of drug resistance 
Drug resistance in malaria has been defined by the W.H.O. as "the ability of a parasite 
strain to multiply or to survive in presence of concentrations of a drug that normally 
destroy parasites of the same species or prevent their multiplication" (W.H.O., 1963). 
The W.H.O. has classified drug resistance in vivo at three different levels, according to 
the time elapsed between the disappearance of parasites from the blood-stream after 
treatment, and their re-emergence (W.H.O., 1973): 
RI- The parasites are cleared initially but re-appear 7 or more days later, despite 
continuous treatment; 
RI!- There is an initial reduction in parasite numbers, but after seven or more days 
numbers increase once more; 
RI!!- The drug has little or no effect on parasite numbers. 
Natural populations of P. falciparum consist of an array of parasites that may include 
individuals with different degrees of sensitivity to one or more anti-malarials (Thaithong 
et al., 1984). Drug resistance arises when one or more individuals within the parasite 
population carry one or more mutations which give it a selective growth advantage over 
other parasites in the presence of drug concentrations which inhibit proliferation of the 
drug sensitive fraction of the parasite population in normal conditions (Peters, 1990; 
Wernsdorfer,1994). After removal of drug treatment, the surviving parasites will then 
grow in the vertebrate host, giving rise to a new generation containing a higher 
proportion of drug-resistant mutants. These will then spread in the vertebrate host 
population if the drug-resistant parasites are transmitted to other host(s) by anopheline 
mosquitoes. Consequently, the prevalence of drug-resistant parasites will increase at a 
faster rate in areas of high intensity malaria transmission. 
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The emergence of drug-resistant malaria parasites depends on many different factors, the 
most influential being drug misuse, anti-malarial pharmacokinetics and 
pharmacodynamics, general immune status of the population living in endemic areas, 
and malnutrition (White, 1999; Hess et al., 1997). 
In the next section I will describe the conditions under which parasite resistance to 
specific anti-malarial drugs arose and spread. This may provide clues to the mechanisms 
underlying drug resistance in Plasmodium. 
1.3 Pyrimethamine. chloroquine mefloquine and quinine resistance in natural 
populations of P. falciparum 
Although there are at present many different and potentially very effective anti- malarial 
drugs available (Table 1), both in vivo or in vitro resistance have been reported for most 
of them (Peters, 1987). There have not been any reports of resistance to artemisinin and 
its derivatives in human malaria, although artemisinin-resistant parasites from rodents 
have already been obtained by artificial in vivo selection (Walker et al., 2000). 
CLASS OF COMPOUND EXAMPLES 
CINCHONA ALKALOIDS Quinine, quinidine 
4- AMINOQUINOLINES Chioroquine, amodiaquine 
8- AMINOQUINOLINES 	1 Primaquine 
4- QUINOLINE METHANOLS Mefloquine 
9- PHENANTHRENEMETHANOLS Halofantrine 
ACRIDINE DERIVATIVES Quinacrine 
QINGHAOSU and DERIVATIVES Artemisinin, artemether 
DHFR INHIBITORS Pyrimethamine, proguanil 
ANTIBACTERIAL DRUGS Tetracyclines, sulpha drugs 
Table 1 - Main groups of anti- malarials in use 
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1.3.1 Pyrimethamine resistance 
Pyrimethamine was first introduced as an anti-malarial for human use in 1952, being one 
of two highly effective and widely used antifolates; the other being proguanil. The hopes 
for this drug were high, since it appeared to be very effective even at low doses, 
presented low degrees of toxicity to humans, and very few side effects. However, reports 
of pyrimethamine-tolerant P. falciparum followed soon after its introduction, when in 
1952 McGregor and Smith reported that normal curative doses of pyrimethamine failed 
to cure a baby with P. falciparum in Gambia (cited in Peters, 1987). After this, several 
reports of pyrimethamine-resistance followed from many different areas around the 
world, and subsequently pyrimethamine-resistant P. falcipa rum parasites have become 
widespread in all areas where malaria is endemic (reviewed in Peters, 1987). Thus 
pyrimethamine resistance appears to have originated in several independent different 
geographical points, rather than appearing in just one region and spreading from there. 
1.3.2 Quinine resistance 
Quinine, the oldest anti-malarial known to the western world, is one of the four alkaloids 
that can be extracted from the bark of several species of Cinchona trees; the other three 
are quinidine, cinchonine and cinchonidine. Quinine was first isolated from the bark of 
the Cinchona tree in 1820 by the French chemists Pierre Pelletier and Joseph Caventou, 
but it was synthesised in the laboratory only in the mid 1940's by R. B. Woodward and 
W. von Eggers Doering (cited in Wernsdorfer and McGregor, 1988). Quinine is highly 
effective against erythrocytic schizonts of P. falcipa rum, and it is also active against 
mature gametocytes of P. vivax, P. malariae and P. ovale. It is a very significant drug, 
being the most effective and commonly used for the treatment of cerebral malaria. 
Reports of P. falciparum resistant to quinine date back to 1910 in the region of Porto 
Veiho, Brazil (reviewed in Peters, 1987; Wernsdorfer, 1994). Werner (1911) proposed 
the interesting hypothesis that quinine resistance might have developed in north-west 
Brazil because of its proximity to the Peruvian forests, home of the cinchona trees, 
where extracts of this plant had been used for many years as a therapeutic agent (cited in 
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Peters, 1987). There have since been a few reports of quinine-resistant parasites, but 
interestingly in most cases, this resistance coincides with that to other drugs, especially 
chloroquine and mefloquine (reviewed in Peters, 1987; Watt et al., 1992; Arnold et al., 
1990; Looareesuwan, 1990 et al.; Pukrittayakaame et al., 1994). 
Quinine resistance in natural parasite populations appears to be a distinctive 
phenomenon in comparison with resistance to structurally similar anti-malarials. 
Although there have been a few reports of quinine resistance in P. falciparum, quinine 
tolerant parasites appear to emerge, establish and spread at uncommonly slow rates, and 
this drug still retains high levels of efficacy in the field despite having been in use for 
more than three centuries. The reasons for quinine's success are not fully understood 
(Meshnick, 1997) but there may be lessons to be learned from it, as we try to preserve 
the effectiveness of existing anti- malarials and plan the design of new ones. In addition, 
as parasites become more resistant to new synthetic anti-malarials, attention needs to be 
paid to older drugs such as quinine, which despite having lost some efficacy over the 
years, is still useful in the prevention and cure of malaria. It has been suggested that 
advanced quinine resistance could lead to untreatable falciparum malaria (Philips and 
Solomon, 1990). 
1.3.3 Chloroguine resistance 
Chioroquine is a derivative of quinine, belonging to a group of chemicals called the 4-
aminoquinolines. It was first created in Germany during the Second World War by 
Andersag and his colleagues at I.G. Farbenindustrie (part of the Bayer group) (reviewed 
in Krishna and White, 1996). Some time after its synthesis, chloroquine underwent large 
comparative trials, where it was shown to be superior to both quinine and quinacrine, 
and after some development it was soon adopted as the chemical of choice for treatment 
and prophylaxis of all human malarias (reviewed in Krishna and White, 1996). In 
addition to being highly effective in normal conditions, chloroquine is safe and 
affordable. 
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In contrast to pyrimethamine, chioroquine resistance took a long time to emerge and 
spread, and it was only nearly thirty years later, during the war in Vietnam that it started 
to become a real practical problem. Chioroquine-resistant P. falciparum was first 
reported in the late 1950's in two independent distant places; Colombia (Moore and 
Lanier, 1961; Young and Moore, 196 1) and Thailand (Harinasuta et al., 1962). From the 
initial focus in South America, chloroquine resistance spread relatively fast and by the 
late 1960's it had already reached the southern part of the continent. Chioroquine-
resistant parasites in South-east Asia diffused west from the initial focus in Thailand, 
from where they reached Africa in the late 1970's (Campbell et al., 1979; Fogh et al., 
1979). Figure 1 depicts the chronological origin and spread of chloroquine resistance in 
the different areas of the world. 
The spread of chloroquine resistance has since been slow but relentless, and it is now 
well established in most areas where malaria occurs (Peters, 1987), posing a real threat 
to its control. It is thought that chloroquine resistance first appeared due to extensive 
misuse of the drug; for example the distribution of chloroquinated salt as part of large 
scale control programs meant that parasites were continuously exposed to sub-curative 
doses, probably encouraging selection of drug-resistant mutants (Payne, 1988). 
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from different areas of the world, ranging from West Africa to Papua New Guinea, 
which indicate that cross-resistance between these drugs is a complex subject in which 
patterns vary in different geographical regions. Some authors report cross-resistance 
between mefloquine and quinine (Brasseur et al., 1992; Warsame etal., 1991; Subsaeng 
et al., 1986), others between quinine and chioroquine (Brasseur et al., 1988; Basco et al., 
1995; Knowles et al., 1984; Warsame et al., 1991; Basco and Bras, 1992; Silveira et al., 
1996; Duraisingh et al., 2000b), while others find no significant correlation (Childs et 
at., 1991). Parasite isolates resistant to all three drugs, quinine, mefloquine and 
chloroquine, have also been reported (Smrkovski et al., 1985). 
In the previous sections I have mainly reviewed epidemiological data on resistance to 
the drugs concerned in this study. This resistance is likely to be caused by genetic events 
which require to be elucidated. Studies on the genetics of drug resistance require an 
understanding of the genetic organisation of malaria parasites, which is described in the 
next section. 
1.4 Genetics of Plasmodium 
1.4.1 Life-cycle of malaria parasites 
Mammalian malaria parasites, are introduced by mosquitoes of the genus Anopheles. 
The bite of an infected mosquito introduces haploid sporozoites into the bloodstream 
(Figure 2), which are carried to the liver and invade hepatocytes. Here, the parasite 
undergoes a pre-erythrocytic cycle, producing thousands of merozoites by mitotic 
divisions, which are then released into the bloodstream. Each merozoite is capable of 
invading a red blood cell, giving rise to a ring stage parasite, which divides mitotically to 
form a trophozoite, and then a schizont containing from 4-24 new merozoites. Each 
schizont then ruptures releasing the merozoites which re-invade new erythrocytes. 
Although most of the invading merozoites give rise to schizonts, a small percentage 
produce the male and female sexual stages of the parasites, the micro and macro-
gametocytes respectively. When a susceptible mosquito feeds on an infected animal, 
gametocytes are taken up in the blood meal and become gametes which fuse together in 
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1.3.4 Mefloguine resistance 
After it had become evident that chioroquine-resistance was going to pose a serious 
obstacle for the control of malaria, the United States army created a drug development 
project with the primary purpose of finding a replacement for chloroquine (reviewed in 
Peters, 1998). Two potent blood schizontocides were created as result of this program, 
halofantrine and mefloquine. Mefloquine proved to be the most satisfactory of the two 
after early clinical trials and it was thus adopted as the treatment of choice for 
prophylaxis of malaria. However, as early as 1977, experimental work showed that 
resistance to this drug could emerge rapidly, once it had been instituted as a 
monotherapeutic agent (Peters, 1977). In order to minimise this risk, mefloquine was 
introduced in combination with sulphadoxine and pyrimethamine (MSP) in areas of high 
malaria transmission (reviewed in Peters, 1998). However, the introduction of MSP 
proved to be a futile measure, as the efficacy of mefloquine declined severely over the 
1980's, particularly in some areas of South-east Asia (reviewed in Peters, 1998). 
At present, mefloquine resistance presents a real threat for the control of P. falciparum 
malaria in Africa and South-east Asia, especially in the Thai/Cambodia and 
Thai/Myanmar border areas (cited in Wernsdorfer, 1994). Interestingly, intrinsic 
mefloquine resistance has even been recorded in areas where the drug had never been 
used before (White, 1994), possibly because of selective pressure through other 
antimalarial drugs. 
1.3.5 Multi- drug resistance 
In some areas the parasite population is resistant to more than one anti-malarial drug, a 
phenomenon known as multi-drug resistance. For instance, at the present time resistance 
to quinine is in the great majority of cases associated with resistance to other drugs, 
especially quinoline-containing anti-malarials such as mefloquine and chloroquine. 
It is frequently claimed that quinine and mefloquine resistance are associated (reviewed 
in Peters, 1998). However, field studies on P. falciparum have been made on isolates 
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the mosquito stomach, producing a motile ookinete (zygote), the only diploid stage of 
the parasite. The ookinete then migrates through the mosquito gut wall and gives rise to 
an oocyst, where haploid sporozoites are later formed following meiosis. When fully-
developed, the oocyst ruptures releasing the sporozoites which invade the mosquito's 
salivary glands, where they become fully mature. If the mosquito bites a susceptible 
host, sporozoites are inoculated into the bloodstream and the cycle starts again. 
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Figure 2- Life-cycle of a typical mammalian malaria parasite (adapted from the 
Carlo Denegri Foundation: http://www.cdfound.to.it/)  
1.4.2 The Plasmodium genome 
As mentioned above, malaria parasites are haploid during exoerythrocytic and 
erythrocytic blood stages, sporogony and microgametogenesis, where they multiply by 
mitotic divisions; the only diploid phase is the ookinete, which occurs just briefly prior 
to meiosis (Sinden et al., 1985). 
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Malaria parasites have three genomes (reviewed in Wilson et al., 1991): 1) a linear 
extrachromosomal mitochondrial genome (known as the 6kb element) which contains 
the genes encoding proteins for the electron transport system; 2) a large (35kb) circular 
genome, thought to encode principally rRNAs, tRNAs and ribosomal proteins and 3) a 
large nuclear genome. The next section will focus only on the nuclear genome, as this is 
where the potential candidate genes determining resistance to the drugs used in this 
study are likely to reside. 
1.4.3 The nuclear genome 
The haploid nuclear genome is thought to contain up to 7500 genes (Reddy, 1995) and 
2-2.5 x i0 7 base pairs of DNA (Wilson et al., 1991). Most of these nucleotide bases are 
A + T (Kemp et al., 1990); estimates on base size composition of P. falciparum point to 
a G + C content of about 17-19% (Pollock etal., 1982; McCutchan etal., 1984). 
The chromosomes of malaria parasites do not condense during mitosis, which makes 
them difficult to study by conventional approaches. However, with the advent of Pulsed-
field Gradient Gel Electrophoresis (PFGE) (Carle and Olson, 1984; Schwartz and 
Cantor, 1984) it has been possible to ascertain that malaria parasites have 14 
chromosomes, which can be visualised on agarose gels. The chromosomes of malaria 
parasites are subdivided into central domains, which contain conserved coding regions, 
and chromosome ends, which are polymorphic regions (Lanzer et al., 1994). Each 
chromosome end consists of telomeric repeat sequences and subtelomeric repeat regions. 
There can be a high degree of chromosome size polymorphism when different lines and 
clones of the same species are compared on the same gel, and these are mainly due to 
large-scale re-arrangements in transcriptionally silent sub-telomeric regions (Frontali et 
al., 1991). However, inter-species chromosome size polymorphisms can also be caused 
by other genetic events such as a) unequal crossing-over between homologous 
chromosomes during meiosis (Corcoran et al., Sinnis and Wellems, 1998), b) gene 
amplifications (Foote et al., 1989; Triglia et a!, 1991; Gervais et al., 1999) or c) the 
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deletion or addition of telomeric and sub-telomeric DNA sequences (Pologe and 
Ravetch, 1998). 
1.4.4 Crossing and recombination 
When mosquitoes feed on a host infected with two parasite clones, both selfing and 
cross-fertilisation events between the gametes of each clone are likely to take place in 
the mosquito stomach. A diploid zygote is formed as result of fertilisation, which 
undergoes meiosis shortly afterwards, whereby haploid sporozoites are subsequently 
formed. These can be derived from homozygotes as a result of selfing, giving rise to 
parasites which are representative of one of the parental clones; or may have originated 
from meiosis of heterozygotes (which resulted from crossing between the two parental 
clones), producing recombinant haplotypes (see Figure 3). 
Recombination has been demonstrated in genetic crossing experiments. In P. chabaudi, 
evidence for recombination was presented (Walliker et al., 1975), when a genetic cross 
was made between two parasite clones which differed in the electrophoretic patterns of 
two enzymes, 6-phosphogluconate dehydrogenase (6-PGD) and lactate dehydrogenase 
(LDH) as well as in their response to pyrimethamine. The cross was performed by 
feeding equal numbers of both parasite clones to mosquitoes. Analysis of the cloned 
progeny showed recombination to occur between the two enzyme forms and that 
pyrimethamine susceptibility segregated independently from either enzyme iso-form. 
In P. falciparum, two genetic crosses have been carried out with well characterised 
parasite clones, in each of which an equal mixture of cultured gametocytes of each clone 
was fed to mosquitoes and the resulting haploid sporozoites were used to infected 
splenectomised chimpanzees (Walliker et al., 1987; Wellems et al., 1990). Karyotypic 
analysis and long-range restriction mapping of progeny clones cultured in human blood, 
showed that recombination between parental genes had occurred both by simple re-
assortment of unlinked genes on different chromosomes and by crossing-over events 
between genes on homologous chromosomes. 
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Figure 3- Fertilisation and meiosis in malaria parasites [(kindly made available by David 
Walliker). I and 4 - sporozoites resulting from selfing; 2 and 3 - sporozoites resulting from crossing 
between the two parental clones] 
The next section discusses how our knowledge of recombination following genetic 
crosses may be used to identify genes involved in drug resistance. 
1.5 Identifying genes involved in drug resistance 
The most useful starting material to identify genes responsible for drug resistance is to 
select drug-resistant mutants from cloned sensitive parasites (Canton et al., 2000); in 
this way, the resultant mutant parasites should have identical genetic backgrounds to the 
starting sensitive forms, except for the gene(s) determining resistance. 
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Genetic crosses such as those stated above allow studies to be carried out on the 
frequency of recombination. If fertilisation occurs through random mating in malaria 
parasites, 50% of the progeny of a cross are expected to be recombinant products of both 
parents, and 50% to originate from self-fertilisation events. However, two genetic 
crosses appeared to have shown that the frequency of self-fertilisation is much lower 
than the frequency of cross-fertilisation. Walliker et al. (1987), observed that only 3 out 
of 22 progeny clones from the P. falciparum HB3 x 3137 genetic cross, had inherited 
parental type markers only (Walliker et al., 1987). Similarly, the P. falciparum HB3 x 
Dd2 genetic cross did not produce any progeny clones which presented parental type 
markers alone (Wellems et al., 1990). It is possible however, that the over-representation 
of recombinant clones among the progeny of the two crosses was due to selection acting 
in the chimpanzees (the vertebrate hosts used in the crosses) or during in vitro culture, as 
suggested by Ranford-Cartwright et al (1993). Indeed, it has been observed that both 
selfing and crossing events occur between gametes of HB3 and 3D7, as shown by the 
analysis of oocysts which resulted from a genetic cross between the two parasites 
(Ranford-Cartwright et al, 1993). 
Linkage analysis and fine genetic mapping of the P. falciparum H133 x Dd2 cross has 
shown that meiotic crossovers occur at high rates in the genome (average of 17 
kilobases/centimorgan) (Su et al., 1999). 
In natural parasite populations of P. falcipa rum, it has also been demonstrated that 
recombination occurs at high rates (Conway et al., 1999). 
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In vitro selection for drug resistance in P. falciparum is a very difficult process due to 
the difficulties of maintaining sufficient numbers of parasites in culture to allow mutants 
to be detected. Only a few P. falciparum drug-resistant clones have been achieved in this 
way which present stable resistance in the absence of drug pressure (Oduola et al., 1998; 
Lim and Cowman, 1996). It is of fundamental importance that drug selected parasite 
clones present stable resistance in the absence of drug pressure, since this is an 
indication of genetic changes that are likely to persist, and be passed onto subsequent 
parasite generations. 
In contrast to P. falciparum, selecting for drug resistance in rodent malaria parasites is a 
relatively straightforward matter, and studies on stability of drug resistance in the 
absence of drug pressure and after mosquito transmission are easy to perform. Stable 
drug-resistant mutants have been selected from all four rodent malaria species: P. 
berghei, P. yoelii, P.vinckei and P. chabaudi. (reviewed in Carlton et al., 2000). 
Furthermore, studies on these parasites have provided important information on genes 
determining drug resistance (reviewed in Canton et al., 2000). 
Two major methods have been adopted to select resistant parasites by drug exposure 
(Beale, 1980): 1) a single treatment with a high dose, in which most of the parasites are 
eliminated and only a few resistant ones persist and multiply subsequently; 2) long-
lasting selection over many passages, starting with a very low dose and then gradually 
increasing the doses. The choice of an experimental method for selection of drug-
resistance in vivo depends on several factors, such as drug pharmacokinetics and 
pharmacodynamics, host and parasite strains used, etc. 
An understanding of the circumstances under which drug resistance arises in natural 
parasite populations is also important, as one should attempt to mimic these conditions 
when selecting for drug resistance in vivo. By way of illustration, the slow appearance 
and spread of P. falciparum mutants resistant to chioroquine, is suggestive of a multi-
genic trait where the accumulation of all the required mutations is a long process. In this 
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case, selection for choroquine resistance in vivo would need to be done by multiple 
parasite passages with slow increases in drug dose after each passage. In contrast, the 
fast emergence of pyrimethamine resistance and the fact that it originated in several 
different geographical foci at about the same time, suggests that a mutation at a single 
locus is sufficient to generate resistance. It would therefore seem appropriate in this 
instance to use the single step/high dose method. 
To identify the genetic loci involved in drug resistance, stable drug-resistant mutants 
need to be crossed with genetically unrelated sensitive parasites. Genetic markers, such 
as Restriction Fragment Length Polymorphisms (RFLPs), microsatellites, etc, which 
distinguish the drug-sensitive and drug-resistant parasite strains are a pre-requisite. The 
crosses are made by feeding equal numbers of both parasite clones to mosquitoes, 
allowing fusion of gametes and hence recombination of parental markers to occur. When 
the parasite cycle is completed in the mosquitoes, these are allowed to infect mice where 
an array of possible recombinant clones will proliferate (see figure 2 for the schematic 
representation of a genetic cross). Progeny clones can be analysed for linkage of drug 
resistance with inheritance of parental markers, and the location of potential candidate 
genes can then be determined by chromosome mapping (Su et al., 1999). The precise 
role of such genes may ultimately be established by transfecting the candidate gene(s) 
for resistance into drug-sensitive parasites. 
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Figure 4- Diagram of a Plasmodium genetic cross 
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1.6 Modes of action and mechanisms of resistance of some of the most important 
anti- malarial drugs 
From a biochemical point of view it can be stated that here are 3 principal ways by 
which a malaria parasite may become resistant to a given drug (Hyde, 1990), which may 
or may not be related to the drug's mechanism of action: 1) Drug accumulation may be 
reduced by decreased uptake or increased export from the cell, which may or may not be 
due to genetic changes in the membrane molecules involved in the transport of the 
drugs. 2) The drug may be sequestered or inactivated before reaching its metabolic 
target. 3) Mutational changes may occur, which may either reduce the affinity of the 
target molecule for the drug or lead to enhanced production of the target molecule. 
In the next few sections I consider our present understanding on the mode of action and 
mechanisms of resistance of chioroquine, mefloquine, quinine and pyrimethamine. 
Pyrimethamine is considered first, because it provides the most simple paradigm. 
1.6.1 Mode of action of and mechanism of resistance to pyrimethamine 
The antifolate pyrimethamine is the only anti-malarial drug for which the mode of action 
and mechanism of resistance are well understood. 
Malaria parasites need to synthesise pyrimidines de novo, since they appear to be unable 
to use those of the host. To do this, they require a supply of dihydrofolate and tetra-
hydrofolate, which are produced via the folate biosynthetic pathway (Ferone, 1977), 
which comprises a number of cyclic enzymatic reactions. One of these reactions 
involves the synthesis of thymidylate (dTMP) from dihydrofolate and this conversion 
depends on the action of three enzymes; thymidylate synthase (TS), dihydrofolate 
reductase (DHFR) and serine hydroxymethyltransferase (SHMT) (reviewed in 
Sirawaraporn et al., 1998). The inhibition of any of these three enzymes may possibly 
give rise to thymidylate depletion with ensuing disruption of DNA synthesis and 
resultant parasite death. Hence, these enzymes represent potential chemotherapeutic 
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targets. Pyrimethamine binds to the enzyme dihydrofolate-reductase (DHFR), disrupting 
its activity. DHFR is required for folate metabolism in both parasite and host but 
conveniently, pyrimethamine binds several hundred times more avidly to the DHFR of 
the parasite, causing its death, while having no detrimental effect on the host. 
The mode and speed by which pyrimethamine resistance arose in the field (section 1.3.1) 
appeared to be highly suggestive that a single gene point mutation could account for the 
phenotype observed. Initial experiments on animal malaria models appeared to confirm 
this theory, since it was observed that a) a single-step, high dose method was sufficient 
to select pyrimethamine resistant parasites (Diggens, 1970, Morgan, 1972; Walliker et 
al., 1973, 1975) and b) the rate by which resistant parasites were selected for, appeared 
to be independent of the drug dose used in the selection procedure (Bishop, 1962). 
Confirmation of this came with the results of genetic crossing experiments between 
pyri methamine- sensitive and pyrimethamine-resistant lines of P.yoelii, in which the 
inheritance of pyrimethamine resistance demonstrated a pattern expected from the result 
of a mutation in a single locus (Walliker et al., 1973). Analysis of later crosses, 
including those done with P. chabaudi, also confirmed these results (Walliker et al., 
1975; Rosario, 1976; Knowles et al., 1981; Sharkey et al., 1988). 
The gene involved in pyrimethamine resistance was finally identified as a result of a 
linkage study on progeny clones of a genetic cross between a P. falciparum 
pyrimethamine resistant clone (HB3) and a sensitive one (3D7); Peterson and colleagues 
(1988) observed that all pyrimethamine resistant clones retained a DHFR RFLP from the 
resistant HB3 parent and all sensitive clones possesed the allele present in the drug-
sensitive 3D7. This was the first demonstration of the involvement of DHFR in 
resistance to this drug. 
The gene for DHFR is contiguous with that encoding thymidylate synthase (TS). By 
designing degenerate oligonucleotides based on the TS gene consensus sequences, the 
complete DHFR-TS gene was cloned (Bzik et al., 1987; Cowman et al., 1988). Several 
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independent research groups then analysed DHFR-TS sequences from diferent P. 
faciparum isolates: The findings point strongly to the involvement of an amino acid 
change at position 108 in pyrimethamine resistance, where sensitive parasites possess 
serine or threonine at this position and resistant ones, asparagine (Cowman et al., 1988; 
Peterson et al., 1988; Basco et al.; 1995; Plowe et al., 1998; Urdaneta et al., 1999). This 
mutation induces a change in the conformation of the DHFR, reducing the kinetics of 
pyrimethamine binding. 
Full confirmation of this gene's involvement in pyrimethamine resistance was obtained 
as a result of transfection studies in which the mutant DHFR was used as a selectable 
marker both in the rodent malaria parasite Plasmodium berghei (van Djik et al., 1995) 
and P. falciparum (Wu et al., 1995). 
There have not been any reports of amplification of DHFR as cause of pyrimethamine 
resistance in natural parasite populations. However, drug selection experiments both in 
vivo and in vitro, have shown that DHFR amplification can account for some degree of 
pyrimethamine resistance (van Djik et al.., 1994; Cowman and Lew, 1989; Thaithong et 
al., 2000). 
The simplicity of pyrimethamine's mode of action and mechanism of resistance 
contrasts with that of chloroquine, mefloquine and quinine, which is now discussed. 
First, in the next section we consider mode of action of some antimalarial drugs. 
1.6.2 Mode of action of chioroguine, mefloquine and quinine 
Blood schizonticides such as chioroquine, mefloquine and quinine are most active on the 
asexual blood stages of the parasites, accumulating in the food vacuole where they exert 
their action and kill the parasite. The means by which they do it remain unclear to some 
extent. There have been several studies made on the lethal mechanism of chloroquine 
and it has been assumed that chemically related compounds such as mefloquine and 
quinine may kill parasites in a similar way. 
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rapidly in the absence of haem polymerase (Egan and Adams, 1994; Dorn et al., 1995). 
Although the precise mechanism of haem polymerisation is yet to be elucidated, it has 
lately been accepted that its inhibition is a chemical process rather than an enzyme-
mediated reaction; it has been shown that chloroquine is able to bind haem, forming a 
chemical complex which prevents its polymerisation, allowing the concentration of free 
haem to reach toxic levels (reviewed in Ginsburg et al., 1999). 
Chloroquine inhibits GSH dependent degradation of haem 
As previously mentioned (section 1.6.2.1) it has been suggested that in P. falciparum, 
only between 25-30% of haem generated by the digestion of haemoglobin is 
polymerized into haemozoin in the food vacuole (Ginsburg et al., 1998) during the 
trophozoite stage, the most sensitive to chloroquine. A model of chioroquine action 
based solely on the assumption that chioroquine binds to free haem in the food vacuole 
preventing its polymerisation neglects the evidence that not all the haem generated is 
converted into haemozoin. 
It has recently been shown that the free haem that escapes polymerisation in the food 
vacuole, exits into the cytosol where it is rapidly degraded by glutathione, although the 
precise mechanism of this degradation is yet to be described (Atamna and Ginsburg, 
1995). However, a recent study has shown that chloroquine is capable of inhibiting this 
process in vitro; Famin and colleagues (1999) have shown that treatment of intact 
infected cells with chloroquine results in accumulation of free haem which leads to the 
permeabilisation of membranes with ensuing cell death. 
Combined theory on the mechanism of action of chioroquine 
Ginsburg and colleagues (1999) have recently put forward an explanation for the 
mechanism of chloroquine action that integrates the theories described in the last two 
sections. This theory assumes that the inhibition of haem-degradation by chloroquine 
takes place both in the parasite's food vacuole and in the cytosol. The fundamentals of 
this hypothesis are as follows: haemoglobin from the host's erythrocyte is digested inside 
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1.6.2.1 Mode of action of chioroguine 
Chioroquine is thought to interfere with the parasite's mechanism for detoxification of 
haem. Malaria parasites digest haemoglobin in the acidic digestive vacuole, and 
proteolysis of haemoglobin produces ferriprotoporphyrin IX (haem or FP), which is 
highly toxic for the parasite, since it has been shown to increase the permeability of 
membranes to cations, leading eventually to cell lysis. (Chou and Fitch, 1980, 1981; 
Slater et al., 1991). In addition haem may also bind to parasite enzymes, inhibiting their 
action (Van der Jagt et al., 1986; Menting et al., 1996). Consequently, parasites need to 
detoxify haem in order to avoid its harmful effects (Yamada and Sherman, 1979; 
Warhurst, 1995), and they are thought do this in two steps (Ginsburg, 1999; Ginsburg et 
al., 1999): 1) polymerisation of haem in the food vacuole, resulting in the formation of 
inert crystals, called malaria pigment or haemozoin (Krishna and White, 1996); 2) the 
unpolymerised haem may exit from the food vacuole into the parasite's cytosol, where it 
is then reduced by cytosolic glutathione (GSH), leading to degradation (O'Neil et al., 
1998). It has been suggested that up to 70% of the detoxification of haem occurs in this 
fashion (Ginsburg et al., 1998). 
The current views on the antiparasitic mechanism of chloroquine action are described in 
the next 3 sections. They conjecture that chloroquine inhibits the process of haem 
detoxification in some way, allowing for high levels of free haem to form and kill 
parasites as a consequence by disrupting membrane function. 
1) Chloroquine binds to free haem in the food vacuole preventing its polymerisation 
It has been suggested that the polymerisation of haem in the food vacuole is mediated 
by a plasmodial enzyme, haem polymerase (Slater and Cerami, 1992), and that this 
enzyme is susceptible to inhibition by blood schizonticidals such as quinine and 
chloroquine, which bind haem (Chou and Fitch, 1980; Warhurst, 1981, 1987; Slater, 
1992; Sullivan et al., 1996). However, haem polymerase has been difficult to 
characterize and it has been shown in vitro that haem polymerisation can occur very 
CHAPTER I - Introduction 	 26 
the parasite's food vacuole. Detoxification of haem should therefore take place through 
polymerisation into haemozoin, but chloroquine preventsthis process to some extent by 
forming a chemical complex with haem. Unpolymerized haem accumulates in the 
parasite's food vacuole, causing some degree of damage to cell membranes. A large 
fraction of non-polymerised haem leaves the food vacuole for the parasite's cytosol, 
where it is degraded by glutathione. This degradation entails several biochemical 
reactions involving a number of enzyme-mediated conversions, but again, chloroquine is 
thought to bind free haem preventing its polymerisation into haemozoin, causing the 
permeabilisation of membranes. The precise mechanism of this inhibitory process is yet 
to be described, but it has been shown that chloroquine can bind to enzymes such as 
glutathione- S- transferase (one of the catalysts of GSH- dependent haem degradation) 
and inhibit their function (reviewed in Ginsburg et al., 1999) 
1.6.2.2 Mode of action of quinine and mefloquine 
It is often assumed that all quinoline anti-malarials interfere with parasite feeding 
mechanisms (Geary et al., 1986). This is likely to be case with chloroquine, a diprotic 
weak base, which accumulates in the parasite's food vacuole, where it presumably 
interferes with haem degradation (see previous sections). However, both quinine and 
mefloquine are monoprotic bases and for this reason these drugs are expected to 
accumulate in the parasite's food vacuole less efficiently. For this reason, it has been 
suggested that mefloquine uptake into the food vacuole is facilitated by the action of an 
active transporter (Vanderkooi et al., 1988). Alternatively, it is conceivable that both 
mefloquine and quinine have additional sites of action. In fact, while chloroquine has 
been shown to interfere with haem polymerisation in P. berghei, mefloquine has no such 
effect (Chou and Fitch, 1993). 
The precise mechanisms of action of quinine and mefloquine are therefore far from 
being elucidated. Nevertheless, it has been shown by photoaffinity labelling studies, that 
mefloquine has the ability to bind peptides present on the surface of P. falciparum 
infected erythrocytes, suggesting that these peptides may be involved in the drug's 
uptake or may represent direct targets of mefloquine action (Desneves et al., 1996). In 
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addition, it has been proposed that the quinolinemethanols, quinine and 
mefloquine,might act differently from chloroquine, by disrupting membrane trafficking 
events involved in the uptake of metabolites essential to the parasite (Foley and Tilley, 
1997) 
1.6.3 Mechanisms of resistance to chioroquine, mefloquine and quinine 
In contrast to pyrimethamine, the genetic basis of drug resistance for chioroquine, 
mefloquine and quinine is not fully understood. The following sections deal with 
evidence which implicates a number of genes in resistance to these drugs. Chioroquine 
is dealt with first, since some of these genes are specific to chloroquine resistance. 
1.6.3.1 Chioroquine resistance 
It has been observed that chloroquine-resistant parasites accumulate the drug very poorly 
when compared to sensitive ones (Fitch, 1970, 1973; Aikawa, 1972; Yayon et al., 1985; 
Geary et at., 1986; Krogstad et al., 1987). However, it is not clear if this is due to a 
difference in drug up-take between sensitive and resistant parasites (Geary et at., 1990; 
Bray et at., 1992; Ginsburg and Krogliak, 1992; Sanchez et al., 1997) or differential 
efflux (Krogstad et al., 1987; Wellems et al., 1990). 
Because chioroquine-resistant parasites accumulate less drug than sensitive ones, it has 
been assumed that resistance to this drug and related compounds is associated with 
exclusion of the drug from the site of action rather than due to changes in the target 
molecule(s) (Yayon et al. 1984). Consequently, a number of theories have been 
proposed, which are based on the assumption that chloroquine resistance is due to the 
parasite's ability to accumulate less drug in the food vacuole. These are described in the 
next sections. 
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1.6.3.1.1 The pfcrt theory of chioroguine resistance 
The analysis of a genetic cross between Dd2 (a chloroquine-resistant parasite) and HB3 
(a chioroquine-sensitive parasite), had initially shown that a 400 Kb locus on 
chromosome 7 segregated with chloroquine resistance in P. falciparum (Wellems et al., 
1991). Subsequent genetic mapping work within this 400 Kb segment, by Su and 
colleagues (1997), further mapped chloroquine resistance to a 36 Kb locus, which 
segregates highly but not totally with chloroquine resistance among parasite isolates 
from Asia and Africa. Analysis of polymorphisms within this region, protein structure 
predictions and subcellular localisation seemed to indicate an involvement of a gene, 
cg2, in the determination of chioroquine resistance in this cross (Su et al., 1997). Only a 
limited number of field studies have been done on the involvement of cg2 on 
chloroquine resistance, but it appears that polymorphisms in this gene are represented 
differentially in chloroquine-sensitive and chloroquine-resistant P. falcipa rum parasites 
(Adagu and Warhurst, 1999; Duraisingh et al., 2000). In addition, it is possible that 
polymorphisms in both cg2 and a different gene,pfindrl (described in section 1.6.3.1.3) 
may play a cooperative role in chloroquine resistance. 
Further analysis of the P. falciparum HB3 x Dd2 cross, has subsequently identified 
another closely linked gene, pfcrt (P. falciparum chloroquine resistance tranporter), 
which segregates perfectly with low chloroquine resistance among field parasite isolates 
of P. falciparum (Fidock et al., 2000, in prep). Furthermore, the peptide product of this 
gene has been localised to a site of chioroquine transport associated with the parasite's 
digestive food vacuole, where chloroquine inhibits haem polymerisation (section 
1.6.2.1). 
1.6.3.1.2 The chioroguine importer theory 
It has been claimed that chloroquine import into the food vacuole is carrier-mediated 
(Sanchez et al., 1997) and that the kinetics of this import differ between the chloroquine-
resistant P. falciparum Dd2 and its sensitive counterpart HB3 (Wellems et al., 1990). 
Moreover, differences in up-take kinetics of chloroquine are linked with chloroquine 
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resistance in a genetic cross between P. falciparum Dd2 and HB3 (Wellems et al., 
1990). This observation suggests that these differences are necessary for the generation 
of the chioroquine-resistance phenotype. By analysing differences in chioroquine import 
kinetics between Dd2 and HB3 parasites, it has been claimed that the influx of 
chioroquine in P. falciparum is carrier-mediated by a Na/H exchanger (Sanchez et al., 
1997). Consequently it has been suggested that alterations in the gene encoding this 
importer, may account for chioroquine resistance in P. falciparum (Sanchez et al., 
1997). In addition, it has been suggested that cg2 is the gene that encodes this Na/H 
exchanger (Sanchez et al., 1998). However, this hypothesis has been questioned mainly 
due to the interpretation of the kinetic data involving the Na/H exchanger (Wellems et 
al., 1998; Bray et al., 1999). 
1.6.3.1.3 The MDR theory of chioroguine resistance 
MDR (multi-drug resistance) genes code for ATP-dependent membrane transporter P-
glycoproteins, which are a sub-group of a superfamily identified by ATP-binding 
cassettes (ABCs), and were first identified in mammalian tumour cells. In cancer cells, 
MDR genes are responsible for resistance to a wide spectrum of anti-cancer drugs, 
mainly by being over-expressed (Riordan and Ling, 1985; Gros etal., 1986; Roninson et 
al., 1986; Kartner and Ling, 1989; Edincott and Ling, 1989), causing increased export of 
the drugs from the cells involved. This phenomenon can be reversed by several drugs, 
such as the calcium channel blocker verapamil, which binds P- glycoproteins, 
inactivating the transport as a consequence. Since it was observed that verapamil and 
other calcium modulators could also reverse chioroquine resistance in P. falciparum 
(Martin et al., 1987, Kyle et al., 1990), this suggested that P-glycoprotein homologues 
could also be involved in drug resistance in malaria parasites. 
The similarities mentioned above, between the phenotypic manifestation of drug 
resistance in cancer cells and chioroquine-resistant P. falcipa rum, mainly reversal of 
resistance by calcium channel blockers and multi-drug resistance, (Martin et al., 1987; 
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Kyle et at., 1990, Karcz and Cowman, 1991a, 1991b) led researchers to try to identify 
homologues in this parasite. 
The P- glycoproteins of mammalian cells contain hydrophobic transmembrane regions, 
and two hydrophilic regions, each containing an ATP-binding site. These hydrophilic 
regions are highly conserved among mammals and bacterial transporter proteins. By 
making use of these conserved areas to design degenerate oligonucleotide primers, two 
MDR-like genes, pfmdrl and pfmdr2, were amplified, cloned and characterised in P. 
falciparum (Foote et at., 1989; Wilson et at., 1989). Pfindrl is present on chromosome 5 
in P. falcipa rum and it consists of a continuous open reading frame of 4257 nucleotides 
(Foote et at., 1989). It encodes a 162 kDa polypeptide, which has been named P-
glycoprotein homologue 1 (Pghl) (Cowman et at., 1991). Pghl is expressed in the 
membrane of the parasite's digestive vacuole throughout all asexual blood stages in the 
life-cycle (Cowman et al., 1991). It is predicted to consist of two nucleotide-binding 
sites as well as 12 transmembrane domains (Foote et at., 1989). The functional analysis 
of Pghl (reviewed in Rubio and Cowman, 1996) suggests that Pghl is involved in 
nucleotide-regulated transport across the membrane of the food vacuole. For this reason 
there were earlier suggestions to hint that Pghl could also be involved in the active 
transport of drugs across the membrane of the parasite's food vacuole. 
The observations that chloroquine-resistant parasites accumulate less drug than sensitive 
ones (Fitch, 1970, 1973; Aikawa, 1972; Yayon et al., 1985; Geary et al., 1986; Krogstad 
et at., 1987) suggests that Pgh 1 may play a role in this process by regulating the degree 
of chloroquine accumulation in some way. Two major models have been put forward to 
explain the differences in chloroquine accumulation between sensitive and drug-
resistant parasites: 
1) Pghl is an ATP -dependent pump that expels chioroquine from the food vacuole 
It has been suggested that chloroquine-resistant parasites have acquired the ability to 
expel the drug from the food vacuole through increased expression or mutations in mdr- 
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like genes (Wilson et al., 1989; Foote et al., 1989, 1990). However, in a P. falciparum 
genetic cross (HB3 x Dd2), no linkage was found between chioroquine resistance and 
either the pfmdrl or the pf7ndr2 genes (Wellems et al., 1990). In addition, this theory 
assumes that the Pghl acts as a chloroquine transporter, but up to the present date there 
is no evidence to suggest that it has this ability (Ginsburg and Krugliak, 1999). 
Similarly, it has been shown that photoactivatable analogues of chloroquine which can 
cross-link interacting proteins, do not covalently bind Pgh-1 (Foley et al., 1994). 
2) The weak base effect and chioroquine import 
Chloroquine is a weak base, and for this reason is thought to accumulate in the acidic pH 
of the food vacuole, where it is di-protonated, preventing it from diffusing out again 
(Homewood et al., 1972). It has been suggested that Pghl may play a role in 
chioroquine import by changing the pH inside the parasite's food vacuole. 
Consequently, Pghl may influence chloroquine accumulation by behaving as a pH 
modulator, perhaps by acting as a chloride channel that regulates the chloride 
permeability of the vacuolar membrane (Van Es et al., 1994b). If this is the case, 
chloroquine resistance may be explained by differential expression or mutations in the 
pfindrl gene, which would alter Pghl's ability to regulate the pH of the food vacuole. 
The transfection of Chinese Hamster Ovary (CHO) with wild-type pfindrl, has resulted 
in cells expressing Pghl that exhibited increased sensitivity to chioroquine due to an 
increased drug uptake (Van Es et al., 1994a). In addition, the transfection of mutants of 
pflndr] into S. cerevisiae, resulted in increased sensitivity to chioroquine (Ruetz et al., 
1996), suggesting that Pgh-1 may play an important role in chioroquine-import in 
sensitive organisms. This is consistent with results obtained by in vitro selection for 
chioroquine resistance in P. falciparum, which resulted in de-amplification and reduced 
expression of the pfmdr] gene (Barnes et al., 1992). Conversely, in vitro selection for 
mefloquine, quinine and halofantrine resistance, which resulted in an increase in copy 
numbers and over-expression of pfmdrl, was associated with an increase in 
susceptibility to chioroquine (Cowman et al., 1994; Peel et al., 1994). 
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Interestingly, the transfection into CHO cells of mutant alleles of pfmdrl previously 
linked to chloroquine resistance, did not produce increased chioroquine sensitivity (Van 
Es et al., 1994a, 1994b), possibly because the function of Pghl had been altered due to 
mutation. 
Evidence for the involvement of pfindr] in chioroquine resistance 
In 1990, Foote and colleagues sequenced the pfindrl gene from several isolates from 
both South America and South-east Asia and tested these isolates in vitro for 
chloroquine resistance. They identified two alleles of pfmdrl , thought to be involved in 
chloroquine resistance. One of these alleles was defined by an aminoacid substitution at 
position 86 in the chioroquine-resistant South-east Asian isolate Ki, where Asn is 
replaced by Tyr. The second one, the 7G8 South-American chloroquine-resistant isolate, 
was characterised by four amino-acid substitutions: Tyr 184 to Phe 184 , Ser 1034 to 
Cys 1034 , Asn' 042 to Asp' 042 and Asp 1246 to Tyr 1246 . Based on these amino-acid 
polymorphisms, the authors claim to have correctly predicted the chioroquine-
resistant/chloroquine sensitive status of 34 out of 36 isolates. However, it should be 
noted that there were several inconsistencies in this work. Specifically, the criteria for 
the classification of the level of resistance were not described. This may be the source of 
several apparent ambiguities in the relationship between chloroquine responses and 
alleles of the pcmdrl gene, among the isolates studied. 
Nevertheless, these initial findings led to subsequent studies from other laboratories to 
investigate further the role of pfindrl in chioroquine resistance, and some of the results 
of these studies appeared to be in agreement with the findings of Foote and colleagues, 
1990 (Basco et al., 1995; Cox- Singh et al., 1995; Silveira et al., 1996; Duraisngh et al., 
1997; Basco et a/.,1999; Adagu and Warhurst, 1999; Duraisingh et al., 2000). Similarly, 
amplification of the pfmdrl gene also appeared to confer chioroquine resistance in some 
field isolates (Foote et al., 1989). 
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However, in experimental crossing work, analysis of 16 progeny clones of a cross 
between a P. falciparum chioroquine-resistant clone (Dd2) and a chloroquine sensitive 
one (HB3), showed that neither amplification nor mutations in the pfmdrl gene 
segregated with chioroquine resistance (Wellems et al., 1990). Likewise, other field 
studies have found no significant association between allelic variants or level of 
expression of pfindrl and chloroquine resistance (Awad-el-Kariem et al., 1992; Wilson 
et al., 1993; Cremer et al., 1995; Basco et al., 1996; Bhattacharya et al., 1997; von 
Seidlein et al., 1997; Povoa et al., 1998; Bhattacharya and Pillai, 1999; Chaiyaroj etal., 
1999), suggesting that there can be no simple association between mutations in the 
pfindrl gene and the degree of chloroquine susceptibility. 
Transfection work has shown that pfindr] can modulate sensitivity to chioroquine. The 
"resistant" pfmdrl allele of the P. falciparum 7G8 isolate was replaced by a "sensitive" 
form containing codons determining amino-acids Ser' 034, Asn 1042 and Asp 1246 (Reed 
et al., 2000). It was observed that the transfectants accumulated nearly twice the level of 
chioroquine of that of the original 7G8 isolate. 
Overall, these results appear to show that mutations or increased expression of pflndrl 
may be important for the modulation of chloroquine responses observed in some, but not 
all parasite isolates and laboratory clones. These observations appear to point to a more 
complex genetic mechanism, where additional mutations in the same gene or other genes 
are needed for a full chioroquine resistance phenotype, presumably reflecting its slow 
appearance and diffusion. 
The following sections review work that has been done on the involvement of the 
pfindrl gene in mefloquine and quinine resistance. 
1.6.3.2 Mefloguine and Quinine resistance and Pfmdrl 
The first study of the involvement of pfmdrl in mefloquine resistance showed that the 
gene was amplified two to four-fold in a parasite line, W2-MEF, which had been 
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selected for mefloquine resistance (Wilson et al., 1989). This amplification was also 
associated with an increase in transcript levels (Wilson et al., 1989). Two subsequent 
independent laboratory studies on P. falciparum, which selected for parasite lines that 
are more resistant to mefloquine, also resulted in an increase in copy numbers of pfindrl 
and/or over-expression of Pgh-1 (Cowman et al., 1994; Peel et al., 1994). In addition, 
mefloquine resistance in these parasites was associated with a decrease in susceptibility 
to quinine and halofantrine. Subsequently, selection for increased chloroquine resistance 
from W2-MEF has been shown to result in de-amplification of pfmdrl and increased 
sensitivity to quinine, mefloquine and halofantrine (Barnes, 1992). 
Field studies on the association between the pflndrl gene and the parasite's response to 
mefloquine have provided conflicting results. Some appear to have shown an association 
between the amplification of the pfmdrl gene and mefloquine resistance (Wilson et al., 
1993; Price et al., 1997; Price et at., 1999), but exceptions have also been reported 
(Chaiyaroj et al., 1999). Thus, pflndrl amplification and/or increased expression of Pgh-
1 do not invariably occur in parasites lines selected for increased mefloquine resistance 
(Lim et at., 1996; Ritchie et at., 1996; Rubio and Cowman, 1996), or in P. falciparum 
mefloquine-resistant isolates (Chaiyaroj et al., 1999) suggesting that other mechanisms 
may mediate the resistance phenotype. Furthermore, a single genetic crossing 
experiment between a P. falcipa rum clone exhibiting both chloroquine and mefloquine 
resistance with a sensitive clone (HB3 x Dd2) showed clearly that pf,ndrl was not the 
cause of either type of resistance (Wellems et at., 1990). In addition, it is possible that 
mutations in the pfmdrl gene may be correlated with increased mefloquine-sensitivity. 
In fact, some field studies, genetic crossing work and transfection experiments, have 
indicated that increased mefloquine sensitivity might be caused by mutations in the 
pfmdrl gene. Price and colleagues (1999), reported that a mutation at codon 86 
(Asn86Tyr) was associated with increased mefloquine tolerance in P. falciparum from 
the western border of Thailand. Likewise, recent studies on fresh P. falcipa rum field 
isolates from the Gambia (Duraisingh et at., 2000), have shown that tyrosine at 
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aminoacid position 86 was related to increased mefloquine sensitivity. Similarly, it was 
observed that highly mefloquine-sensitive P. falciparum isolates from Brazil, contained 
point polymorphisms in other areas of pfmdrl (Zalis et al., 1998). In addition, genetic 
crossing work has shown that polymorphisms at codon 184 (Phe to Tyr) and 1042 (Asp 
to Asn) in the Pghl protein can be associated with incresead sensitivity to both 
mefloquine and halofantrine (Duraisingh et al., 2000a); it was suggested that these 
aminoacid substutions may bring about changes in the configuration of the Pghl peptide 
which may decrease its efficiency by changing the substrate specificity of the pump, 
since they are predicted to lie in transmembrane domains (TM) - 184 in TM3 and 1042 
inTMll. 
Recent transfection studies have also suggested strongly that point mutations in the 
pfmdrl nucleotide sequence which encode polymorphisms at codons 1034 (Ser to Cys), 
1042 (Asn to Asp) and 1246 (Asp to Tyr), may also cause P. falciparum parasites to 
accumulate more mefloquine and halofantrine, but less quinine (Reed et al., 2000). 
The results mentioned above suggest that there may be a complex relationship between 
sensitivity to mefloquine and quinine and either copy number/expression of pfmdrl or 
allelic polymorphisms. It is probable however that resistance to these drugs consists of a 
complex mechanism whereby different genes may be involved at different levels of 
resistance, or be selected differentially in different geographical areas. 
1.7 Genetics of chloroquine mefloquine and quinine resistance in rodent malaria 
models 
1.7.1 Chioroguine resistance 
The first studies on the genetics of chioroquine resistance were made in P. chabaudi. 
Rosario, 1976, selected a parasite clone exhibiting a low level of chloroquine resistance 
[AS (3CQ)] from a chloroquine sensitive, but pyrimethamine-resistant cloned parasite P. 
chabaudi AS (pyr). This involved multiple parasite sub-inoculations through mice with 
slow increases in drug concentration during passages. It is also interesting to note that 
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Rosario was unable to select for chloroquine resistance from a totally drug sensitive 
parasite, P. chabaudi AS(sens), although the biological reasons for this are not 
understood. 
It was also later observed that the resulting chloroquine-resistant P. chabaudi AS(3CQ) 
exhibited reduced accumulation of chloroquine in comparison to the initial sensitive 
clone (Ohsawa et al., 1991), a similar property described in P. falciparum (see section 
1.8.3). 
Rosario then made a genetic cross between the low chloroquine-resistant clone 
AS(3CQ) and a genetically unrelated sensitive clone, AJ. Chloroquine tests on the cross 
progeny clones revealed that the resistance trait underwent a typically Mendelian form 
of inheritance expected of a single genetic locus, although it was not possible at the time 
to ascertain the gene concerned. Genetic analysis of this cross, in which twenty 
independent recombinants were typed for their susceptibility to chloroquine and the 
inheritance of 46 chromosome-specific markers allowed the loci involved to be mapped 
(Carlton et al., 1998). Quantitative trait mapping indicated that a locus located on 
chromosome 11 was tightly linked to chloroquine resistance, and that other genes on 
chromosomes 3, 5 and 9 were linked to a lesser extent. No association was found 
between the inheritance of chioroquine resistance and pcmdrl, the P. chabaudi 
homologue of pfindrl (Carlton et al., 1998). 
Pccrt, the P. chabaudi homologue of the pfcrt gene (section 1.6.4) has recently been 
identified by Paul Hunt in this laboratory, and provisionally assigned to chromosome 14. 
Intronic gene sequence differences have been found between AS and AJ parasites, which 
allow typing of cross progeny clones for the parental inheritance of this gene. Typing of 
the twenty AS (3CQ) x AJ progeny clones, making use of this polymorphism has shown 
no association between the inheritance of pccrt and chloroquine resistance (Hunt, 
personal communication). 
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After selection of P. chabaudi AS(3CQ) (Rosario, 1976), these parasites were subjected 
to increased levels of chloroquine pressure in serial passages through mice (Padua, 1980, 
1981). Two resistant clones were thus generated, which possessed intermediate and high 
levels of chloroquine resistance, denoted AS (15CQ) and AS (30CQ), respectively. AS 
(30CQ) was crossed with AJ and it was observed that the resulting progeny clones 
showed various degrees of chloroquine susceptibility, indicating that the high level of 
chioroquine resistance observed in AS(30CQ) could be due to the accumulation of 
genetic mutations at different loci, each conferring a low level of resistance. It was 
considered that differences in resistance levels of the progeny clones were due to the 
random segregation of the different genes into the various clones. 
Other rodent malaria models have been used to study chloroquine resistance, but they 
appear to be less suitable models for P. falciparum. Selection for chloroquine resistance 
in P. berghei has been achieved, but proved to be an unstable feature in the absence of 
drug pressure (Peters, 1965). On the other hand, all P. yoelii isolates studied so far 
appear to be innately resistant to chloroquine, making this species inappropriate for 
studying gene mutations concerned with chloroquine resistance. 
1.7.2 Mefloguine resistance 
Field studies and laboratory work on P. falcipa rum appear to point strongly to a 
correlation between amplification of the pfmdrl gene and both mefloquine and quinine 
resistance, although a few exceptions have also been reported (see section 1.6.3.1). By 
way of illustration, two independent laboratory studies where P. falciparum parasites 
had been selected in culture for increased tolerance to mefloquine were accompanied by 
an increase in quinine resistance, and resulted in the amplification of the pfindr] gene 
(Cowman et al., 1994; Peel et al., 1994). In addition, point mutations in the pfmdrl 
gene encoding amino-acid substitutions, have also been shown to cause reduced 
sensitivity to mefloquine (Reed et al, 2000). However, it has also been demonstrated that 
mefloquine resistance may be obtained in P. falciparum, without amplification or point 
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mutations in the pfindrl gene (Lim et al., .1996), suggesting a more complex genetic 
mechanism, where different genes may be involved. 
Rodent malaria parasites present the ideal model to clarify the role of genes such as 
mdrl and to identify new genes involved, but, to date, only a limited amount of work has 
been done on mefloquine resistance. Gervais and colleagues (1999) have cloned and 
sequenced part of the pbmdrl, the P. berghei homologue of pfindrl. They report that 
Southern blots and slot blots of genomic DNA indicate that the gene is amplified two to 
three-fold in a mefloqu i ne-re si stance line (N/i 100) in comparison to the mefloquine 
sensitive line NK65. However, the sensitive and resistant lines are unrelated and 
therefore, a causal relationship between amplification of the pbmdrl gene and 
mefloquine resistance remains to be established. 
In P. chabaudi, a mefloquine sensitive parasite, AS (15CQ), has been used to selected a 
mefloquine-resistant clone, AS (15MF) (Padua and Walliker, 1978). Analysis of the 
resistant parasites AS (15MF) has shown that the pcmdrl gene (the P. falciparum 
pfmdrl gene homologue) had been duplicated and translocated as a result of this 
selection (Carlton et al, in prep.). 
1.7.3 Quinine resistance 
With regards to quinine resistance, rodent models have provided insignificant 
information on genes determining resistance to this drug. Jacobs (1965), was the first to 
produce P. berghei quinine-resistant strains, by progressively increasing drug pressure 
on the NYU-2 sensitive line, reporting this resistance to be stable in the absence of drug-
pressure. However, only six parasite sub-inoculations were performed to test the stability 
of drug resistance, and mosquito transmission of the resistant parasites was not done. No 
genetic studies were done on these parasites. Similarly, Robinson and Peters (1986), 
developed another quinine-resistant line, from the N strain of P. berghei (sensitive to all 
standard anti-malarials), by using the relapse technique. They report that resistance 
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developed slowly and parasites became sensitive after 20 blood passages in the absence 
of drug. 
Warhurst and Killick-Kendrick (1967), reported that the newly described parasite P. 
yoelii 17X, was not only innately resistant to chloroquine, but also proved to have 
reduced susceptibility to quinine, pamaquine and mepacrine. 
1.8 Description of the present study 
Because of the technical problems associated with the use of the human malaria parasite 
P. falciparum, mainly in maintaining a complete life-cycle in the laboratory, my studies 
have been undertaken with the rodent malaria parasite P. chabaudi, the most suitable of 
the four rodent malaria species available as a model for P. falciparum (Walliker, 1983). 
Furthermore, P. chabaudi is easily maintained in laboratory rodents and mosquitoes, and 
several mutant parasite lines are already available in this laboratory, which differ from 
each other in their sensitivity to three standard anti-malarial drugs - mefloquine, 
pyrimethamine and chioroquine. 
1.8.1 History of the lines and clones of P. chabaudi used in this study 
P. chabaudi was first isolated by Landau (1965) from thicket rats from the Central 
African Republic. Two lines were used in this study which were originally isolated from 
different rats; P. chabaudi AS and P. chabaudi AJ. These were subsequently cloned by 
limiting dilution of blood forms (Walliker et al., 1975), and found to differ from each 
other in the electrophoretic patterns of three enzymes; lactate dehydrogenase (LDH), 
adenosine deaminase (ADA) and 6-phosphogluconate dehydrogenase (6PGD) (Carter, 
1978, Sanderson et. al, 1981). More recently, they have been found to differ in numerous 
polymorphic DNA markers (Carlton et al., 1998). Prior to the start of this work the clone 
AS had been used to select lines (and subsequently clones) resistant to different drugs as 
shown in table 2 and figure 5. In addition, genetic crosses were made between 
chloroquine and mefloquine resistant parasites, and the uncloned progeny of these 
crosses were immediately available for this study (table 2 and figure 5). 
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CLONE DRUG RESPONSE' 
Parents 
Aj Drug sensitive 
AS (sens) Drug sensitive 
AS (pyr) 
(Walliker et al., 1975)  
Derived from AS (sens); pyrimethamine-resistant 
AS (3 CQ) 
(Rosario, 1976a,b) 
Derived from AS (pyr); resistant to 6 daily doses of chloroquine at 3 
mgfkg body weight. 
AS (15 CQ) 
(Padua, 1980) 
Derived from AS (3 CQ); resistant to 6 daily doses of chloroquine at 
5 mg/kg body weight 
AS (30 CQ) 
(Padua, 1980) 
Derived from AS (15 CQ); resistant to 6 daily doses of chloroquine at 
30 mg/kg body weight 
AS (15MF) Derived from AS(15 CQ); resistant to 4 daily doses of mefloquine at 
1 5 mg/kg body weight  
Progeny of crosses 
AS (3CQ) x AJ Uncloned progeny of a cross between AS (3CQ) and AJ 
AS (30CQ) x AJ Uncloned progeny of a cross between AS (30CQ) and AJ 
AS (15MF) x AJ Uncloned progeny of a cross between AS (15MF) and AJ 
Table 2- Clones of P. chabaudi used in these studies 










Figure 5- Simplified selection history of the P. chabaudi clones and lines used at the 
start of this work (* parasite clones that have been crossed with P. chabaudi AJ) 
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1.8.2 Outline of the proposed work 
Analysis of the mefloquine-resistant clone AS (1 5MF), has shown that the pcmdrl gene 
(the P. falciparum pfmdrl gene homologue) had been duplicated as a result of 
mefloquine selection (Canton et al, unpublished). In addition, two genetic crosses have 
been done between this clone and a mefloquine-sensitive parasite, P. chabaudi AJ, 
which differs from AS (1 5MF) in a number of genetic markers. 
A genetic cross was also made between the high chioroquine-resistant parasite, P. 
chabaudi AS (30CQ) and the drug sensitive parasite AJ (Padua, 1980). 
The uncloned progeny of these crosses were immediately available for this study. 
The specific aims of my study are as follows: 
. I intend to characterise progeny of the AS (15MF) x AJ crosses, to examine the 
segregation between mefloquine resistance and duplication of the pcmdrl among the 
progeny. This is to determine if duplication of the pcmdrl gene is an essential 
requirement for mefloquine resistance. Furthermore, it is also my intention to 
phenotype the cross progeny of this cross for chioroquine and quinine resistance. 
• Since little work has been done towards understanding quinine resistance, making 
use of rodent malaria parasites, I intend to: 
establish a quinine drug test which will distinguish quinine sensitive and resistant 
P. chabaudi parasites; 
expose the already existing sensitive and drug resistant parasite clones 
(mefloquine and chioroquine-resistant) to quinine pressure in mice. This is to 
determine if any kind of selection has already occurred that did not involve direct 
exposure to quinine, but could account for resistance to this drug. This will also 
help us understand any patterns of cross-resistance between the three drugs under 
study 
CHAPTER I - Introduction 	 43 
3. select P. chabaudi quinine-resistant mutants by exposure of drug-sensitive 
cloned parasite lines in mice to low and increasing levels of drug over prolonged 
periods, and then test parasites which survive for their sensitivity to the drug. 
. I wish to characterise the full nucleotide and peptide sequence of the pcmdrl gene, 
and compare these sequences between drug-sentitive and drug-resistant parasite 
clones, to determine whether mutation events have occurred in this gene during 
selection for drug resistance. 
• I propose to obtain clones from the AS (30CQ) x AJ cross, phenotype them for 
resistance to chioroquine, mefloquine and quinine, and use linkage analysis to 
identify potential genes determining resistance. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1 Parasite clones and vertebrate hosts 
2.1.1 Definition of terms 
Isolate- this term refers to a population of parasites that have been collected from 
mosquitoes, humans or rodents living in the wild, and subsequently kept as deep-frozen 
material. An "isolate" does not necessarily represent a homogeneous parasite population 
and may contain more than one representative of the same species or different species. 
Line- the term "line" refers to a population of parasites that have undergone one or more 
in vitro or in vivo laboratory passages. Usually, a "line" is produced when the parasites 
being passaged in the laboratory have been subjected to some kind of induced pressure, 
Such as drug treatment. As for "isolate", parasites constituting a line may not be 
genetically identical. 
Clone- this refers to a collection of parasites in which all individuals have been derived 
from a single cell by asexual reproduction. Therefore, a particular "clone" should 
represent a population of genetically identical parasites, assuming that no spontaneous 
mutations had taken place during parasite growth. Cloning is important for two reasons 
1) studies of drug resistance, since isolates may contain a mixture of parasites with 
different responses to the same drug or different drugs; 2) the partial characterisation of 
the progeny of a genetic cross requires the determination of inheritance of parental 
genetic markers in cloned progeny and the determination of drug responses. 
Stabilate- a "stabilate" refers to a population of parasites that have been preserved in a 
viable condition on a unique occasion (example: deep-freezing - of clones, isolates or 
lines of P. chabaudi) 
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2.1.2 Lines and clones of P. chabaudi used in this study 







(Walliker et al., 1975) 
AS (3 CQ) 
(Rosario, 1976a,b) 
AS (15 CQ) 
(Padua, 1980) 




AS (3CQ) x AJ 
AS (30CQ) x AJ 




Derived from AS (sens); pyrimethamine-resistant 
Derived from AS (pyr); resistant to 6 daily doses of chioroquine at 3 
mg/kg body weight. 
Derived from AS(3 CQ); resistant to 6 daily doses of chloroquine at 5 
mg/kg body weight 
Derived from AS(15 CQ; resistant to 6 daily doses of chioroquine at 30 
mg/kg body weight 
Derived from AS(15 CQ); resistant to 4 daily doses of mefloquine at 5 
mg/kg body weight 
Uncloned progeny of a genetic cross between AS (3CQ) and AJ 
Uncloned progeny of a genetic cross between AS (30CQ) and AJ 
Uncloned progeny of a genetic cross between AS (I5MF) and AJ 
2.1.3 Mouse strains used in this work 
The vertebrate hosts for P. chabaudi used in this study were mice (Mus musculus), 
housed in propylene cages with sawdust as bedding and fed on standard mouse chow. 
Drinking water was supplemented with 0.05% paraminobenzoic acid (PABA), an 
essential element for parasite growth. For routine maintenance of parasites, mixed 
strains of mice supplied by The University of Edinburgh, were used. Inbred CBA or C57 
mice (4-6 weeks old) supplied by M.M.T.0 (Medical Microbiology Transgenic Unit, 
University of Edinburgh) were used for drug tests and selection experiments. All mice 
were kept in a room where temperature was maintained between 22 and 25°C and a 12 
hour lightJ12 hour dark cycle. 
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2.1.4 Routine maintenance of parasites in the laboratory 
Parasites were maintained in laboratory mice by inoculation of parasitised red blood 
cells collected from the tail vein in citrate saline (appendix II), from infected to 
uninfected mice. Thin blood smears were taken 4-6 days after parasite injection, stained 
with Giemsa's stain and observed microscopically for the presence of parasites. When 
necessary, infected blood was cryopreserved according to the following procedure: mice 
were anaesthetised by halothane and bled from the brachial arteries. Blood was collected 
into a tube containing citrate saline (2-3 times the volume of blood). The red cell 
suspension was centrifuged at 2000 r.p.m. for 5 mins after which the red cell pellet was 
mixed with an equal volume of deep-freeze solution (appendix II). This mixture was 
then aliquoted into Nunc cryopreservation tubes and deep-frozen in liquid nitrogen. To 
establish new infections, stabilates were thawed by immersion of tubes in water and the 
contents inoculated intra-peritoneally into rodents, where a patent infection normally 
developed 5-10 days later. 
2.1.5 Parasitaemia estimations 
Parasitaemias were calculated by microscopic examination of thin blood smears first 
prepared from mice 4-6 days post parasite injection. Blood smears were made by 
making a small incision at the posterior end of the mouse tail, and collecting a blood 
drop that was subsequently spread on a microscopic slide. Smears were then fixed with 
methanol and stained with 20% Giemsa's stain for 30 minutes, after which slides were 
allowed to dry. Two different methods were used to estimate parasitaemia: 
% parasitaemia: 
% parasitaemia = no of infected red blood cells / no. of total red blood cells in 
10-20 microscopic fields X 100 
The "+" system, in which parasitaemia is presented as + or - symbols: 
-negative 
± only one parasite seen in a total of 10-20 microscopic fields, with a mean of 
400 r.b.c./field 
± 0.5-0.1 parasites/microscopic field 
+ > 0.5 parasites/microscopic field 
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++ > 2 parasites/microscopic field 
+++ > 5 parasites/microscopic field 
++++> 10 parasites/microscopic field 
+++++> 50 parasites/microscopic field 
++++++ > 200 parasites/microscopic field 
pp (post peak) few or no parasites observed, due to immune clearance 
2.1.6 Preparation of 106  standard parasite inocula 
106 infected red blood cells (iRBCs) was established as the standard parasite number to 
be injected into individual mice at the time of a drug test or during selection 
experiments. The preparation of these inocula was as follows: the parasitaemia and 
RBC/ml (number of red blood cells per ml) were calculated in the donor mouse, after 
which the required amount of blood was collected from the tail with a capillary glass 
pipette and diluted to a final concentration of 106  iRBCs/0.lml in a solution of 
heparinised 1:1 calf serum/mammalian Ringer solution (appendix II). Preparations were 
kept on ice at all times. Mice were then inoculated with 0.1 ml aliquots. 
2.1.7 Cloning 
In order to establish clones of P. chabaudi from uncloned cross progeny, a dilution 
technique was applied (Walliker, 1976). The procedure employed is similar to that 
described in the previous section (2.1.6). Mice with low parasitaemias were most 
suitable as donors, in order to reduce the risk of cells being infected with more than one 
parasite. Calculations for the dilutions were made such that each mouse was injected 
either with a mean of 0.5 or 1 parasite. Groups of 40-50 mice were inoculated in these 
experiments. If approximately 30% of the mice became infected, it could be predicted 
that 75% of the infections had resulted from a single parasite; a lower percentage of 
infected mice would indicate higher proportion of pure clones. In this way, several 
cloning experiments were done from parasites which resulted from the progeny of two 
genetic crosses - AJ x AS(15MF) and AJ x AS(30CQ) 
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2.1.8 Preparation. source and administration of quinine, chioroguine and 
mefloquine 
Quinine dihydrochioride powder was obtained from BDH Chemicals. Chioroquine 
sulphate (Nivaquine) was acquired from May and Baker in liquid form at 40mg/ml. 
Mefloquine hydrochloride powder was obtained from Roche. 
Both chloroquine and quinine were diluted in distilled water (dH 20). Mefloquine was 
diluted in dimethyl suiphoxide (DMSO). All drugs were administered to mice by gavage 
with the use of an appropriate metal catheter adapted to a imi syringe. Drug dose was 
expressed as milligrams of quinine per kilogram (mg/kg) of body weight. All drugs were 
diluted to a concentration such that the amount of drug corresponding to the desired dose 
was present in 0.1ml when given to a mouse weighing 20 grams. At the time of 
drugging, mice were individually weighed so that the amount of drug given could be 
adjusted accurately to each mouse. Chloroquine and quinine solutions were kept at 4° C 
at all times. Mefloquine was kept at room temperature. 
2.2 Drug tests and quinine selection 
2.2.1 Development of a standard quinine drug test 
Initially, quinine drug test trials were carried out on four P. chabaudi clones, to establish 
a standard test to distinguish between resistant and sensitive parasites as well as parasites 
with intermediate levels of resistance. 
Mice received 106  iRBCs each by intra-peritoneal (i.p.) injection. Of five mice, one was 
untreated and used as a control for the infection, while the remaining four were drugged 
at least three hours after injection, to allow parasites to reach the blood stream, and then 
every 24 hours on the following days. Two separate drug tests were initially conducted; 
one in which mice were treated with quinine for four consecutive days (four-day 
suppressive test), and the other one, for six days (six-day suppressive test). Each clone 
was treated with four different daily doses of quinine- 100mg/kg, 150mg/kg, 200mg/kg 
and 250mg/kg. Drug tests were always made in duplicate to assure reproducibility. 
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Blood smears from control and quinine treated mice in the "four day suppressive test" 
were taken on D6 post-infection (p.i.) and every other day thereafter, until the infection 
peaked or it was clear that no parasites were going to appear. Smears from mice in the 
"six day suppressive test" were first taken on D8. All parasitaemias were counted as 
previously described (section 4.3), and recorded. The parasitaemias and number of days 
for recrudescence of the different parasite lines, were compared. Parasites were 
considered to be quinine resistant if recrudescence occurred before day 10 and sensitive 
if recrudescence occurred at day 10 or afterwards. 
2.2.2 Chioroguine standard drug tests 
Groups of 6-8 mice infected with each clone to be tested, received 106  iRBCs each by 
intraperitoneal (i.p.) injection. 1-2 mice were left untreated and used as controls for the 
infection . Drug treated groups consisted of 3-4 mice which were treated with a dose of 
5mg/kg chloroquine, at least three hours after injection, to allow parasites to reach the 
blood stream, and then every 24 hours for six consecutive days. Blood smears were first 
prepared on Day 6 post-infection and every other day thereafter. Parasitaemias were 
recorded by using the "+ system" (section 2.1.5). Parasites were clustered into four 
levels of chloroquine response according to day of recrudescence: Sensitive - day 13; 
very low resistant - day 11; low resistant - day 9; resistant - day 7. 
2.2.3 Mefloguine standard drug tests 
Groups of 6-8 mice infected with each clone to be tested received 106  iRBCs each by 
intraperitoneal (i.p.) injection. 1-2 mice were left untreated and used as controls for the 
infection . Drug treated groups consisted of 3-4 mice which were treated with a dose of 
5mg/kg mefloquine, at least three hours after injection, to allow parasites to reach the 
blood stream, and then every 24 hours for 4 consecutive days. Blood smears were first 
prepared on Day 6 post-infection and every other day thereafter. Parasitaemias were 
recorded by using the "+ system" (section 2.1.5). Parasites were clustered into three 
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levels of mefloquine response according to day of recrudescence: Sensitive - day 13; 
low resistant - day 9; resistant - day 7. 
2.2.4 Quinine selection experiments: general procedure 
3 groups of 2 (4-6 week old) CBA mice were inoculated with 106 parasites of the clone 
to be used for selection for increased quinine resistance. Three hours after inoculation 2 
of the 3 groups were treated orally with different doses of quinine dihydrochloride for a 
total of 4 days. The remaining group was left untreated and served as a control. Both 
controls and parasites which survived drug treatment were passaged weekly from the 
mouse exhibiting the highest parasitaemia into uninfected mice and the treatment 
repeated. Parasites from control mice were also inoculated weekly into mice, in parallel 
with the treated mice. 
Drug doses were increased according to the parasite response to treatment in the 
previous passage. After a number of passages under drug pressure, parasites were tested 
for reduced susceptibility to quinine by comparing their sensitivity to those of control 
parasites, with the use of the standard "quinine 4-day suppressive test". 
To increase the likelihood of success, the procedure was done in duplicate by the 
generation of two lines, called A and B in which exactly the same procedure was applied 
throughout the course of the selection. This method for quinine selection was attempted 
in 4 different P. chabaudi clones - AJ, AS (sens) and AS (15CQ). 
2.3 Analysis of the A.J x AS (15MF) and A.! x AS (30CQ) genetic crosses 
2.3.1 Pulsed-field Gradient Gel Electrophoresis (PFGE) 
For analysis of chromosomes from parasites, pulsed-field gels (PFGs) were prepared, 
blotted, and hybridised with pcmdrl and chromosome 4-specific probes in order to 
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establish the inheritance of pcmdrl amplification and translocation among the progeny. 
The following sections elucidate these procedures. 
2.3.1.1 Preparation of parasite pellets 
Mice with high parasitaemias (> 30%) at the trophozoite stage were most suitable as 
donors for the preparation of parasite pellets. Mice were thus ex-sanguinated by section 
of the brachial artery, and blood was collected into a tube containing an excess of 
heparinised-PBS (137 mM NaCl, 2.7 mM KCI, 4.3 mM Na2HPO4, pH 8.8, 1.4 MM 
KH2PO4) at 2-3 times the volume of blood to be collected. The diluted blood was then 
passed down a CF  1 cellulose powder column to remove host leucocytes. Parasites were 
first released from red blood cells by saponin lysis and washed twice with citrate saline 
by 2 ten minute centrifugations at 2000g. 
2.3.1.2 Preparation of PFG blocks and agarose gels 
PFG blocks were prepared from P. chabaudi by the following procedure (Kemp et al., 
1985). After saponin lysis the parasite pellet was diluted with 1 X PBS to a 
concentration of - 4 X 10 9 parasites/ml, after which an equal volume of 2% Low 
Melting Temperature agarose (LMT) prepared in 1 X PBS and cooled to 42°C, was 
added. This solution was then mixed thoroughly, pipetted into a pre-warmed BioRad 
mould and left to set at 4°C for at least 20 minutes, when a solid PFG block was formed. 
PFG blocks were then carefully removed from the mould and incubated at 42°C in PFG 
lysis solution (appendix II) containing 2mg/mi proteinase K (Boehringer Mannheim), for 
48 hours with one change of lysis solution. After this, PFG blocks were ready for use or 
could be stored at 4°C in lysis solution only. 
2.3.1.3 Preparation of PFG electrophoresis and running conditions 
1% chromosomal grade agarose (CGA - BioRad) PFGs were prepared in 0.5 X TBE 
(appendix II) and allowed to cool to 10°C. They were transferred onto a CHEF 
(Contour-clamped Homogeneous Electric Field) gel tray, in which the current is 
generated from electrodes disposed hexagonally around the area set for the gel. The gels 
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were run in 0.5 X TBE buffer in a cold room to ensure that the temperature of the buffer 
would not exceed 14°C. Pulsed-field gels were run for three days under the following 
conditions: 
day 1- voltage 140 V; pulse-time 120 seconds; run 24 hours 
day 2- voltage 130 V; pulse-time 300 seconds; run 24 hours 
day 3- voltage 140 V; pulse-time 180 seconds; run 24 hours 
After the run, gels were stained with ethidium bromide at a concentration of 0.5 p.gIml, 
for 30 minutes, visualised under ultra-violet light and photographed. In this way 
karyotypic analysis was made from the parent clones of the AJ X AS (15MF) cross, as 
well as progeny clones, to establish karyotype inheritance among the progeny. 
Saccharomyces cerevisiae chromosomes (BioRad) were used as chromosome size 
markers. 
2.3.1.4 Southern blots of Pulsed-field gels 
PFG gels to be blotted were depurinated in 0.25M HC1 for 30 minutes, followed by 
alkaline transfer in 0.4M NaOH in a Tyler vacuum blotter. The membranes used for the 
transfer were Hybond N+ (Amersham). After blotting, membranes were carefully 
marked, washed in 2xSSC, and stored in Saran wrap at 4°C. 
2.3.1.5 Detection of pcmdrl duplication and translocation by Southern 
hybridisation 
To determine the inheritance of pcmdrl , membranes from all PFGs were hybridised with 
pcmdrl as well as the chromosome 4-specific DNA probe, P9. A PCR-amplified 600 bp 
fragment of the pcmdrl gene of P. chabaudi (Carlton, 1998), was used. P9 originated 
from a genomic DNA library (J. Carlton, PhD Thesis 1995). 
The methods for labelling of DNA probes and Southern hybridisation procedures will be 
described later. 
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2.3.2 Detection of RFLPs 
2.3.2.1 Genomic DNA isolation 
A parasite pellet was produced by the methods described previously (section 2.3.1.1) 
and kept over night at -20°C. This frozen parasite pellet was then incubated at 42°C for 
at least 4 hours with an equal volume of DNA lysis solution (appendix II) containing 
Proteinase K at a concentration of 1mg/mi. DNA was then extracted once with 
equilibrated phenol (pH 8.0), twice with phenol: chloroform (1:1) and twice with 
chloroform: isoamyl-alcohol, (25:1) (Sambrook et at., 1989), followed by precipitation 
with 0.3 M ammonium acetate. After this, DNA was resuspended in TE, pH 7.4 and 
stored at -20°C. 
2.3.2.2 Genomic DNA digests 
DNA was extracted from all clones as previously described (section 2.3.2.1) and its 
concentration estimated by comparing band intensities between each clone and X 
bacteriophage molecular weight markers of known concentration, on a 1% agarose gel. 
Approximately 1 0pg of genomic Plasmodium DNA were digested with a number of 
different restriction enzymes. Enzymes producing suitable RFLPs had already been 
identified by Carlton, (1995), and some of these were used here. Enzyme buffers used 
were those supplied by the manufacturers (Promega and Boehringer Mannheim). 
Genomic DNA digests were set-up, using standard procedures (Sambrook et al., 1989), 
in a total volume of 20 tl. Digestions took place overnight at 37°C, followed by 
electrophoresis in a 1% agarose (Sigma or Bio-Rad) gel in 1 X TBE buffer. After 
electrophoresis, gels were visualised under ultra-violet light and photographed. 
2.3.2.3 Southern blots 
Agarose gels to be blotted were depurinated in 0.25M HC1 for 15 minutes, followed by 
alkaline transfer in 0.4M NaOH in a Tyler vacuum blotter. The membranes used for the 
transfer were Hybond N+ (Amersham). After blotting, membranes were carefully 
marked, washed in 2xSSC, and stored in Saran wrap at 4°C. 
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2.3.2.4 DNA probes 
A number of polymorphic Plasmodium genetic markers exhibiting RFLPs between P. 
chabaudi AJ and AS, produced or stored from other sources in this laboratory by Jane 
Canton (Canton et al., 1998) were available for the present study (Table 3). Most of 
these markers were obtained as cloned inserts in polylinker sites of plasmid DNA 
transformed into E. coli and stored as glycerol stocks (Sambrook et al., 1989) at -70°C. 
Probe Enzyme producing Stringency 
RFLP  
Chromosome Reference 
PCNA HindU 1XSSC, 45°C 11 
Carlton et al., 1998 
Pcm4rl EcoRI 0.1XSSC, 65°C 12 
RESA Hinfi O.IXSSC, 65°C 6 
Ag3040 Hinfi O.IXSSC, 65°C 14 
R102 Hinfi 0.1XSSC, 65°C 14 
Ag3024 Dral 0.IXSSC, 65°C 5 
R104 RsaI 0.1XSSC, 65°C 13 
Ag3003a RsaI O.IXSSC, 65°C 3 
P9 HindlI 0.IXSSC, 65°C 4 
DHFR HindII 0.1XSSC, 65°C 7 
Ag3010 Dial 0.1XSSC, 65°C 8/9? 
DNApolS RsaI 0.1XSSC, 65°C 5 
5srRNA HindlI 1XSSC, 50°C 10 
Ag3012 Hinfi 0.IXSSC, 65°C 7 
Ag3027 Hinfl 0.IXSSC, 65°C 9 
Table 3- RFLPs analysed in this study 
2.3.2.5 Isolation of DNA probes 
In order to isolate the desired marker, bacteria were transferred from the glycerol stocks 
and cultured on LB agar plates containing the appropriate antibiotic. Single colonies 
containing recombinant plasmids were cultured in LB medium with the appropriate 
antibiotic (ampicylin or kanamycin) at 50-100.tg/ml. Plasmids were isolated from these 
cultures using a Wizard 
TM  Miniprep protocol (Promega), following the manufacturer's 
instructions. Inserts were freed from the plasmids by digestion with the appropriate 
restriction enzyme, following standard procedures (Sambrook et al., 1989). Digests were 
then electrophoresed in 1% LMT agarose (Gibco BRL) in 1XTBE buffer together with 
DNA size standards VI and VII (Boehringer Mannheim). A gel slice containing the 
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insert was removed, melted at 70°C and the DNA purified using the Wizard 1M PCR 
preps DNA purification system (Promega), following the manufacturer's instructions. 
Inserts were stored in TE, pH 7.4 at -20°C. 
2.3.2.6 DNA labelling 
Probe inserts were radiolabelled with [a 32P] dATP (Amersham International) by using a 
random prime DNA labelling kit supplied by Boehringer Mannheim, following the 
manufacturer's instructions. Approximately 25ng of template were used in each 
labelling reaction. 
2.3.2.7 Hybridisation and stringency washes 
Hybridisations of probes to Southern blots were carried out in glass hybridisation bottles 
(Hybaid). Membranes were washed briefly in 5xSSC, placed inside the bottles and 
hybridisation solution (appendix II) was added. Denatured herring sperm DNA was 
added to a concentration of 100 pg/ml and membranes were then allowed to pre-
hybridise for at least 1 hour in a Maxi-Oven (Hybaid) at the desired temperature 
(hybridisation temperatures varied from 40-65°C, depending on the degree of homology 
between the DNA probe and P. chabaudi DNA; see Table 3). After the pre-hybridisation 
period, denatured labelled probe was added, and hybridisations were allowed to take 
place over night. After this, hybridisation solution was discarded and stringency washes 
took place at hybridisation temperature in 2xSSC, 2x30 mins, followed by 0.5xSSC, 
2x30 mins, followed by 0.1xSSC, 2x30 mins. Stringency was varied depending upon the 
degree of homology between the probe and P. chabaudi (the list of probes used and 
stringency conditions is shown in Table 3) 
Blots were autoradiographed with intensifying screens at -70°C. 
2.3.2.8 Stripping Southern blots 
Probes were removed by two 15 minute washes of 0.1M NaOH at room temperature, 
rinsed in 5XSSC and then stored in Saran wrap at 4°C. 
CHAPTER 11 - Materials and Methods 	 56 
2.4 RNA analysis 
Expression studies of pcmdrl mRNA were carried out to determine whether different 
levels of expression occurred in mefloquine, quinine or choroquine-resistant forms 
among the AJ X AS (15MF) clones. 
2.4.1 RNA isolation 
After release from red blood cells, parasite pellets (section 2.3.1.1) were incubated with 
9 - 19 volumes of RNA isolator from Genosys® and this mixture was deep-frozen at - 
20°C. Parasite RNA was isolated from this solution by the following procedure: samples 
were thawed on ice and left for 15 minutes at room temperature, after which the mixture 
was divided into two Eppendorf tubes; lSOjil of chloroform were then added to each 
tube, the samples were mixed for 15 seconds and left at room temperature for 2-15 
minutes. After this, the mixture was spun in a cold centrifuge for 15 minutes to separate 
the parasite debris from the aqueous phase, where the RNA was present. The aqueous 
phase was then mixed with 0.75 ml isopropanol at room temperature for 10 minutes in 
order to precipitate the RNA. This was followed by a 10 minute centrifugation in a cold 
centrifuge in order to obtain an RNA pellet that was visible at the bottom of the tubes. 
This pellet was then washed thoroughly with at least 1.5 ml 70% ethanol, air dried for a 
short time and dissolved in 50j.il RNAse-free TE. RNA samples were then stored at - 
70°C. 
2.4.2 Denaturing RNA gel 
Gel tank, tray, gel combs and ends were presoaked in 1% hydrogen peroxide overnight, 
after which 1% agarose gels were made in 25ml of lOX MOPS buffer, 180 ml sterile 
distilled water (DEPC treated) and 2.5 g agarose, by boiling in a heat sterilised conical 
flask. This solution was allowed to cool to 55°C, when 45m1 of formaldehyde (37%) 
were added. The gel was then mixed and poured. 
RNA samples were prepared as follows: two volumes of RNA sample buffer were added 
to the sample RNA and heated to 65°C for 5 minutes. These samples were allowed to 
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cool to room temperature, after which 2 pi of RNA loading buffer were added. The gel 
was then run at 4- 5 V/cm. 
2.4.3 Northern blots 
After the RNA had run, gels were washed several times in DEPC treated water to 
remove formaldehyde, soaked in 50mM NaOH for 20 mins and washed in DEPC-treated 
water. Subsequently the gel was soaked in 20X SSPE for 45 minutes, after which the 
RNA was blotted onto a Hybond- N nitrocellulose membrane by capillary transfer in 
20X SSC overnight. After transfer had taken place, gels were stained with ethidium 
bromide and visualised on a transilluminator to ensure that the transfer had been 
completed. Membranes were then washed in 5X SSC, dried and placed under ultra-
violet light to fix RNA. Blots were then ready to be used immediately or could be stored 
dry at room temperature between 3MM paper and aluminium foil. 
2.4.4 Northern hybridisation 
Membranes were washed in 5X SSC and placed in Hybaid hybridisation bottles. Pre-
hybridisation solution was heated to 42°C and added to the bottles at a volume of 
0.2ml/cm2 , after which incubation at 42°C was allowed to take place for 1-2 hours. 
Labelled probes (see section 2.3.2.6) were then denatured by boiling for 5 minutes and 
quenching on wet ice. Each probe was then added to the hybridisation solution and 
incubated overnight at 42°C, after which membranes were washed for 20 minutes at 
60°C twice with 2 x SSC, 0.1% SDS, followed by two 20 minute washes in 0.5 x SSC, 
0.1% SDS and twice in 0.1 x SSC, 0.1% SDS. 
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2.5 Characterisation of the pcmdrl gene 
2.5.1 Experimental approach to obtain nucleotide sequence for the pcmdrl gene 
Carlton (1995) had previously amplified, cloned and partially sequenced a 600bp 
fragment of the pcmdrl gene, by designing PCR oligonucleotides which recognise 
highly conserved nucleotide binding sites within the two ATP binding cassettes of the 
Pfindrl gene; the resulting plasmid was named pcATP-PCR (Carlton, 1995), and used as 
the starting material for these studies. 
2.5.2 Oligonucleotide primers 
Oligonucleotide primers were designed taking into account the biased base size 
composition of the Plasmodium genome. In this way, primers were designed to contain 
between approximately 30 and 50% G+C content, but this range depended highly on the 
base size composition of the area of the gene in which they were located. As a 
consequence, there was some variation in the melting temperature of different primers 
and therefore. The design of all primers was done in a way that primers to be used in 
pairs would present very similar melting temperatures. For sequencing of cloned PCR 
fragments, the primers used were those based on the sequence of the pCR®2. 1- Topo 
(Invitrogen) plasmid vector. Vectorette primers were those supplied in the Vectorette kit. 
The description of all primers and the fragments obtained through their application is 
given in CHAPER V. 
2.5.3 Methods used to obtain new sequence for the pcmdrl gene 
Due to the unavailability of a suitable P. chabaudi genomic library at the start of this 
work, a variety of different methods were attempted to obtain new nucleotide sequence 
for the pcmdrl gene. These included, 
Vectorette libraries 
Inverse PCR 
Degenerate primers used to amplify P. chabaudi DNA 
Screening of P. chabaudi genomic libraries 
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Following, is a description of each of these methods 
2.5.3.1 The vectorette system 
Vectorette is a system whereby sequence information may be extended upstream or 
downstream of a known genomic DNA fragment. Fragments of the genomic DNA are 
ligated to Vectorette adaptors and fragments specific to the gene amplified, using 
Vectorette primers and gene-specific primers. PCR products may be sequenced or 
cloned prior to sequencing. 
Vectorette is based on the principle of "one- sided" PCR, whereby no sequence 
information upstream or downstream of the known primer is needed to amplify DNA 
fragments. Genomic DNA is first digested with a restriction enzyme. The digested DNA 
is then ligated to the Vectorette DNA fragments, forming a Vectorette library. To 
amplify DNA containing the sequences of interest, two primers are used; one which 
corresponds to one of the ends (5' or 3') of the gene sequence that is already available; 
and the second the Vectorette PCR primer. The Vectorette adaptor relies on the fact of 
being only partially double- stranded, and contains a mismatch. The Vectorette PCR 
primer has the same sequence as the top strand of the Vectorette mismatched region and 
for this reason it has no complementary DNA strand to anneal in the first cycle of PCR. 
The products of the first round of amplification will thus be generated by the specific 
gene primer. These will contain the complementary Vectorette primer sequence, to 
which the Vectorette PCR primer can now anneal. After this second cycle, the PCR 
continues normally, resulting in the amplification of PCR products that should in theory 
be specific to the gene primer used. In addition, Vectorette is also supplied with a nested 
PCR primer, which can be used in a second reaction to increase further the specificity of 
the PCR. 
Vectorette libraries constructed from P. chabaudi (AS) DNA which had previously been 
made by Paul Hunt and Karen Hayton in this laboratory were kindly made available for 
this work. The following Vectorette libraries were used to obtain sequence for the 
pcmdr] gene: Alul, BamHI, Clal, EcoRI, MfeI, TaqI. 
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2.5.3.2 Inverse PCR 
This technique is also used to amplify DNA fragments that lie outside the limits of 
known sequences (Sambrook et al., 1989). Genomic DNA is first digested with one or 
more restriction enzymes that have no restriction sites within the target sequence. The 
digested DNA is then diluted and ligated in a manner favouring the formation of 
monomeric circles. This forms an inverse PCR library. The regions flanking the target 
sequence can then be amplified by PCR using oligonucleotide primers that procced 
outwards from the known sequence. These may be sequenced or cloned prior to 
sequencing. The junction between the upstream and downstream fragments is 
determined by the presence of the restriction site corresponding to the enzyme(s) used 
originally to digest the genomic DNA. The following inverse PCR libraries were 
constructed: Dral, BfaI, DraI/BsuRI, DraI/MseI, Mph 1031, BsuRI, SphI, BfaI, NdeI, 
VspI, BfaIINdeI, BfaIlVspI, NdeI/VspI, BfaIINdeIJVspI, A1uL/MseI, AluIJBsuRI, 
Alul/Dral. 
PCR reactions were set up with these libraries as template DNA, using oligo- nucleotide 
primer pairs corresponding to the extreme 5' and 3' ends of the target pcmdrl sequence. 
2.5.3.3 Degenerate and P. falciparum oligonucleotide primers 
Degenerate oligonucleotide primers and oligonucleotide primers based on pfindrl , were 
also designed in order to obtain sequence for pcmdrl. Primers were designed based on 
the pfindrl gene nucleotide sequence, as well as a partial sequence from pbmdrl (the P. 
berghei gene homologue of pfmdrl), both available at the BLAST. When planning the 
design of these oligonucleotide primers, areas of the gene were chosen which presented 
the highest degree of conservation possible between the two species. On occasions 
where the targetted pcmdrl sequence lay outside the boundaries of the known partial 
pbmdrl sequence, oligonucleotide primers were designed based solely on the pfmdrl 
nucleotide sequence. 
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2.5.3.4 Screening of genomic libraries 
2.5.3.4.1 Origin and nature of the P. chabaudi plasmid library 
P. chabaudi genomic libraries were made in the University of Glasgow by Dr. Chris 
Janssen and kindly given to this laboratory. These had been made by sonicating P. 
chabaudi AS(sens) DNA and ligating the resulting fragments on to the Smal blunt end 
sites of puC18. The resulting recombinant plasmids were diluted in TE and brought to 
this laboratory. 
2.5.3.4.2 Transformation 
Plasmids were transformed into E. coli XL1B1ue (Stratagene) competent cells by 
electroporation. Competent cells were thawed on ice, after which 1-2p1 of a suitable 
dilution of plasmid library in sterile distilled water was added. This was then transferred 
to a pre-cooled 0.1 cm cuvette. The electroporation pulse was as follows; 
Single pulse 1700 V, 25 gF, 201 Ohm 
1 ml of SOC medium was added immediately, the cells were mixed and incubated at 
37°C for 1 hour in an orbital incubator, after which, cells were plated out on 20cm x 20 
cm LB- agar plates containing selective antibiotic, in order to generate 5.000 - 20.000 
colonies. 
2.5.3.4.3 Identification of bacterial colonies containing candidate pcmdrl fragments 
Plated bacterial colonies were blotted onto a nitrocellulose membrane following 
standard procedures (Sambrook et al. 1989). Membranes were carefully marked so that 
the location of positive colonies could be determined accurately. After transfer, the 
colonies present on the membrane were lysed ((Sambrook et al. 1989) and the DNA 
fixed by a 5- minute exposure to u.v. light. 
For identification of colonies carrying plasmids with fragments of the pcmdrl gene, 
membranes were hybridised with pcmdrl probes by methods described previously 
(section 2.3.2.6). 
After having determined the location of positive colonies, which hybridise with pcmdrl 
probe, these were individually picked from the plates by using a sterile toothpick, and 
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replated at lower density on another selective LB-agar plate. This plate was again blotted 
onto a nitrocellulose membrane and hybridised with a radioactive pcmdrl probe, by 
methods described previously (section 2.3.2.6). 
2.5.3.4.4 Isolation of DNA fragments from positive bacterial colonies 
Positive colonies were subsequently cultured in selective LB medium, after which 
plasmid DNA was extracted. Inserts were then sequenced, by using vector specific 
primers. 
2.5.4 PCR reactions 
2.5.4.1 PCR reagents and reaction conditions 
Individual PCR reactions were carried out in 50il volumes containing 10pM of both 
oligonucleotides, 1 X PCR buffer, 1 X dNTP solution, 1 unit Taq DNA polymerase 
(Boehringer Mannheim) and 1-3ng template genomic DNA (1-3pg if template is plasmid 
DNA). This mixture was overlayed with 1 drop of sterile mineral oil. Negative controls 
were also prepared, which contained ijil of TE in place of template DNA. 
PCR reactions were carried out using a TRIO- Thermoblock machine (Biometra), under 
the following standard conditions; 
Denaturing 94°C for 1 minute x 35 cycles 
Annealing 55°C for 2 minutes  
Extension 	65°C for 3 minutes 
A 72°C, 10 minute step was added at the end of PCR reactions, in occasions when PCR 
fragments were to be cloned; this allows for an A overhang to be added onto the 3' end 
of the strand, required for cloning with the TA system. 
PCR products were run and visualised on a 1.5% agarose gel in TAE buffer in order to 
evaluate the success of amplification and determine the fragment size. 
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2.5.4.2 Purification of candidate PCR products 
Candidate PCR products were purified by using the the QIAGEN QlAquick
TM  Spin 
Handbook, following the manufacturer's instructions. These were later analysed on 
agarose gels to determine approximate DNA concentrations prior to sequencing. 
2.5.4.3 Cloning of candidate PCR products 
Candidate PCR products were cloned into PCR2. lTopo plasmid and transformed into E. 
coli competent cells by using the INVITROGEN TOPO TA Cloning   kit, following the 
manufacturer's instructions. Transformed bacteria were spread on LB-AGAR plates 
containing the appropriate selective antibiotic at 50-1001g/ml and X-Gal for blue/white 
selection. Plates were then incubated at 37°C overnight, to allow for growth of bacterial 
colonies. 
2.5.4.4 Analysis of cloned candidate PCR products 
5-10 positive colonies were picked from LB-AGAR plates and cultured at 37°C 
overnight in lOmI of LB medium with selective antibiotic at lOmg/ml. Recombinant 
plasmid DNA was then extracted from the cultured bacteria by using the QIAGEN 
QlAprep® kit, following the manufacturer's instructions. After DNA purification, 
plasmids were digested with EcoRI restriction enzyme and visualised on agarose gel in 
order to confirm the insert size, which could be compared to the PCR product size. 
2.5.4.5 Sequencing and purification of PCR products 
Sequencing PCR reactions were set up and the resulting products precipitated by using 
the ABI PRISM  Big Dye TM Terminator Cycle Sequencing Ready Reaction Kit, (PE 
Applied Biosystems). PCR reactions were prepared to a final volume of lOpJ, containing 
the following reagents: 4j.tl template DNA (100-250ng), 4111  Terminator Ready Reaction 
Mix, 1111  primer (3.2pmol), 1111  sterile distilled water; this mixture was overlayed with 
40111 of sterile mineral oil. 
Sequencing PCR conditions were as follows; 
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Denaturing 96°C for 30 seconds 
Annealing 50°C for 15 seconds 	
x 25 cycles 
Extension 	60°C for 4 minutes 
PCR sequencing products were purified, following the manufacturer's instructions, by 
precipitation with sodium acetate and 95% ethanol, washed in 70% ethanol and re-
suspended in sterile TE buffer. 
For sequencing of purified PCR products, both internal and oligonucletotide primers 
covering the extreme 5' and 3' ends of the fragments were used. For sequencing of 
cloned PCR products, the primers used were those corresponding to the sequence of the 
pCR®2. 1- Topo (Invitrogen) plasmid vector - M13 primers. 
All fragments were sequenced in opposite directions. Any ambiguities were eliminated 
by repeating PCRs of sequencing reactions. 
2.5.4.6 Sequence analysis 
All nucleotide sequences obtained were computer analysed through BLASTnucleotide 
search and the Gene Jockey II Sequence Processor from BIOSOFT. Pcmdrl sequences 
were identified by comparison with known pfmdrl. Pcmdrl nucleotide and peptide 
sequences were compiled from different sequence files by joining internal fragments 
within the gene. The degree of homology and identity between the pcmdrl and pfmdrl 
genes was determined using alignment software. New nucleotide sequences could be 
used for design of new primers which could be used for further extension of sequence 
data. 
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RESULTS 
The results of the present work are divided into three chapters: 
• Chapter III deals with the characterisation of mefloquine, quinine and chioroquine 
responses among some of the P. chabaudi clones under study. Data that resulted 
from the establishment of a quinine standard drug test, which allowed the 
determination of the quinine tolerance of all mefloquine and chioroquine-sensitive 
and resistant parasites, available in this laboratory, are also presented. Results of the 
attempts to select for quinine resistant parasites are shown. 
Chapter IV describes the analysis of a genetic cross between a drug sensitive P. 
chabaudi clone AJ and a clone resistant to mefloquine, quinine and chloroquine, AS 
(1 5MF). The linkage between chromosome specific markers and drug resistance is 
presented. In particular, the possible linkage between the. duplication and over-
expression of the pcmdrl gene and drug resistance is investigated. 
I also present analysis of another genetic cross; that between the drug sensitive 
parasite P. chabaudi AJ and the highly chloroquine-resistant clone AS (30CQ). A 
description of the clones produced from this cross and some of the RFLPs studied is 
given, since this represents an important source of data that can be used in future 
work. 
• Chapter V presents data arising from the cloning and sequencing of the pcmdrl 
gene. Nucleotide sequences from drug-sensitive and drug-resistant clones were 
compared to determine whether mutation events had occurred in this gene during 
selection for drug resistance. 
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CHAPTER III 
DRUG RESPONSES AND QUININE SELECTION EXPERIMENTS 
This chapter deals with the characterisation of drug responses among different clones of 
P. chabaudi, whereby sensitive, AJ and AS (sens) chioroquine-resistant, AS (3CQ), AS 
(15CQ) and the mefloquine-resistant parasite clones, AS (I5MF), AS (30MF), are 
phenotyped for their drug sensitivity. Results of the development of a quinine standard 
drug test are presented. The patterns of resistance between the three drugs are compared. 
Results on the selection for quinine resistance from three different parasite clones, AS 
(sens), AJ and AS (15CQ), are presented. 
3.1 Development of a test for quinine resistance 
In order to evaluate and compare the quinine responses of different clones of P. 
chabaudi, it was necessary to develop an optimum in vivo quinine drug test. 
Tests for quinine sensitivity were planned using different drug treatment regimes to 
determine the optimum conditions for distinguishing different patterns of sensitivity 
(section 2.2.1). Initial assays were carried out on P. chabaudi clones, AS (sens), AS 
(15CQ), AS (15MF) and AS (30MF). After these preliminary trials (data not shown), 
there appeared to be differences in the quinine tolerance level of the clones under study, 
which were most apparent when the "four-day suppressive-200mg/kg" (section 2.2.1) 
was used. For full confirmation of its validity, this standard test was again performed on 
AS (sens), AS (15CQ), AS (15MF) and AS (30MF), along with clones AJ and AS 
(3CQ). It was concluded that there were differences in the quinine tolerance level among 
the clones under study. 
Results are summarised in Table 4 (the detailed data from the initial quinine drug tests 
are shown in appendix I). The four days of 200mg/kg treatment did not clear any of the 
clones completely. For the purpose of this work, however, parasites were classified as 
quinine sensitive when recrudescence occurred 10 or more days following quinine 
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treatment, where day 0 is the first day of treatment. Parasites which recrudesced before 
day 10 where classified as quinine resistant. 
P chabaudi clone Day of recrudescence Quinine sensitivity  
AJ 10 Sensitive 
AS (sens) 10 Sensitive 
AS (3CQ) 14+ Sensitive 
AS (15CQ) 8 Low-resistant 
AS (15MF) 6 Resistant 
AS (30MF) 6 Resistant 
Table 4 - Results from initial quinine drug tests * A parasite was considered to have 
recrudesced after quinine treatment, when parasites were microscopically detectable in the blood for the 
first time, in at least 2 out of 3 mice. The number shown is a mean of two independent tests. 
3.2 Tests for chiorop nine resistance 
These parasite clones were also tested for chloroquine resistance by methods described 
previously (section 2.2.2) to assess for possible associations between resistance to the 
two drugs. 
The results from these drug tests are presented in appendix I and Table 5 below (the data 





AJ S S 
AS (sens) S S 
AS (3CQ) lowR S 
AS (15CQ) R lowR 
AS (15MF) R R 
AS (30MF) R R 
Table 5 - Results from initial quinine and chioroquine drug tests 
(S- sensitive; R- resistant; lowR- low resistance) 
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3.3 Tests for meflouuine resistance 
The mefloquine response of these parasites was determined by methods described 
previously (section 2.2.3) to check for possible associations between resistance to the 
three drugs. 
The detailed results from these drug tests are presented in appendix I and Table 6 below 
(the data from the quinine and chloroquine resistance drug tests is also included). 
WOR gm 
AS (sens) S S S 
AS (3CQ) S lowR S 
AS (15CQ) S R lowR 
AS (15MF) R R R 
AS (30MF) R R R 
Table 6 - Results from initial quinine, chioroquine and mefloquine drug tests 
(S- sensitive; R- resistant; lowR- low resistance) 
3.4 Main observations from quinine, chlorouuine and meflopuine drug tests 
The main results from the drug tests described in the previous three sections can be 
summarised as follows, 
both chloroquine and mefloquine-sensitive parasites, AJ and AS (sens), are also 
quinine-sensitive (Table 6); 
low chloroquine-resistant parasites, AS (3CQ), appear to be both mefloquine and 
quinine-sensitive (Table 6); 
low chioroquine-resistant parasites, AS (3CQ), appear to be more sensitive to 
quinine than drug sensitive parasites, AJ and AS (sens) (Table 6); 
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4) 	AS (15CQ) presents some degree of quinine resistance, but still sensitive to 
mefloquine (Table 6); 
5) 	the mefloquine-resistant parasites AS (I5MF) and AS (30MF) are resistant to 
both chloroquine and quinine (Table 6). 
3.5 Quinine selection experiments 
In order to map quinine resistance genes, we wanted to generate quinine-resistant 
parasites, AJ or AS-type, which could be genetically crossed. Selection for quinine 
resistance was attempted from P. chabaudi clones AS (sens), AS (15CQ) and AJ. The 
results from these experiments are described here. 
3.5.1 Selection from AS (sens) 
Initially, an attempt was made to select for quinine resistant parasites from the P. 
chabaudi clone AS (sens). Parasites were first treated with a low dose of 25mg/kg 
quinine and subsequently inoculated into clean mice, with increasing drug doses. At the 
end of the fifth passage, the drug dose had been raised to 100 mg/kg. However, the 
parasites did not appear to respond well to further increases in drug dose over the next 4 
weekly passages (Figure 6). These parasites were tested for quinine resistance; both 
treated lines A and B did not show signs of decreased susceptibility to quinine when 
compared to the control unselected parasites, and for this reason, the selection attempts 
on this clone were discontinued. 
3.5.2 Selection from AS (15C0) 
The initial drug tests carried out on AS (15 CQ) showed that this clone presented a slight 
degree of quinine resistance (Table 6). For this reason, attempts were made to select this 
clone for high quinine resistance. Parasites were treated with 100 mg/kg quinine for 4 
days. The parasites that survived this treatment were passaged and the dose was 
increased to 150mg/kg. However, after a further 5 passages under drug pressure there 
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were no detectable signs of increased resistance, the dose for treatment remaining the 
same. At this stage, treatment was altered from a 4 day regime to continuous daily 
drugging. However, it was not possible to increase drug doses, and after 15 weekly 
passages under quinine pressure, selection was discontinued (Figure 7). 
3.5.3 Selection from AJ 
AJ parasites appeared to respond well to increasing drug concentrations as the quinine 
dose was elevated from 50 to 150mg/kg only after 3 weekly sub-inoculations. However, 
after 3 further passages there was no increase in dose (Figure 8). At this stage, (6th 
passage under drug pressure) treated lines were tested for signs of decreased quinine 
susceptibility, by comparison with untreated lines. However, the selected lines did not 
appear to have acquired increased tolerance to quinine. These experiments were thus 
discontinued. 








Figure 6 - Attempts to select quinine resistance in P. chabaudi AS (sens) 
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Figure 7- Attempts to select quinine resistance in P. chabaudi AS (15CQ) 
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Figure 8- Attempts to select quinine resistance in P. chabaudi AJ 
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3.6 Summary of Chapter III 
No quinine-resistant clone was selected through quinine pressure alone. However, it was 
observed that the mefloquine resistant parasites P. chabaudi AS (15MF) were also 
quinine-resistant as well as chloroquine-resistant. Therefore, the analysis of the gene(s) 
involved in resistance to the three drugs could be performed using the P. chabaudi AJ x 
AS (1 5MF) genetic crosses already available in this laboratory. 
The detailed analysis of the AJ x AS (15MF) genetic crosses is considered in the next 
chapter (CHAPTER IV). 
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CHAPTER IV 
Analysis of the P.chabaudi A.! x AS (15Mfl and AJ x AS (3000) genetic crosses 
4.1 P. chabaudi AS (15MF) has an extra copy of the pcmdrl gene 
Before the present work was initiated, a mefloquine-resistant parasite, P. chabaudi AS 
(15MF) had been selected from the mefloquine-sensitive clone, P. chabaudi AS (I5CQ). 
Karyotypic analysis of both parasites revealed differences in chromosome size 
distribution (see Figure 9). Chromosome 4 appears to be missing in AS (15MF) and a 
new larger band appears, which is absent in AS (15CQ) and AJ (see Figure 9). Due to 
the fact that amplification of pfindrl gene had been related to mefloquine resistance in P. 
falciparum (Peel et al., 1994, Cowman et al., 1994), the role of the P. chabaudi 
homologue (pcmdrl) in these karyotype changes was investigated. 
The pcmdrl gene is present as a single copy on chromosome 12 in all P. chabaudi 
mefloquine-sensitive parasites. Southern blot analysis of pulsed-field gels, where 
pcmdrl and chromosome 4 specific probes were used, indicated that in the mefloquine-
resistant parasites, AS (15MF), a 400 kb section chromosome 12 containing the pcmdrl 
gene, had been duplicated and transposed onto chromosome 4 (Carlton et al, 
unpublished). This had caused a significant increase in size in chromosome 4 of AS 
(15MF), which now migrated as a much larger band between chromosomes 7 and 8. 
This "new chromosome" 4, containing a section of chromosome 12 which includes the 
pcmdrl gene, has been termed chromosome 4/12 (Canton et al, unpublished) (see 
Figure 9). 
Also, previous to my study, two genetic crosses had been performed between P. 
chabaudi AS (15MF) and the genetically unrelated parasite P. chabaudi AJ. The data 
arising from the analysis of these genetic crosses is presented in this chapter. 
Throughout CHAPTER IV I will: 
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• describe the progeny clones that I have produced from this cross, 
• determine and compare the mefloquine, quinine and chloroquine responses of the 
cloned progeny, 
• establish how the inheritance of the pcindrl gene duplication relates to mefloquine, 
chioroquine and quinine resistance among these clones, 
perform linkage analysis on the cloned progeny, 
present results of work on another cross, between AJ and the high chloroquine-








Figure 9- Pulsed-field gel of mefloquine- sensitive [AJ, AS(15CQ)] and mefloquine- 
resistant [AS(15MF)] P. chabaudi with corresponding Southern blot hybridised 
with pcindr]. (note I) absence of chromosome 4 in AS (I5MF), but presence of large chromosome 
(4/12) in this clone: 2) hybridisation of perndrl to chromosome 12 and 4/12) 
4.2 Description of the A.I x AS (15MF) genetic crosses 
• Two parallel crosses, A and B, had already been made in this laboratory between P. 
chabaudi AJ and AS (I5MF), previous to this work, by methods described before 
(section 1 .5). The progeny of these crosses A and B, developed as sporozoites in 
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two different populations of A. stephensi mosquitoes, which were used to infect mice 
(Al, A2, A3 orBi, B2)(Figure 10). 
• The uncloned progeny of these crosses were given different designations according 
to the mouse upon which mosquitoes carrying the sporozoites of the cross had fed 
(Figure 10). In this way, Al, A2 and A3, denote three uncloned parasite populations 
that yielded blood forms which could be frozen down for subsequent cloning; B 1 
and B2 result from cross B. Subsequently, each of these uncloned parasite 
populations was removed from the deep-freeze and either left untreated or treated 
pyrimethamine and/or mefloquine prior to cloning. 
• It was observed that the parent clone P. chabaudi AS (15MF) could not be 
transmitted through mosquitoes on its own. Mosquito dissections made ten days after 
blood feeds showed oocysts to be present in mid-guts of both AJ and AS (15MF) 
parasites. However, AS (15MF) oocyst-infected mosquitoes did not produce 
infections in mice (Figure 10). It is not known whether these mosquitoes carried 
sporozoites, since no observation of salivary glands was done prior to blood feeds. 
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AJ• 	 AS(1SMF) 
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Figure 10- Schematic representation of the AJ X AS (15MF) genetic crosses (Untr - untreated; pyr - pyrimethamine treated (10mg/ kg 
for 4 days); MF - mefloquine treated (5mg/ kg for 4 days); pyr+MF - treated with pyrimethamine and mefloquine, subsequently) 
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4.3 Cloning of the A.J x AS (15MF) proenv 
Several cloning experiments were performed with the uncloned progeny of both crosses 
A and B outlined above, by the limiting dilution technique described previously (section 
2.1.7). In this way, progeny clones were obtained, which originated from Al, A2, A3, 
B 1 or B2 uncloned parasites. These are represented in the table below, 
Al 	A2 	A3 	BI 	B2 









----I 	 _j 	 I, 
 
61 clones total 
Table 7 - Origin of the clones obtained from crosses A and B (nd - not done) 
4.4 Karyotypic analysis of the cloned progeny 
Pulsed-field gels (PFGs) were prepared to determine the karyotypes of progeny clones. 
Parasites exhibiting both parental forms were considered as mixtures and thus 
disregarded from further studies. 
In order to simplify the analysis and understanding of these results, choromosome 4 has 
been renamed 4/12 in AS (15MF), since in these parasites this is a "hybrid chromosome" 
carrying a segment of chromosome 12, containing the extra copy of the pcmdrl gene 
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(section 4. 1). Figure 11 is an example of a PFG, showing progeny clones exhibiting 
different parental karyotypes. Note that all progeny clones shown in this example have 
inherited the parent AJ karyotype (12), except clones 731/12 and 640/14, which present 
the AS (I5MF) karyotype (4/12). 
Notice that large molecular weight chromosomes tend to migrate together (for separation 
























l ' -) 
Figure 11- PFG showing progeny clones with different karyotypes 
(top of the picture- clone name; left of the picture - chromosome number) 
4.4.1 Southern hybridisation of PFGs 
Hybridisation of radio-labelled perndrl gene fragment (Carlton, 1996) and a 
chromosome 4 specific probe (P9) to PFG blots was carried out on all AJ X AS (15MF) 
progeny clones. The results are shown in Figures 12a, 12b and 12c and details are 
summarised in Table 8. 
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The main findings of this analysis are summarised as follows: 
• PFGs and Southern blot hybridisation of AJ and AS (15MF) confirm previous 
results, where AJ has a single copy of the pcmdrl gene on chromosome 12, while 
AS (15MF) carries an additional copy, which has been translocated onto 
chromosome 4. 
• There is a distribution of both AJ and AS (15MF) karyotypes among the progeny 
clones. 
• AJ-type karyotypes tend to be found in progeny clones which have been untreated 
prior to cloning, while AS (15MF) karyotypes are more frequent among those clones 
which have been obtained after drug treatment: 
Treatment prior to cloning AJ karyotype AS (15MF) karyotype 
Untreated 	 16 	 0 
Pyrimethamine+Mefloquine 	4 	 23 
• The only other evidence of differently sized chromosomes among the progeny, was 
observed that in some clones chromosomes 5 and 6 migrated together. 
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Table 8 - 
Clone Cross Treatment Karyotype 
388/12 
388/13 A2 P ND 
396111 A4 PM 4/12 
39716 A3 PM 4/12 
411/8 A2 P 4 
440/5 Al PM 4 
440/8 Al PM 4/12 
440/9 Al PM 4 
440/10 Al PM ND 
440111 Al PM 4/12 
440/I5 Al PM 4 
431/11 Al PM 4 
442/1 A2 PM 4/12 
442/3 A2 PM 4/12 
442/9 A2 PM 4/12 
44314 A2 PM 4/12 
433/6 A2 PM 4/12 
443/8 A2 PM 4/12 
445/12 A2 PM 4/12 
449/9 Al P 4 
45018 Al P 4 
45316 Al P 4 
638/4 A3 P 4/12 
638/12 A3 P 4/12 
638/13 A3 P 4/12 
638/15 A3 P 4/12 
639/8 A3 P 4/12 
639/9 A3 P 4/12 
640/12 A3 P 4/12 
640/14 A3 P 4/12 
642/2 B2 PM 4/12 
64217 82 PM 4/12 
634/13 82 PM 4/12 
6111/6 BI U 4 
681/14 BI U 4 
683/10 HI U 4 
68413 BI U 4 
684/14 BI U 4 
688/6 82 P 4 
688/8 82 P 4 
731/12 HI M 4/12 
1016/11 	 Al 
P. chabaudi A.l x AS (15MF 
P 	 4 
) nroenv clones with co rresponding 
karyotypes Untr - untreated. PY - pyrinietharnine treated (10mg/ kg for 4 days); mf - mefloquine 
treated (5mg/ kg for 4 days); pyr+mf - treated with pyrimethamine and mefloquine, subsequently) 
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- - 	- 
00  : 	:3 
4/12 
4 
Figure 12a - PFG displaying 
karyotypes from several AJ X 
AS (15MF) progeny clones 
ip of the picture - clone 
nttne: left - chromosonie 




4/12 	 I Figure 121) - l'l(; Southern blot hybridised with pcmdrl 
radiolabelled probe 
* 
Figure 12c - PFG Southern blot 
hvbridised 	with 	P9 
omosome 4-specific probe)  
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4.5 Meflouuine resistance tests 
RFLP (Restriction Fragment Length Polymorphism) analysis was performed on all 
clones described above, which allowed identification of 16 independent recombinant 
groups (section 4.11.2). The mefloquine response of clones representing each of the 
recombinant groups was determined. The following clones were chosen for this 
experiment, 
Clone Recombinant Derived from cross Treatment prior to cloning 
group progeny (pyr - pyrimethamine; MF - 
mefloquine) 
388/12 1 A2 pyr 
396/11 2 A3 pyr+MF 
411/8 3 A2 Pyr 
440/5 4 Al pyr+MF 
440/8 5 Al pyr+MF 
440/9 6 Al pyr+MF 
441/11 7 Al pyr+MF 
442/9 8 A2 pyr + MF 
449/9 9 Al Pyr 
450/8 10 Al Pyr 
453/6 11 Al Pyr 
638/4 12 A3 Pyr 
640/14 13 A3 Pyr 
644/13 14 B2 pyr+MF 
731/12 15 Bi MF 
1016/11 16 Al Pyr 
The detailed results from these drug tests are shown in appendix I. Table 9 is a compiled 
simplification of the results from these tests. 
The principal results are as follows: 
. Three levels of mefloquine-sensitivity were detected among the cloned progeny: 
sensitive, low-resistant and resistant. Sensitive denotes a mefloquine response equal 
to that of the sensitive parent of the cross, P. chabaudi AJ; resistant reflects a 
mefloquine-resistant phenotype similar to that of the resistant parent, AS (15MF); 
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low-resistant refers to a mefloquine response that is intermediate between AJ and AS 
(15MF) 
























Table 9 - Mefloquine responses of the cloned progeny of 
the AJ x AS (15MF) genetic cross 
(MeJR - mefloquine response; S - sensitive; lowR - low resistant; R - 




















4.5.1 Meflopuine responses of progeny clones and their relationship to ycmdrl 
The relationship between the duplication and translocation of the pcmdrl gene and 
mefloquine resistance was investigated. The principal findings were as follows (Table 
10) 
a) Five clones were mefloquine-resistant, and contained duplicated pcmdrl, on 
chromosome 12 and 4/12. 
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Six clones were mefloquine-sensitive and had only a single copy of pcmdrl 
(chromosome 12). 
Pc,ndrl duplication is linked with parental mefloquine phenotypes in 12/16 progeny 
clones. The exceptions were as follows, 
. One clone (440/5) was mefloquine-resistant at the same level as the resistant parent 
AS (15MF), but had only one copy of pcindrl on chromosome 12. This clone was 
tested 4 times for mefloquine resistance for full confirmation of the phenotype; the 
results were consistent throughout. 
• Two of the recombinant progeny clones (396/I1 and 441/11) carried two copies of 
the perndrl gene but were resistant to mefloquine only to a low level 
• One of the progeny clones, 1016/I1, displayed low mefloquine resistance, even 
though it had only one copy of the perndrl gene. 















441/I1 - 	- 
AS(I5MF) 
Resistant 








Table 10 - \lclloquine sensitivity phenotypes of AJ x AS (15MF) progeny clones, 
and its relation to pcindrl duplication 
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4.5.2 Further characterisation of progeny clone 440/5 
As described above, progeny clone 440/5 was mefloquine-resistant at the same level of 
AS (ISMF), but contained only one copy of pcmdrl on chromosome 12. 
It was thought that this could be due to 440/5 being a mixture of sensitive and resistant 
clones, in which the resistant clones containing the perndrl duplication were present in 
such small numbers, that they could not be detected by PFG and Southern hybridisation 
with pcmdrl. If this were the case, it would be possible that after mefloquine treatment, 
this "invisible" population of resistant parasites would be selected, leading to the 
mefloquine resistant phenotype observed. This was investigated as follows, 
4.5.2.1 Mefloguine selection 
Deep-frozen P. chabaudi 440/5 parasites were thawed and injected into one mouse, from 
which two parallel lines were derived subsequently: one of the lines was treated with 
mefloquine and the second was left untreated. PFG blocks were prepared from both 
untreated parasites, and from those which survived mefloquine treatment (Figure 13). 
440/5 in liquid N, 
'or 
I mouse 
2 mice 	 2 mice 
Mefloquine treatment 
Untreated parasites 	Mefloquine selected parasites 
'or 'or 
PFG blocks 	 PFG blocks 
Figure 13 - Method for the characterisation of P. chabaudi 440/5 






4.5.2.2 Karyotype analysis of P. chabaudi 440/5 before and after meflopuine 
treatment 
PFGs were prepared from both untreated and mefloquine-treated lines. Subsequently, 
Southern blots were made from these gels and hybridised with the pcmdrl and P9 gene 
probes. The results showed that no duplicated perndrl was present before or after 
treatment. Figures 14a and 14b show the karyotype and the corresponding southern blots 
of 440/5 parasites before and after treatment. 
Figure 14a - AS (15MF) and 440/5 	Figure 14 b - PFG southern blot of 
before and after mefloquine AS (15MF) and 440/5 before and 
treatment 	 after mefloquine treatment. 
Probed with pcindrl 
[b.m.t - before mefloquine treatment; a.m.t - after niefloquine treatment (5mg/kg, 4 days); 4 - 
chromosome 4; 12 - chromosome 4/12; 12 = chromosome 121 
4.6 Studies on perndrl levels of mRNA expression among the progeny clones 
The transcript levels of pcmdr] were studied in both parents of the cross and in some 
progeny clones by Northern blot analysis (section 2.4). This was done in order a) to 
determine whether perndrl duplication is invariably accompanied by over-expression 
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and b) to examine whether the progeny clone, 440/5, with the non-parental combination 
of drug resistance and pcmdrl duplication could be correlated with differences in levels 
of expression of the pcmdrl gene. 
It was observed that the duplication of the pcmdrl gene appears to be accompanied by 
an increase in the level of RNA expression (see Figure 15); note specifically that clone 
440/5 that is highly resistant to mefloquine, does not show increased expression of the 
pcmdrl gene. These observations suggest that the exceptions noted in the linkage 
between pcmdrl duplication and the mefloquine resistance phenotype among the 
progeny clones, cannot be explained by atypical expression of the gene. 
.4 3Q57 	Abod1k, -*L 	*.. -_-- •r* _T 
Figure 15 - Northern blot of progeny clones hybridised with pcmdrl and ribosomal 
Ag3057 radiolabelled gene probes (top; clone designation; photograph top - Northern blot of 
progeny clones hybridised with radiolabelled pcmdrl gene probe; photograph bottom - same Northern 
blot, stripped and hybridised with ribosomal control gene probe Ag3057). 
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4.7 Summary of the mefloguine responses and ycmdrl 
• Three levels of mefloquine resistance have been detected among the progeny clones. 
• 	There is high linkage between mefloquine responses and the duplication of the 
pcmdrl gene (11/15) with the exception of four clones. 
• These exceptions cannot be explained by atypical expression of the pcmdrl gene. 
4.8 Tests for quinine response 
Since P. chabaudi AS (1 5MF) proved to be quinine resistant, progeny clones of the AJ x 
AS (I5MF) cross were tested for their response to quinine to investigate a) whether 
quinine and mefloquine resistance were correlated among the cloned cross progeny, b) 
to examine for possible linkage between the perndrl gene and quinine resistance, and c) 
to map other gene(s) potentially involved in quinine resistance 
4.8.1 quinine responses of the cloned progeny 
The main observations from the quinine drug tests were as follows (Table 11, appendix 
I): 
• Three levels of quinine-sensitivity were detected among the progeny clones-
sensitive, low-resistant and resistant. 
• 13/15 clones showed an inverse relationship between mefloquine and quinine 
responses. 
• Only one clone, 453/6, was sensitive to both mefloquine and quinine 
• No clones were as resistant to both drugs simultaneously as in the parent AS 
(I 5MF). However, one clone, 440/5, was resistant to both drugs, although at a low 
level for for quinine. 




AJ S S 
AS (I5CQ) S LowR 
AS(I5MF) R R 
PROGENY 
388/12 S R 
411/8 S R 
440/9 S R 
449/9 S R 
450/8 S R 
453/6 S S 
396/11 lowR S 
441/11 IowR S 
1016/11 IowR S 
440/5 R LowR 
440/8 R S 
442/9 R S 
638/4 R S 
644/13 R S 
731/12 R S 
640/14 nd nd 
Table 11 - Quinine and mefloquine 
responses of the cloned progeny of the AJ x 
AS (15MF) genetic cross 
(MeJR - mefloquine response; S - sensitive; lowR - 
low resistant; R - resistant; nd - not determined) 
4.8.2 Quinine responses of progeny clones and their relation topcmdrl 
The relationship between the duplication and translocation of the pcmdrl gene and 
quinine resistance was investigated. The principal findings were as follows (Table 12) 
. 12/15 clones showed linkage between the pcmdrl copy number and quinine 
responses, with seven clones carrying two copies of the gene being quinine-sensitive 
and five carrying one copy being resistant. The exceptions are as follows: a) clones 
453/6 and 10 16/11 contain a single copy of pcmdrl but are quinine-sensitive and b) 
clone 440/5 does not contain the duplication, but is slightly resistant to quinine. 
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Clone 	I pcmdrl duplicated? 	QuinR 
PARENTS 
AJ no S 
AS (I5CQ) no lowR 
AS (15MF) yes R 
PROGENY 
388/12 No R 
411/8 No R 
440/9 No R 
449/9 No R 
450/8 No R 
453/6 No S 
396/I1 Yes S 
441/11 Yes S 
1016/11 No S 
440/5 No LowR 
440/8 Yes S 
442/9 Yes S 
638/4 Yes S 
644/13 Yes S 
731/12 Yes S 
640/14 Yes nd 
Table 12 - Quinine responses of the AJ x AS (15MF) progeny clones and their 
relationship to pc,ndrl. (QuinR - quinine response: S - sensitive; lowR - low resistant; R - 
resistant: nd - not determined) 
4.9 Tests for chLoropuine response 
Since P. chabaudi AS (1 5MF) proved to be chioroquine resistant, progeny clones of the 
were also tested for their response to chloroquine to investigate a) whether chloroquine, 
quinine and mefloquine resistance were correlated among the progeny clones, b) to 
examine for possible linkage between the pcmdr] gene and chloroquine resistance and 
c) to map other genes involved. 
4.9.1 Chloroguine responses of the cloned progeny 
The main observations from the chloroquine drug tests can be summarised as follows 
(Table 13, appendix I): 
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• There appear to be three levels of chloroquine-sensitivity among the cloned progeny 
as six clones were chloroquine-sensitive, four displayed very low levels of resistance 
and five were resistant only to a low level. 
• None of the progeny clones demonstrated the same level of chioroquine resistance as 
that of the AS (1 5MF) parent. 
• There is no evident association of chloroquine and mefloquine or quinine resistance. 
Clone MefR QuinR CQR 
PARENTS 
AJ S S S 
AS(I5CQ) S LowR R 
AS(I5MF) R R R 
PROGENY 
388/12 S R LowR 
411/8 S R LowR 
440/9 S R S 
449/9 S R S 
450/8 S R LowR 
453/6 S S S 
396/11 lowR S S 
441/11 lowR S V.lowR 
1016/I1 lowR S Nd 
440/5 R LowR V.lowR 
440/8 R S V.lowR 
442/9 R S LowR 
638/4 R S S 
644/13 R S S 
731/12 R S V.lowR 
640/14 nd nd nd 
Table 13 - Chloroquine, quinine and mefloquine responses of the cloned progeny of 
the AJ x AS (15MF) genetic cross 
(MeJR - mefloquinc response; QuinR - quinine response; CQR - chloroquine response; S - sensitive; 
V.lowR - very low resistance; lowR - low resistant; R - resistant; nd - not determined) 
The relationship between the duplication and translocation of the pcmdrl gene and 
chloroquine resistance was investigated. There appears to be random segregation 
between chioroquine resistance and the pcmdrl gene duplication (Table 14). 
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Clone 	I pcmdrl duplicated? 	CQR 
PARENTS 
AJ no S 
AS (15CQ) no lowR 
AS (I5MF) yes R 
PROGENY 
388/12 No LowR 
411/8 No LowR 
440/9 No S 
449/9 No S 
450/8 No LowR 
453/6 No S 
1016/11 No Nd 
440/5 No V.lowR 
396/11 Yes S 
441/11 Yes V.IowR 
440/8 Yes V.IowR 
442/9 Yes LowR 
638/4 Yes S 
644/13 Yes S 
731/12 Yes V.lowR 
640/14 Yes Nd 
Table 14 - Chioroquine sensitivity of the AJ x AS (15MF) progeny clones and its 
relation topcmdrl. (CQR - chioroquine response; S - sensitive; V.lowR - very low resistance; lowR 
- low resistant; R - resistant; nd - not determined) 
4.10 Summary of the results of mefloquine, chioroquine and quinine tests on the 
cloned pro2eny, and their relationship to perndrl. 
Three levels of mefloquine response were detected among the cloned progeny. These 
appeared to be highly linked to perndr] copy number, where AJ parental-type 
mefloquine-sensitive clones have only one copy of the gene and fully resistant ones, AS 
(1 5MF)-type, have two. However, there were four exceptions. 
Quinine responses could also be classified into three different levels. There was a high 
inverse association between quinine and mefloquine resistance and consequently 
between perndri copy number and quinine responses. 
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Chioroquine resistance profiles were also catalogued in three different categories. There 
were no apparent correlations between chioroquine resistance and either mefloquine or 
quinine responses. Chloroquine resistance was not related to pcmdrl copy number. 
In order to investigate the incomplete associations between mefloquine responses and 
the number of copies of the pcmdrl gene and to map genes involved in chloroquine and 
quinine resistance, linkage of other genetic markers was carried out on the cloned 
progeny. The results are described in the next sections. 
4.11 Genetic analysis of the progeny clones 
Restriction Fragment Length Polymorphism (RFLP) analysis of the genetic markers of 
all the progeny clones was carried out by the methods described previously (section 
2.3.2). This was done in order to: 
identify parasite mixtures among the progeny, which could be removed from further 
studies 
. detect unique recombinant groups among the progeny of the cross 
. allow linkage analysis between genetic markers and drug responses 
4.11.1 Example of a RFLP and identification of parasite mixtures 
Figures 16a and 16b show an example of the RFLP patterns for a genomic Hinf I digest, 
hybridised with a radiolabelled Ag 3027 polymorphic probe. 
A mixture is identified through RFLP analysis when a progeny clone exhibits both 
parental alleles, AJ and AS (1 5MF), of a given polymorphic genetic marker. Note that 
clone 440/10 is actually a parasite mixture since it presents both parental bands of Ag 
3027 
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Figure 16b - Hinf I Southern 
Blot probed with Ag 3027 
[first column - AJ RFLP; second 
column - AS (I 5MF) RFLP; remaining 
colums - progeny clones; note 
that clone 440/10 is actually a parasite 
mixture since it contains the RFLP 
from both parents AJ and AS (I 5MF)] 
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4.11.2 Number of independent recombinants among the progeny 
In the same way described as previously, fourteen RFLPs (Carlton et al. 1998) were 
analysed in the cloned progeny (Table 15). On the basis of these results, the clones could 
be classified into 16 unique recombinant groups. Each clone in a group showed identical 
patterns of parental markers, and arose through sampling of a limited number of 
independent clones. 
None of the progeny clones appeared to have the same genotype as the AS (I5MF) 
parent, whereas seven presented pure AJ genotypes. Note also that AS (15MF) did not 
successfully propagate through mosquitoes in the parental control of the cross (section 
4.2) 
A representative parasite clone from each of the independent recombinant groups was 
therefore chosen for further studies, shown in Table 15. 
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RFLP marker 





























388/12 A2 P AS AJ AJ AS ND AJ AJ AJ AJ ND ND ND ND AS 1 
8113 \ I 	I ND NI) NI) NI) NI) NI) ND ND ND ND ND NI NI) NI) - 
396/I I A3 PM AJ AS/AJ AJ A) AJ AS AJ AJ AS NI) NI) Ni) NI.) AJ 2 
397/6 A3 I'M AJ ND AJ AJ AJ AS AJ AJ AS Ni) NI) Ni) Ni) AJ 2 
411/8 A2 I' AS AS A] AS AS AS NI) AJ A] NI) NI) NI) NI) A] 3 
440/5 A1PM AJ AJ AJ A S A S AS ASAJ AS NI) ND ND Ni.) AS 4 
440/8 Al I'M AS .\5/\J AS AS AS AS AS A] AS NI.) NI) NI) NI) A] S 
440/9 Al PM AJ AJ A] AS AS A] AS AS AS NI) ND NI) ND AS 6 
440/10 Al PM AJ ND AJ AS AS AJ AS AS AS ND ND ND ND M 6 
441/5 Al PM AS NI) AS \S AS AS AS A] AS NI) NI) NI) NI) A] 5 
440/11 Al I'M N. AS/A] AS AS AS AS AS A.I AS NI) NI) NI) NI) A] 5 
440/15 Al PM AJ ND A] AS AS AJ AS AS AS NI) ND NI) NI) AS 7 





































441/10 MPM A] Ni) AJ AS AS AJ AS AS AS ND NI) ND Ni) AS 7 
441/11 Al PM AJ ND AJ AS AS A] AS AS AS ND ND ND NT) AS 7 
442/1 A2 I'M AS ND AJ A] !\] NI AS AS AS IN, 1) ND NI) ND A.l 8 
442/3 A2 PM AS ND AJ A] AJ M AS AS AS NI) Ni) ND ND Ai 8 
442/9 A2 PM AS AS/AJ AJ AJ AJ AS ND AS AS ND ND NDND AJ 8 
443/3 A2 I'M AS ND AJ AJ AJ M AS AS AS NI) ND ND ND AJ 8 
443/6 A2 PM AS ND AJ AJ AJ AS AS AS AS NI) NI) ND Ni) AJ 8 
443/8 A2 PM AS ND AJ AJ AJ AS AS AS AS NI) ND ND NI) AJ 8 
445/12 A2 PM AS NI) A] A] A] AS AS AS AS Ni) NI) ND NI) A] 8 
449/9 Al P M AJ AJ AS ND A] AS AS AS ND ND ND ND AS 9 
450/8 Al P AJ ND A] AS AS AJ AS AS AS NT) Ni) ND NI) AS 10 





































638/13 A3 P ND AS ND AS ND AS ND A] Ni) AS ND ND AJ AJ 12 
638/15 A3 P ND AS ND AS ND AS ND AJ ND AS Ni) ND Al AJ 12 
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TA RI F I (continued) 
639/8 A3 P ND AS N) I AS NE) AS ND Al ND AS ND ND AJ Al 12 
639/9 A3 P ND AS ND AS ND AS ND Ai NI) AS NI) ND Al Al 
12 
640/12 A3 P ND AS NI) AS NI) AS ND AJ Ni) AS Ni) NI.) Al Al 
12 
640/14 A3 P ND AS/Al ND AS NI) AS ND Al NI) AS ND Nil) AJ Al 13 
642/2 132 PM NI) AS/AJ ND AS NI) AS ND AS NI:) AS ND NI.) AJ AJ 
14 
642/7 132 I'M ND ASIAJ ND AS NI) AS ND AS Ni) AS NI) NI) AJ Al 14 
644/13 82 PM ND AS/AJ ND AS ND AS ND AS ND AS ND NI) AJ AJ 14 
681/6 B! U AJ ND ND N[) ND AJ Ni) AJ Al AJ AJ Ai ND ND AJ 
681/14 BI U Al ND ND ND ND AJ ND AJ AJ AJ AJ AJ ND ND AJ 
683/10 B) U AJ NE) NI) ND ND Al ND AJ AJ AJ ND AJ ND ND AJ 
684/3 BI U AJ ND ND ND ND AJ ND AJ Al AJ ND AJ ND ND AJ 
684/14 BI U AJ ND ND ND ND AJ ND AJ AJ AJ AJ AJ ND ND AJ 
688/6 132 P Al NI) ND NI) NI) Al ND Al A.J A.! A.! Al Ni) ND  AJ  
688/8 132 P Al NI) N) NI) N) Al N) Al A.I \ 2 ND '.1 
731/12 131 M AS ND ND ND Ni) Al ND Al AS Al AS Al ND Ni) 15 
1016/11 Al P I 	ND ND ND ND ND ND ND ND Nil) ND ND ND NE) Ni) t 16 
Ial)Ie 1 - independent recombinant groups of the AJ x AS (l5iF) genetic CrOSS 
(R.G. - recombinant group; ND - not determined; cross - origin of the cross; drug - drug used to treat mice prior to cloning i.e., U - untreated, P - I 
pyrimetharninc treated; PM - treated with pyrimethamine and mefloquine subsequently) 
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4.11.3 Genetic markers and resistance to mefloquine, quinine and chloroquine 
Table 16 presents the compiled results of the analysis of polymorphic genetic markers 
and resistance to the drugs under study. Although no statistical analysis was done to test 
the significance of the linkage, due to the limited number of RFLPs studied, some of 
these preliminary results deserve some attention. 
4.11.3.1 Mefloquine resistance 
pcmdrl duplication correlates highly with mefloquine resistance as expected 
(linkage ratio 12/15) and this result is further confirmed by the linkage between the 
gene's RFLP and mefloquine responses: mefloquine linkage ratio 8/10. 
4.11.3.2 Chloroquine resistance 
• There also appears to be linkage between a chromosome 11 specific probe (PCNA) 
and chioroquine resistance (chloroquine linkage ratio 8/11). These observations can 
be separated into two results considering that two levels of chloroquine resistance 
are found among the progeny clones: very low resistance - chloroquine linkage ratio 
2/4: low resistance, 6/7. 
4.11.3.3 Ouinine resistance 
• Three chromosome 14 specific probes, pccrt, R102 and Ag 3040, seem to show 
some degree of linkage to quinine resistance: quinine linkage ratio 7/9 for pccrt; 6/8 
for R102 and 11/13 for Ag 3040. 
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Probe 	C 388 396 411 440 440 441 449 45() 440 442 453 638 644 731 1016 ME CQ QN 
name - 12 11 8 9 5 II 9 8 8 964 13 12 11 linkage linkage linkage  
CQres. LR S LR S VIR \LR S LR VIR IR S S S VIR ND 
MEres. S LR S S R JR S S R R S R R R LR 
QNres. R S R R LR S R R S S S S S S S _____ 
Cross A2 A A2 .\I Al Al Al Al Al A2 Al A 112 01 Al 
Treatment P P)l P l'I PM I\1 P 1 1 PM I'M P I' PM \l P 
mdrdnpl. J S J .1 1 5 J S S J S S S J 11/15 8/14 2/15 
Ag3003A J J? S S S S 5 .1 S S 1 S J ND 6/14 6/14 6/14 
1 119 4 J S J S S S S S S S S NI) NI) S ND 9/12 5/12 4/12 
Ag3024 5 J S S J J J J .1 S S J S S J ND 9/13 6/13 3/12 
RESA 6 J I J J J J J I S ND J NI) NI) ND ND 8/10 6/10 4/10 
Ag3027 ') S I I S S S S S J J S NI) J ND ND 4/12 5/12 7/12 
PCNA II S I S J i I ND I S S J NI) ND S NI) 6/I1 S/Il 7/I1 
Pcmdrl 1 2 J IS S J J NO J NI) JS JS ND S S ND ND 8/10 7/10 4/10 
Ag3040 14 S I S S S S S S S J I S S ND ND 6/12 7/12 11/13 
J)ccr(* 14 S I S S ND NI) S ND ND i S I ND S ND 2/10 5110 7/9 
R102 4 ND .1 S S S S ND S S J ND NI) NI) ND Ni) 7/I1 8/11 6/8 
R104 1$ J I ND S S S S S S ND S NI) ND ND ND 5/9 3/9 3/8 
Table 16 - Linkage between genetic markers and drug resistance 
(top row - progeny clones; rows 2 to 4 From top show Ihe drug response of each of the progeny clones (S - sensitive; VLR - very low resistant; LR - low 
resistant; R - resistant; ND - not determined); rows 5 and 6 refer to the cross origin and treatment of the progeny prior to cloning (P - pyrimethaniine; M - 
mefloquine; PM - pyrimethamine followed by mefloquine); rows 8 to 19 display the name of the genetic probe producing a RFLP between AJ and AS 
(I5MF) (J - AJ-type RFLP; S - AS-type RFLP, ND - not determined); 2 column from left indicates the chromosome in which each of the genes are 
contained; the three columns on the far right present the linkage ratio corresponding to each of the genetic probes (CQ - chloroquine; MF - mefloquine; 
QN —quinine)j 
* the peer! RFLP was determined by Paul Hunt in this laboratory 
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4.12 Analysis of the A.! x AS(30C0) genetic cross 
4.12.1 Cloning experiments from the A.! x AS (3000) genetic cross 
Several cloning experiments were carried out from the uncloned progeny of the AS (30 
CQ) x AJ cross. This was aimed particularly at performing linkage analysis that would 
allow to detect genes accountable for both high and intermediate chioroquine resistance. 
In addition, since it has been observed that AS (30CQ) is also quinine resistant, (Padua, 
1980) these studies may also provide important information in uncovering genes 
responsible for increased parasite tolerance to quinine. 
4.12.2 Clones obtained 
The uncloned progeny of the cross was either left untreated or it was submitted to 
chloroquine or quinine treatment. Untreated parasites and those that survived treatment 
were cloned as previously described (2.1.7). In this way, 38 clones were produced 
(Table 17). 
untreated 	CQ treated QUIN treated CQ + QUIN Total 
progeny progeny 	progeny 	treated 
progeny 
n.of 	16 	 9 	 4 	 9 	38 
clones 
Table 17 - Clones from AJ x AS (30CQ) genetic cross 
(CQ treated progeny - 5mg/k g, 6 days; QUIN treated progeny - 200mg/kg quinine, 4 days; CQ + QUIN - 
treatment with chioroquine, followed by quinine) 
4.12.3 Southern blots 
DNA was extracted from all clones as previously described (2.3.2.1) and its 
concentration calculated by comparing band intensities between each clone and A. 
molecular weight markers on an agarose gel. Genomic digests were set-up (section 
2.3.2.2), electrophoresed on an agarose gel and blotted as previously described (2.3.2.3). 
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In this way, 22 of 38 clones have already been digested with Rsa I, Hindu, Eco RI, 
Hinfi, DraT, Hindill, and the resulting gels, blotted. 
4.12.4 Detection of RFLPs 
Each Southern blot was hybridized with a probe already known to detect a 
polymorphism between AS (30CQ) and AJ (Carlton et al., 1998). In this way it was 
possible to ascertain which of the parent alleles had been inherited by each of the clones 
that resulted from the cross which is being presently analysed. Some of the clones have 
already been analysed for a number of RFLPs and the results are illustrated in Table 18. 




787/2 CQ+Q AS Al nd Al Al AS Al nd AS Al nd nd 
787/1 CQ+Q AS Al Nd Al Al AS Al Nd AS Al Nd Nd 
788/7 CQ+Q Al Al Nd nd AS Al AS Nd Al AS Nd Nd 
788/1 CQ+Q Al AJ Nd nd AS Al AS Nd Al AS Nd Nd 
89/10 CQ+Q AS Al Nd Al AS Al AS Nd AS Al Nd Nd 
790/5 ('Q+Q AS Al Nd nd AS nd nd Nd AS Al Nd Nd 
790/6 CQ+Q AS Al Nd Al AS Al M Nd AS Al Nd Nd 
790/8 CQ+Q nd Al Nd nd AS nd nd Nd AS Al Nd Nd 
790/9 CQ+Q AS Al Nd Al AS Al M Nd AS Al Nd Nd 
803/2 CQ Al Al Nd Al AS Al AS Nd Al AS Nd Nd 
804/4 CQ Al Al Nd Al AS Al AS Nd Al AS Nd Nd 
804/5 CQ Al Al Al nd nd nd nd Al nd Al Al Al 
804/9 CQ Al Al Al Nd Nd Nd Nd Al Nd AS Al Al 
805/2 CQ AS Al AS Nd Nd Nd Nd AS Nd Al Al Al 
805/6 CQ Al Al Al Nd Nd Nd Nd Al Nd AS Al Al 
805/1 CQ Al Al Al Nd Nd Nd Nd Al Nd AS Al Al 
816/1 tint Al Al Al Nd Nd Nd Nd Al Nd Al Al Al 
816/2 tint nd Al Al Nd Nd Nd Nd nd Nd Al AS Al 
816/7 Urn Al AS Al Nd Nd Nd Nd AS Nd AS Al AS 
816/1 Unt Al Al Al Nd Nd Nd Nd Al Nd Al Al Al 
818/1 Urn Al AS M Nd Nd Nd Nd Al Nd AS AS AS 
818/2 	tint 
Table 18 - 
Al 	Al 
RFLPs analysed 
Al 	Nd 	Nd 	Nd 	Nd 	I 	Al 	I Nd 	I AS 	Al 	Al 
in the AJ x AS (3000) nroenv 
[1st column on the left represents the different clones being studied. 2nd column shows the treatment 
before cloning (Unt- untreated, CQ- chioroquine treated, Q- quinine treated). Top row shows the probe 
used to determine RFLPs. AJ- AJ parental type; AS- AS parental type; M- mixture; nd- not determined.] 
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4.12.5 Independent recombinant groups 
RFLP analysis on this genetic cross has allowed the identification of 7 independent 
recombinant groups (Table 19). Further RFLP analysis of this cross is presently 
underway, along with quinine drug tests on the cloned progeny. 
RFLP 
clone T 3024 3027 3040 Pena 3003A P9 DHFR 3010 pol8 Ag TBP Ag R.G 
3012 3027 
787/2 CQ+Q AS AJ Nd AJ AJ AS AJ rid AS AJ ad rid 1 
787/I CQ+Q AS AJ Nd AJ AJ AS AJ Nd AS AJ Nd Nd I 
788/7 CQ+Q AJ AJ Nd rid AS AJ AS Nd AJ AS Nil Nd 2 
788/1 CQ+Q AJ AJ Nd nd AS AJ AS Nd AJ AS Nd Nd 2 
805/6 CQ AJ AJ AJ Nd Nd Nit Nd AJ Nd AS AJ AJ 2 
805/I CQ AJ AJ AJ Nd Nd Nd Nit AJ Nd AS AJ AI 2 
03i2 (Q AJ Ai Nd AJ AS AJ AS Nd AJ AS Nd Nd 2 
804/4 CQ AJ AJ IN  AJ AS AJ AS Nd AJ AS Nd Nd 2 
804/9 CQ AJ AJ AJ Nd Nit Nd Nd AJ Nd AS AJ AJ 2 
89/10 CQ±Q AS AJ Nd AJ AS AJ AS Nil AS A) N  Nd 3 
790/5 ('Q+Q AS AJ Nd lid AS rid ad Nil AS A) Nd Nd 3 
790/6 CQ+Q AS AJ Nd AJ AS AJ M Nd AS AJ Nd Nd 3 
790/8 CQ-i-Q rid AJ Nd ad AS rid ad Nd AS AJ Nd Nd 3 
790/9 CQ+Q AS AJ Nd A) AS A) NI Nd AS AJ Nd Nd 3 
805/2 CQ AS A) AS Nd N  Nd N  AS N  A) AJ AJ 4 
816/2 Unt ad AJ A.) Nd Nd N  Nd rid Nd AJ AS AJ 5 
816/7 lint AJ AS AJ Nd Nit Nd Nd AS Nd AS AJ AS 6 
818/1 tint AJ AS M Nd Nd Nd Nd A.) Nd AS AS AS 7 
8h.4!5 C() AJ •\J ni ii n lid •\J nj \J A] Al U 
81i/I U111 A) A) AJ IN  Nd Nil Nd AJ Nd AJ A) AJ AJ 
818/2 tint AJ AJ AJ Nd Nd Nd Nd AJ Nd AS AJ AJ AJ 
Table 19 - Independent recombinant groups of the AJ x AS (30CQ) genetic cross 
[1st column on the left represents the different clones being studied. 2nd column shows the treatment 
before cloning (Unt- untreated, CQ- chioroquine treated, Q- quinine treated); AJ- AJ parental type; AS- 
AS parental type: M- mixture; nd- not determined; R.G. - recombinant group] 
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4.13 Summary of CHAPTER IV 
In order to determine whether perndrl duplication is an essential requirement for the 
mefloquine resistance phenotype, we performed two genetic crosses between AS 
(I5MF) and a drug sensitive clone, AJ, which differ in a number of genetic markers. 
Sixteen independent progeny recombinants were produced which were tested for their 
mefloquine-response to determine whether co-segregation of mefloquine resistance with 
pcndrI amplification occurred. There appeared to be a strong correlation between 
mefloquine resistance and duplication of this gene, but there were four exceptions. 
Progeny clones were also tested for their quinine responses, since the mefloquine 
resistant parent of the cross, AS (1 5MF), presented some degree of quinine resistance. A 
negative correlation was found between quinine resistance and pcmdrl duplication in the 
great majority of the cloned progeny. 
There appears to be some degree of linkage between three chromosome 14-specific 
markers, pccrt, R102 and Ag 3040, and quinine resistance. 
The chloroquine response of the progeny clones was assessed, and it was classified into 
four different levels. There appeared to be no correlation between chioroquine resistance 
phenotypes and perndrl copy number. 
There is linkage between a chromosome 11-specific marker, PCNA, and low 
chioroquine resistance. 
The cloned progeny of the crosses presented various degrees of sensitivity to the drugs 
under study. To investigate whether point mutations in the pcmdrl could account for the 
different levels of mefloquine, chloroquine or quinine resistance observed, the gene was 
cloned and sequenced. The results of these experiments are presented in the next 
chapter, CHAPTER V. 
CHAPTER IV - Results 	 104 
CHAPTER V 
CHARACTERISATION OF THE pcmdrl GENE 
The previous chapter (Chapter IV) presented data that pointed to a strong correlation 
between the number of copies of the pcnzdrl gene and mefloquine responses. However, 
this correlation was found to be incomplete, i.e. some of the clones showed an atypical 
association between pcmdrl copy number and the level of mefloquine sensitivity 
(Section 4.5.1). One clone particularly, 440/5, is highly mefloquine-resistant and 
contains only a single copy of the gene. Furthermore, increased expression at the mRNA 
level was not detected in this clone. To investigate if these atypical associations could be 
related to nucleotide point polymorphisms in either copy of pcmdrl, the gene was 
cloned and sequenced. 
Thus, a partial nucleotide sequence was obtained for the perndrl gene, which was 
compared between the different parasite clones under study. This chapter deals with 
these data. I will first elucidate how this sequence was obtained through different 
experimental methods. Second, I will compare the nucleotide sequences of drug-
sensitive and resistant P. chabaudi parasites to check if drug responses may be mediated 
by point polymorphisms in the gene. Finally, I will establish comparisons between the 
pcnidrl gene and pfrndrl, its P. falciparuin homologue. 
5.1 Methods producing nucleotide sequence corresponding to the pcmdrl gene 
The perndrl gene was extended from a partial sequence of the gene comprising 300b.p. 
that was already available from a PCR product, pcATP-PCR (Carlton, 1995). Two 
oligonucleotide primers, perndrl-3 and pcmdrl-8, were designed based on this sequence. 
These were used initially to obtain nucleotide sequence extending both 5' and 3' beyond 
the boundaries of this known sequence, by using a variety of different methods 
described previously (section 2.5.3), using P. chabaudi AS (sens) DNA as template. 
New primers were designed every time new perndrl segments were obtained, based on 
the new nucleotide sequence corresponding to this fragments. These were again used to 
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extend the gene to both 5' and 3' ends, by using template DNA of P. chabaudi AS(sens) 
vectorette, inverse PCR and genomic libraries (described in section 2.5.3). 
A description of all primers producing results in obtaining fragments of the pcmdrl 









in the gene 
(nucleotide 
number) 
Pcrndrl 3 5 CGAGTTGCTA TTGCTAGAGC CC- 3' 61.9 P. chab. 3814-3835 F 
Pc,ndrl-5 5'. GTAGGACCTTATGGAAAAAGC 3' 559 P. chab. 3772-3792 F 
Pcmdrl-6 5' GCUATCAGGTGGTCAAAAAC 	' 55,9 P. chab. 3791-3811 F 
Pc,ndr1-7 5'C'flTCAAATCGTAAAATCCGATCC 	' 576 P. chab. 3371-3394 R 
Pcmdrl-8 5' CGTTCATAGAGGTTGCATTAG 	' 55.9 P. chab. 3467-3487 R 
Pcmdrl-9 5' CTAATGCAACCTCTATGAACG 3' 559 P. chab. 3467-3487 F 
Pcmdrl-10 5' CIII flGACCACCTGATAAGC 	' 55,9 P. chab. 3791-3811 R 
Pcnidr/-J 1 ' CAA11TITCCAUCGTACTCTFGC 	' 57.6 P. chab. 2692-2715 R 
Pc,ndrl-12 5' CGGAGATAAAAAAGATGGATG3' 56.6 P. chab. 2733-2753 F 
Pcmdrl-13 ' AATTGGAGAAAAGGTFGAAAG 	' 54,7 P. chab. 2409-2429 F 
Pcmdrl-14 5' C CCT1T 	' 54.7 P. chab. 1 	2414-2434 R 
Pcmdr/-15 5' GGAGATATfATFGTAAATGATTC 	' 5 1.7 P. chab. 2852-2874 F 
Pcmdrl-16 5' GAATCATTTACAATAATATCTCC 3' 51.7 P. claab. 2389-2412 F 
Pfindrl-17 5'- GGTGGAGATCAAAAATTGG-3' 52.4 P. faic. 1265-1283 F 
Pftndr/-18 5'CCAAT1TVFGATCTCCACC3' 524 P.falc. 1265-1283 R 
Pcrndrl-20 5'. TTCATGGTGAATCCAmCCC 3' 559 P. chab. 1323-1343 R 
Degndr1-21 5'TATGCATTCGG(N)TT(Y)TGGTA(Y)GG 	' 59.8 Deg. 775-797 F 
Pcrndrl -24 ' GAAATCGCTGGGTGAACTCAG 	' 59.8 P. chab. 829-849 R 
Pc,ndrl-25 5' CTGAGTI'CACCCAGCGA'ITFC 3' 598 P. chab. 829-849 F 
Pcmdrl-26 5'. GATTGAGTACTATTCGATATGC 3' 547 P. chab. 1751-1772 F 
Pcmdrl-28 5' GTAACAGTACCCATGCATAAA 	' 56.5 P. chab. 246-266 R 
Pcmdrl-29 5' GTrTATGCATGGGTACTGTFAC 	' 56.5 P. chab. 244-266 F 
Pcmdrl-31 5' GTCATAGATCAAGAGTGAGC 3' 553 P. chab. 4192-4211 R 
PJmdrI-34 5' ATCAAAGAAGAGGT1GAAAAA 	' 52.8 P.falc.. - 
Pcindr/-37 5'. CCACTGTI'GATCTGlTfAAAAAG 	' 55.3 P. chab. 2-24 F 
MP13for.-21 5'. TGTAAAACGACGGCCACT 	' 53.7 pCRc2.1 - 
MP13for.-40 5'.GmCCCCAGTCACGAC3' 52.8 pCR®2.1 - 
MPl3reverse 5' CAGGAAACAGCTATGAC3' 50.4 pCR2.1 - 
Vectorette unknown Vect. - 
Vec. Seq. unknown Vect. - 
Table 20 - Oligonucleotide primers used to obtain sequence tor the pcmarl gene 
(F- forward; R- reverse) 
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5.1.1 PCR products obtained through Vectorette 
Several Vectorette libraries made from the P. chabaudi clone AS (sens) had already 
been constructed by Karen Hayton in this laboratory; which were kindly made 
immediately available for these studies. The libraries used to obtain new nucleotide 
sequence for the pcmdrl gene were as follows, 
Alul , BamHI, Clal, EcoRI, Hindlil , MfeI, TaqI 
All these were used with different oligonucleotide primers, but only a few produced 
PCR products that were fragments of the pcmdrl gene. It was observed that this method, 
although useful, produced PCR products that appeared to have resulted from non-
specific amplifications in the majority of cases. Nevertheless, three PCR products were 
obtained that proved to be part of the pcmdrl gene: 
Vectorette library Primers Fragment size Location in the pcmdrl 
gene (nucleotide 
number 5 1 -3') 
Alul Pcmdrl-20 + vect. 408 b.p. 1092-1500 
TaqI Pcmdrl-24 + vect. 316 b.p. 336- 652 
EcoRI Pcmdrl-24 + vect. 611 b.p. 213-824 
5.1.2 Products obtained through inverse PCR 
Inverse PCR was also used to generate pcmdrl-specific sequence, but in some cases this 
produced unspecific amplifications. Several PCR reactions were set-up using different 
libraries in combination with different primers pairs. Five PCR products were obtained 
which represented new nucleotide sequence corresponding to pcmdrl: 
Inverse PCR Primers Fragment Location in the pcmdrl 
library size gene (nucleotide 
number 5'-3') 
BsuRI Pcmdrl-6 + pcmdrl-14 1033 b.p. 1495-2527 
BsuRI Pcmdrl-5 +pcmdrl-18 785 b.p. 3672-4506 
SphI Pcmdrl-5 +pcmdrl-8 789 b.p. 3668-4506 
DraIJMseI Pcmdrl-3 +pcmdrl-1O 615 b.p. 3842-4506 
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5.1.3 Products obtained through screen ing of genomic libraries 
One fragment representing part of the pcmdrl gene was obtained through screening of a 
P. chabaudi genomic library. This originated from a transformed bacterial colony, which 
contained a 1133 base pair fragment that was part of pcmdrl. This segment is located 
from nucleotides 2318 to 3450. 
5.1.4 Products obtained through the use of degenerate primers 
Three products were obtained, which originated by using either degenerate or P. 
falciparum-specific oligonucleotide primers, used in PCR reactions containing P. 
chabaudi genomic DNA as template: 
Template DNA 	Primers 
P. chabaudi AJ Pcmdrl-28 + pf7ndrl-34 
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Figure 17 is a schematic representation of the way in which the pcmdrl nucleotide gene 
sequence was obtained 
DraIIMseI, pcmdrl-3 + pcmdrl-1O 
No 
BsuRI, pcmdrl-5 +pcmdrl-18 
SphI, pcmdrl-5 + pcmdrl-8 
P. chabaudi (AJ) genomic 1brary 
BsuRI, pcmdrl-6 +pcmdrl-14 
10. 
Pcrndrl-14 + pf,ndrl-1 7 
No 
Alul, pcmdrl-20 + vect. 
TaqI, pcmdrl -24 + vect 
10 
EcoRI, pcmdrl-24 + vect. 
10 
Pcmdrl-28 + Pfindrl- 34 
5' 	* 	 3' 
it I i 
0 	1000 	 2000 	 3000 	 4000 
pcmdrl nucleotide number 
Figure 17 - Diagram showing different methods producing sequence of the pcmdrl 
gene (each arrow represents the clone obtained through the use of a specific library and a set of two 
primers) 
5.2 Amolification of the pcmdrl ienebv different primer pair combinations 
Several PCR products representing fragments of the pcmdr] gene were obtained by 
using Vectorette, Inverse PCR, Genomic libraries and degenerate primers described 
above. In this way, a partial pcmdrl gene sequence was compiled, which contains 4506 
nucleotides. 
Due mainly to the insufficient amplification range of DNA polymerases, the 
amplification of the full length pcmdrl gene sequence was done through eight separate 
PCR reactions, each of which resulted in the amplification of overlapping sub-fragments 
of the gene (Figure 18). 
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Figure 18 - 1.5% agarose gels, showing PCR products resulting from the 
amplification of the perndrl gene from P. chabaudi AS [numbers on top - primer 
pairs (ex. 10 12 - pcnidrl-10 +perndrl-12); Mk XIV - molecular weight marker XIV, Boehringer 
Mannheim; bp - base pairs; Kb - Kilobase] 
The perndrl gene was amplified for several P. chabaudi parasite clones in the same way 
shown above. All PCR products were purified by methods described previously, and 
sequenced with the same primers used in the amplification. 
5.3 pcindr] sequence of P. chabaudi AS (sens) 
A partial nucleotide sequence of the pcmdrl gene was assembled by joining the internal 
fragments obtained by methods described before (Sections 5.1 and 5.2). To ensure that 
this nucleotide sequence had been correctly determined, each PCR and sequencing 
reactions were repeated on at least five independent occasions. In this way, a sequence 
containing 4506 nucleotides was obtained from P. chabaudi AS (sens) (Figure 19). 
The partial pcmdrl coding region begins 93 nucleotides downstream of the start codon 
of P. falciparum and consists of an open-reading frame of 4170 nucleotides, encoding a 
predicted aminoacid sequence of 1389 aminoacids. Note that sequence starts 31 triplets 
into the ORF (open reading frame). 
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The coding region consists mostly of A (40%) and T nucleotides (32%), G and Cs being 
represented in smaller proportions, 16 and 12% respectively. 
Peptide structure predictions indicate that the pcmdrl gene encodes a membrane peptide 
containing 11 trans-membrane helices with the N-terminus lying inside the organelle 
(Table 21) [source: Baylor College of Medicine (BCM) Search Launcher; web site 
http://dot.imgen.bcm.tmc.edu:  9331 /seg-searchlstruc-predict.html]. 
TM number From (a.a. number.) To (a.a. number.) Length (a.a.) Orientation 
1 25 44 20 i-o 
2 67 90 24 0-i 
3 139 157 19 i-o 
4 160 179 20 0-i 
5 248 265 18 i-o 
6 288 307 20 0-1 
7 754 776 23 i-o 
8 796 814 19 0-i 
9 874 894 21 i-o 
10 999 1019 21 0-i 
11 
Table 21 - 
1023 	 1047 	 25 	 i-o 
Pcmdrl nentide structure prediction (TM - trans-membrane domain; a.a. - 
aminoacid; i-o - inside to outside; 0-i - outside to inside) 
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93 ATTAAAAAGATAAAGAAACAAAATATCCCACTGTTTTTGCCATTTCATTCACTACCATCCAAACACAAGAGATTATTAGCTATATCTTTTATATGTGCGACAAT ATCAGGAGCTGCGTTA 
I K K I K K Q N I P L F L P F H S L P S K H K R L L A I S F I C A T I S G A A L 
	70 
213 CCCATTTTTATTTCGGTGTTTGGTCTTACTATGGCAAATATGAATATGGGAGAGAGCGTAAATGACATAGTTTTAAAATTAGTAATAGTTGGTATATGCCAATTTG TGATATCATCGATT 
P I F I S V F G L T N A N M N N G E S V N D I V L K L V I V G I C Q F V I S S I 	110 
333 TCATGTTTATGCATGGGTACTGTTACAACAGAGATTATAAGAATGTTAAAATTAAAATATTTAAAAAGTGTTTTTCATCAAGATGGAGAATTTCATGATAATAACCCAGGTTCTAAATTA 
S C L C N G T V T T E I I R N L K L K Y L K S V F H Q D G E F H D N N P G S K L 150 
453 ACATCCGATTTAGATTTTTATTTAGAACAAGTAAATTCAGGAATAGGAACAAAATTTACTACAATATTTACATATAGCAGTTCATTCTTAGGTTTGTATTTCTGGTCACTATATAAAAAT 
T S D L D F Y L E Q V N S G I G T K F T T I F T Y S S S F L G L Y F N S L Y K N 190 
573 GTAAGATTAACATTATGTGTTACATGTGTTTTTCCAGTAATATATATAATCAGTACGATATGTAATAAAAGAGTTCGATTAAATAAAAAAACATCATTATTATATAATAACAATTCAATG 
V R L T L C V T C V F P V I Y I I S T I C N K R V R L N K K T S L L Y N N N S N 230 
693 TCTATAATTGAAGAAGCATTAGTTGGTATTAAAACTGTTGTAAGTTATTGTGGAGAAAGTACAATATTAAAAAAATTTAAATTATCAGAACAATTTTACAGTAAATACATGTTAAAGGC A 
S I I E E A L V G I K T V V S Y C G E S T I L K K F K L S E Q F Y S K Y M L K A 270 
713 AATTTTATGGAATCGCTACATGTTGGTTTTATTAATGGATTTATATTAGCTTCATATGCTATGGGATTTTGGTATGGTACTAGAATTATGATACATGATATTAAAAATCTGAGTTCACCC 
N F M E S L H V G F I N G F I L A S Y A M G F N Y G T R I M I H D I K N L S S P 310 
933 AGCGATTTCAATGGAGGATCAGTTATATCAATTTTATTAGGAGTTCTTATAAGTATGTTTATGCTTACTATTATATTACCAAATGTTACTGAATATATGAAAGCGTTAGAGGCAACGAAC 
S D F N G G S V I S I L L G V L I S N F M L T I I L P N V T E Y N K A L E A T N 350 
1053 AATATACATGAAGTTATTAACAGAAAACCAGCTGTTGACAGAAATCAAAATAAAGGTAGAAAATTAGATGATATTAAAAAAATAGAATTTAAAAATGTCAAATTTCATTATGGTACTAGA 
N I H E V I N R K P A V D R N Q N K G R K L D D I K K I K F K N V K F H Y G T R 390 
1173 AAAGATGTTGAAATTTATAAGGATTTAAATTTTACATTAAAAGAAGGAAATACTTATGCATTTGTTGGAGAATCTGGATGTGGTAAATCAACAATTTTAAAATTGCTTGAGCGATTTTAT 
K D V E I Y K D L N F T L K E G N T Y A F V G E S G C G K S T I L K L L E R F Y 430 
1293 GATCCAACAGAAGGAGATATTGTTATTAATGGTGCACACAATTTGAAAGACGTTGACTTAAAATGGTGGAGATCTAAAATTGGAGTAGTTAGTCAAGATCCTTTATTATTTAGCAATTCG 
D P T K G D I V I N G A H N L K D V D L K N N R S K I G V V S Q D P L L F S N S 470 
1413 ATTAAAAATAATATTAAATATAGTTTAATAAGTCCAAATACTTTAGAAGCAATGGAAAATGGATTCACCATGAACGGAAGTAGCGATTCTTCATTAAATAATAACAAAAATGGAAAGTCC 
I K N N I K Y S L I S P N T L E A N E N G F T N N G S S D S S L N N N K N G K S 510 
1533 ACTAGTATTTTGGATGAAATATCTAAGAGAAATACAACTAATGATTTATTAGAAGTAATATCATCTATTAATTCAGTTGAAGATTCAAAAGTAGTTGATGTATCTAAGAAAGTGCTAATC 
T S I L D E I S K R N T T N D L L E V I S S I N S V E D S K V V D V S K K V L I 	550 
1653 CACGATTTTGTTGCAGCATTACCAGACAAATATGACACTTTAGTAGGTTCTAGCGCATCTAAGTTGTCAGGTGGACAAAAACAAAGAATATCGATAGGTAGAGCTGTTATTAGAAATCCT 
H D F V A A L P D K Y D T L V G S S A S K L S G G Q K Q R I S I G R A V I R N P 590 
1773 AAGATTTTAATACTTGATGAAGCTACATCATATCTTGATAATAAATCAGAATATTTAGTTCAGAAAACAATTAACAATTTAAAAGGAAATGAAAATCGTATCACCATTATTATTGCTCAT 
K I L I L D E A T S Y L D N K S E Y L V Q K T I N N L K G N E N R I T I I I A H 	630 
1893 AGATTGAGTACTATTCGATATGCTAACCAAATTTTTGTCTTATCAAATAGAGATCAAGAATCAACAGGAATTGATGAAAAAAAACAAGGTGCTATAAATAGCAATAACGGAAGTGTAATA 
R L S T I R Y A N Q I F V L S N R D Q E S T G I D E K K Q G A I N S N N G S V I 	670 
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2013 GTTGAACAAGGTACTCATGATAGTTTGATGAAAAATAAAAATGGTATTTACTATTCTATGATTCAAAACCAGAAAGTATCCTCAAGTGGAAATGGTGAAAATGG T GATGACAATAATAGT 
V E Q G T H D S L M K N K N G I Y Y S M I Q N Q K V S S S G N G E N G D D N N S 710 
2133 AGCGTATATAAAGACTCTAATCCAGGTGATGCTAAATCTGTTACTGATACAAATATGGACATTGGTACAAATAAAAATCTTAATACTAAAAAAGAAAAAGAGATTGCTGATGCTGATAAA 
S V '1 K D S N P G D A K S V T D T N N D I G T N K N L N T K K S K E I A D A 0 K 750 
2253 
Q T K P S I F K R N F G K K K K K P N N L N N V Y K E I F S H R K E V A I M L L 790 
2373 AGTACTATAGTAGCAGGTGGTTTATATCCATTGTTTGCTGTATTATATGCAGAATACGTTGTGACATTATTTGATATCCCGAACTTAGAATATAATTCAAATAAATATTCTATATTCATA  
S T I V A G G L Y P L F A V L Y A E Y V V T L F D I P N L E Y N S N K Y S I F I 	830 
2493 TTGTTTACTGCTTTAGCTATGTTTATTTCTGAAACATTAAAAAATTATTACAATAATAAAATTGGAGAAAAGGTTGAAAGCAAAATTAAATATTTATTATTCGAGAATATAATACACCAA 
L F T A L A N F I S E T L K N Y Y N N K I G E K V E S K I K Y L L F E N I I H Q 870 
2613 GAAATTGCCTTTTTTGATAAAGATGCACATGCCCCTGGATTTTTATCATCATATATTAACAGAGATGTACATTTATTAAAAACTGGTTTAGTAAATAATATTGTAATATTTACGCATTTT 
E I A F F D K D A H A P G F L S S Y I N R D V H L L K T G L V N N I V I F T H F 910 
2733 ATTATTTTGTTTATTGTTAGTATGATTTTGTCATTTTATTTTTGCCCAATAATAGCAGCAGCTTTAACATTAACATATACCTTTATAATGCGAGCTGTTACTGCAAGAGTACGAATGGAA 
I I L F I V S N I L S F Y F C P I I A A A L T L T Y T F I N R A V T A R V R N E 950 
2853 AAATCGAATAAAATAGAGAAAATCGGAGATAAAAAAGATGGATGCCTTTCATATACTACTGATGACGAAATATTTAAAGATCCTAACTTTTTAATTCAAGAAGC ATTTTATAACATGCAG 
K S N K I E K I G 0 K K D G C L S Y T T D D E I F K D P N F L I Q S A F Y N N Q 990 
2973 ACAATTATTACATATGGATTAGAAGATTATTATTGTAAACTGATAGAAAATGCAATAGATCATTACAATAAAGAGCAAAGAAAATCAATTATAGTAAATTCAAT ATTATGGGGATTTAGT 
T I I T Y G L E 0 Y Y C K L I E N A I 0 H Y N K E Q R K S I I V N S I L W G F 5 1030 
3093 CAATGTACACAATTATTTATTAATGCATTTGCTTATTGGTTAGGTTCCATTTTGATAAAACACAAAATTATAGTTGTTGATGATTTTATGAAATCTTTATTTACATTTATATTTACTGGT 
Q C T Q L F I N A F A Y W L G S I L I K H K I I V V D 0 F N K S L F T F I F T G 1070 
3213 AGTTATGGTGGTAAGTTAATGTCCTTCAAAGGAGACTCAGATAATGCTAAATTAACATATGAGAAATATTATCCTATAATGGTTAGAAAATCAAATATCGATGTAAG AGATGAAGGTGGT 
S Y G G K L M S F K G D S D N A K L T Y S K Y Y P I M V R K S N I D V R D E G G 
1110 
3333 ATAAGAATAAAGAATCCACATCAAATAGACGGAAAAGTAGAAGTGAAGGATGTTAACTTTAGATATTTATCTCGACCAAATGTACCAATATATAAAGATTTGTCATTTAGT T G TGATAGC 
I R I K N P H Q I D G K V E V K D V N F R Y L S R P N V P I Y K D L S F S C D 5 1150 
3453 AAAAAAACTACTGCTATAGTTGGAGAAACTGGATGTGGTAAATCCACAATTATGCATTTATTGATGCGATTTTACGATTTGAAAGATGACCACGTTTTATTAGATAATCAACATGT TGAA 
K K T T A I V G E T G C G K S T I M H L L N R F Y 0 L K D D H V L L 0 N Q H V E 1190 
3573 AAAGACAATAAAGATAAATCAAATGATATAGAAATGACTAATGCAACCTCTATGAACGAATTGAATGAATTGCATAAGAAAAACGCAACTGAAGAATATACTCTTTACAAAAATAG TGGC 
K D N K D K S N D I E M T N A T S M N E L N E L H K K N A T E E Y T L Y K N S G 1230 
3693 AAAATTTTACTTGATGGTGTAGACATTTGCGATTATAACTTAAAAGATCTAAGAAAATTATTTGCGATAGTTAACCAAGAACCAATGTTGTTTAATATGTCTATTTATGAAAATATAA AA 
K I L L 0 G V D I C 0 Y N L K 0 L R K L F A I V N Q E P H L F N M S I Y E N I K 1270 
3813 TTCGGTAAAGAAGATGCAACATTAGAAGATGTAAAAAGGGCTTGTAGATTGGCTGCTATTGACGAATTTATTGAATCATTACCAAATAAATATGATACTAATGTAGGACCTTATGGAAA A 
F G K E D A T L E 0 V K R A C R L A A I 0 S F I E S L P N K Y D T N V G P Y G K 1310 
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3933 AGCTTATCAGGTGGTCAAAAACAACGAGTTGCTATTGCTAGAGCCCTATTAAGAGAACCTAAAATATTGTTGTTAGACCAGGCTACATCAGCTCTTGATTCACACTCAGAAAAATTAATC 
S L S G G Q K Q  R V A I A R A L L R E P K I L L L D Q A T S A L D S H S E K L I 1350 
4053 GAAAAAACTATTGTTGATATTAAAGATAGAGCTGACAAAACCATCATTACTATTGCTCACAGAATTGCATCTATCAAAAGATCAAATAAAATTGTAGTTTTTAACAACAATGATAAAAAT 
E K T I V D I K D R A D K T I I T I A H R I A S I K R S N K I V V F N N N D K N 1390 
4173 GGATCTTTTGTTCAAGCCCAAAAAACACACGACGAATTGATTCGTGATAAAGATAGTGTTTATACAAAATATGTCAAATTAACTAAATAAACGATTGAAAGTTGGGCAAATACATAACCA 





Figure 19 - pcmdrl nucleotide and predicted aminoacid sequence 
Amino acid code 
A Alanine I 	Isoleucine R Arginine 
C Cysteine K Lysine S Serine 
D Aspartic acid L Leucine T Threonine 
E Glutamic acid M Methionine V Valine 
F Phenylalanine N Asparagine W Tryptophan 
G Glycine P 	Proline Y Tyrosine 
H Histidine Q Glutamine * Termination 
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5.4 Pcmdrl gene sequence of different parasite clones 
By making use of oligonucleotide, primers the pcmdrl gene sequence was obtained from 
each of the following clones of P. chabaudi: AJ, AS (sens), AS (3CQ), AS (15CQ), AS 
(30CQ), AS (15MF) and 440/5. Each PCR and sequencing reactions were repeated at 
least 5 times to ensure that the sequence obtained was reliable and not due to random 
mistakes during the PCR. 
These sequences were compared in order to determine whether point mutations had 
occurred, that could be associated with chloroquine, mefloquine or quinine resistance. 
Special attention was given to regions of the gene associated with drug resistance in P. 
falciparum (reviewed in CHAPTER I). The results of this analysis are described below. 
5.4.1 pcmdrl nucleotide and peptide sequence of P. chabaudi AS and AJ 
The pcmdrl gene of AJ and of all AS clones differ in three nucleotide substitutions, 
which all proved to be synonymous, i.e. did not result in altered aminoacids. These 
substitutions were as follows (Table 22, Figure 20): 
P. chabaudi AS aminoacid P. chabaudi AJ aminoacid 
3342A (TTA) L 3342G (TTG) L 
3435T (TAT) Y 3435C (TAC) Y 
3600T (GGT) G 3600C (GGC) G 
Table 22 - Nucleotide differences in pcmdrl between P. chabaudi AS and AJ 
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3320 	3330 	1 3340 	3350 	3360 	3370 	3380 
P. chabaudi AS TCGACCAAATGTACCAATATATAAAGATTTATCATTTAGTTGTGATAGCAAAAAAACTACTGCTATAGTTGGAGAAA  
•.....................I....... •..............................I.............. 
P. chaba udi AJ TCGACCAAATGTACCAATATATAAAGATTTGTCATTTAGTTGTGATAGCAAAAAAACTACTGCTATAGTTGGAGAAA  
I 	 I 	I 
3320 3330 	3340 3350 	3360 	3370 	3380 
3390 	3400 	3410 	3420 	3430 	3440 	3450 	3460 
I I I I I I I 
P. chaba udi AS CTGGATGTGGTAAATCCACAATTATGCATTTATTGATGCGATTTTATCATTTGA1AGATGACCACGTTTTATTAGAT 
P. chabaudi AJ CTGGATGTGGTAAATCCACAATTATGCATTTATTGATGCGATTTTACGATTTGAAAGATGACCACGTTTTATTAGAT 
I 	I 	I 	I 	I 	I 	 I 
3390 3400 3410 3420 3430 3440 3450 	3460 
3470 	3480 	3490 	3500 	3510 	3520 	3530 	3540 
I I I I I I 
P. chaba udi AS AATCAACATGTTGAAAAAGACAATAAAGATAAATCAAATGATATAGAAATGACTAATGCAACCTCTATGAACGAATT 
P. chaba udi AJ AATCAACATGTTGAAAAAGACAATAA.AGATAAATCAAATGATATAGAAATGACTAATGCAACCTCTATGAACGAATT 
I 	I 	 I 	I 	I 	I 	I 
3470 3480 3490 	3500 3510 3520 3530 3540 
3550 	3560 	3570 	3580 	3590 	3600 	3610 
I I I I I I 
P. chaba udi AS GAATGAATTGCATAAGAAAAACGCAACTGAAGAATATACTCTTTACAAAAATAGTGGTAAAATTTTACTTGATGGTG 
P. chaba udi AJ GAATGAATTGCATAAGAAAAACGCAACTGAAGAATATACTCTTTACAAAAATAGTGGCAAAATTTTACTTGATGGTG 
I 	I 	I 	I 	I 	I 
3550 	3560 3570 3580 3590 3600 3610 
Figure 20 - Area of pcmdrl containing nucleotide differences between clones P. chabaudi AS and AJ 
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5.4.2 pcmdrl gene sequences of P. chabaudi AS clones 
dthough differences were noted between AJ and AS, no nucleotide sequence 
c- jfferences were detected among the different clones of P. chabaudi AS. Thus, drug 
sensitive AS parasites, AS (sens), chioroquine-resistant parasites, AS (3CQ), AS 
(15CQ), AS (30CQ) and mefloquine-resistant ones, AS (15MF), all possess identical 
sequences of the gene, showing that no mutations had occurred in this area of the 
arasite's genome after drug selection. Therefore, it was concluded that there are only 
vo alleles of the pcmdrl gene among the parasite clones studied; AJ and AS. 
.4.3 ,icmdrl gene sequence of clone P. chabaudi 440/5 
he gene sequence of pcmdrl was also obtained for the AJ x AS (I5MF) progeny clone 
440/5, but again, no mutations were detected in the gene. In addition it was observed 
that 440/5 parasites carry the AJ allele of pcmdrl, confirming previous results obtained 
hrOugh both RFLP and karyotype analysis. 
the pcmdrl gene was compared to pfindrl , its P. falciparum homologue. The two genes 
f howed high similarity with 75.2% identity at the nucleotide level and 70.7% at the 
tminoacid level. 
addition, it was observed that there was a particularly high degree of identity between 
pcmdrl and pfmdrl genes in those areas of the gene where the ATP-binding sites are 
oded (Figure 21) 







































MGKEQKEKKDGNLSIKEEVEKELNKKSTAEL-R --- NEK-SF ---- KC 50 
SKHKRLLAI SFICATISGAALPIF ISVFGLTMA.NNNNGESVNDIVLKLVI -69 
AQ-RK-F --- V--VL--GT--F ------ VILK --- L-DDI-P-I-S--S 100 
VGICQFVISS I SCLCMGTVTTEI IRMLKLKYLKSVFI-iQDGEFHDNNPGSK 119 
I-LV--IL-M--SY--DVI-SK-LKT --- E--R---Y --- Q --------- 150 
LTSDLDFYLEQVNSGIGTKFTTIFTYSSSFLGLYFWSLYKNVRLTLCVTC 169 
-R ---------- S ------- I ----- A ------- I---I--A ----- I-- 200 
VFPVIYIISTICNKRVRLNKKTSLLYNNNSMSIIEEALVGIKTVVSYCGE 219 
--- L--VCGV----K-K ------------ T -------- M--R--A 250 
STILKKFKLSEQFYSKYNLKANFMESLHVGFINGFILASYANGFWYGTRI 269 
- I --- --V-A--I-L --- L--V --- F -------- 300 
MIHDIKNLSSPSDFNGGSVISILLGVLISMFMLTIILPNVTEYMKALEAT 319 
I-NSAT-QYPNN ---- A ---------------------- I ---------- 350 
NNIHEVINRKPAVDRNQNKGRKLDDIKKIEFKNVKFHYGTRKDVEIYKDL 369 
-SLY-I-----L-EN-DD. -ET-PN---------R---D----------- 399 
NFTLKEGNTYAFVGESGCGKSTILKLLERFYDPTEGDIVINGAHNLKDVD 419 
S------K------------------I - -L--------IV-DS-----IN 449 
LKWWRSKIGVVSQDPLLFSNSIKNNIKYSLISPNTLEAMENGFTMNGSSD 469 
------------------------------ Y-LKD ------ YY ......E 493 
SSLNNNKNGKSTSILDEISKRNTTNDLLEVISSINSVEDSKVVDVSKKVL 519 
ENT-DTYEN-NF-L.. . --NSM-S-E---MKKEYQTIK--D--------- 540 
IHDFVAALPDKYDTLVGSSASKLSGGQKQRISXGRAVIRNPKILILDEAT 552 
SS -----------N--------------A-- IM ------------ 590 
SYLDNKSEYLVQKTINNLKGNENRITIIIAHRLSTIRYANQIFVLSNRDQ 602 
-S--------------------------------------T-------ER 640 
. ESTGIDEKKQGAINSNN .....GSVIVEQGTHDSLMKNKNGIYYSM 643 
SDNNNNNNN-DNNNNNN-N--KINNE--Y-I----------------HL- 690 
IQNQKVS. . . SSGNG. ENGDDNNSSVYKDSNPG . DAKSVTDTNNDIGTNK 688 
-N---I-SNK--N--ND--S--K--A ---- DT-N--DNN. .NSLS-HE-E 738 
NL . NTKKEKEIADADKQTKPSIFKRNFGKKKKKPNNLNNVYKEIFSHRKE 737 
-IS-NRNC-NT-ENE-EE-VPF ----- RR --- A ---- RII ------ YK-D 788 
VAIMLLSTIVAGGLYPLFAVLYAEYVVTLFDIPNLEYNSNKYSIFILFTA 787 
-T-IFF-IL ------- V--L --- R--S ---- FA ---- - ------ Y--LI- 838 
LANFISETLKNYYNNKIGEKVESKIKYLLFENIIFIQEIAFFDKDAHAPGF 837 
I --------------------- KTM-RR ----- LY--MS --- Q-KNT--V 888 
LSSYINRDVHLLKTGLVNNIVIFTHFIILFIVSMILSFYFCPIIAAALTL 887- 
--AH ------------------- S --- M--L --- VM ------- V--V--F 938 
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r. chab 	TYTFIMRAVTARVRNEKSNKIEKIGDKKDGCLSYTTDDEIFKDPNFLIQE 	937 
faic I_FIN__VFAV_A_LT--KE --- KENMSS-VFAFSS --- M ---- S 	 988 
ri. chab 	AFYNNQTIITYGLEDYYCKLIENAIDHYNKEQRKSIIVNSILWGFSQCTQ 	987 
. 	 faic ----- H-V-N ------ F-N --- K --- YK--G-KRR 	 - AA ------ SA- 1038 
. 	 chab LFINAFAYWLGSILIKHKIIVVDDFMKSLFTFIFTGSYGGKLMSFKGDSD 1037 
P. 	faic ---- S ---- F--F --- RGT-L ----------------- A-----L ---- E 1088 
p. chab NAKLTYEKYYPIMVRKSNIDVRDEGGIRIKNPHQIDGKVEVKDVNFRYLS 1087 
p. 	falc ---- SF-----L-I --------- D ------- KNL-K---DI-------I- 1137 
p. chab RPNVPIYKDLSFSCDSKKTTAIVGETGCGKSTIMHLLMRFYDLKDDHVLL 1137 
p. 	faic -------- N --- T -------------- S ---- F-N--L ------ N--Il- 1187 
p. chab DNQHVEKDNKDKSNDIEMTNATSMNELNEL . HKKNATEEYTLYKNSGKIL 1186 
p. 	faic K-DMTNFQDYQNN-N. . . . -SLVLK.NV--FSNQSGSA-D--VFN-N-E -- 1233 
p. chab LDGVDICDYNLIDLRXLFAIVNQEPMLFNMSIYENIKFGKEDATLEDVKR 1236 
p. 	faic --DIN------R---N--S--S---------- -------R---------- 1283 
p. chab ACRLAAIDEFIESLPNKYDTNVGPYGKSLSGGQKQRVAIARALLREPKIL 1286 
. 	 faic VSKF--------------------- ----------- I ------------- 1333 
• chab 	LLDQATSALDSHSEKLIEKTIVDIKDRADKTIITI.AHRIASIKRSNKIVV 1336 
• faic ---E---S---N--------------K-------- ----------D---- 	1383 
chab 	FNNNDKNGSFVQAQKTHDELIRDKDSVYTKYVKLTK* 	 1386 
faic --- P-R--T---SHG ----- LSAQ-GI-K ----- A_* 1420 
re 21 - Pcmdrl and pfmdrl predicted aminoacid sequences (left column, top: 
1; bottom: pfmdrl. Right column: aminoacid numbers. - : identical aminoacid in pfmdrl. Bolded 
acids: areas of the peptided where both N and C-terminus ATP-binding cassettes are predicted to be 
When the pcmdr] and pfindr] genes were aligned, special attention was paid to areas of 
the gene in which polymorphisms have been connected to chioroquine, mefloquine and 
quinine resistance in P. falciparum (reviewed in CHAPTER I). 
The predicted peptide sequence for the pcmdrl gene of all the different clones of P. 
chabaudi, contained the same aminoacids as pfmdrl of the drug-sensitive clone P. 
falciparum 3D7 in positions which have been related to drug resistance in the past, i.e., 
N86, Y184, S1034, N1042 and D1246 (table 23). 
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Drug responses aminoacid 
P. fa1eipru,n CQ MF QUIN 86 184 1034 1042 1246 
:)D/ S S S N V S N D 
K! R S S Y Y S N D 
7G8 R S S N F C D Y 
P. c/icibaiIi 
AJ S S S N V S N D 
AS (sens) S S S N Y S N D 
AS(3CQ) IowR S S N Y S N D 
AS (15CQ) R S lowR N V S N I) 
AS (30CQ) R S IowR N V S N D 
AS(15MF) R R R N Y S N D 
L 440/5 j vlowR R IowR N V S N D 
Fable 23 - pcmdrl and pfmdrl polymorphisms and resistance to chloroquine, 
inefloquine and quinine (S - sensitive; R - resistant: lowR - low resistant; vlowR - very low 
resistant: CQ - chloroquine; MF - mefloquine; QUIN - quinine. Note that all clones of P. chabaudi have 
aminoacids that are homologous to those of the drug-sensitive parasite P. falciparuni 31)7). 
5.6 Summary of CHAPTER V 
. The pcmdrl gene was cloned and sequenced to check whether point polymorphisms 
within the gene could be related to differential drug responses. It was observed that 
the gene sequences of P. chabaudi AS clones did not differ between drug-sensitive 
and resistant parasites. 
Three point polymorphisms within the pcmdrl gene were found between P. 
chabaudi AS and AJ, but after translation, these proved to be synonymous, i.e. did 
not result in altered aminoacid. 
A high degree of similarity was found between pcmdr] and its P. falciparum gene 
homologue, pfmdrl , especially were the ATP-binding sites are encoded. 
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CHAPTER VI 
DISCUSSION 
The discussion of the results arising from this work is divided into several sections. 
Mefloquine resistance is dealt with first, since this is the main subject of my thesis. 
Before discussing my own results regarding mdrl gene amplification and mefloquine 
resistance, I will summarise previous work in both P. falciparum and P. chabaudi. A 
summary and interpretation of the results from the present genetic crosses is presented, 
and four genetic models are proposed that attempt to explain the results. 
Quinine resistance is considered next. I will first discuss the results of the quinine 
selection experiments and explain how they may reflect the situation observed in natural 
parasite populations of P. falcipa rum. The results of the present genetic crosses 
regarding quinine resistance will then be discussed. 
This is followed by a discussion of the findings on chloroquine resistance among 
progeny of the crosses. 
The final section presents general considerations and concluding remarks related to the 
results of this study. 
6.1 Is the amplification of the multi-drug resistance gene 1 an essential requirement 
for mefloguine resistance? 
6.1.1 Evidence from previous work 
There is good evidence for the involvement of pfmdrl in mefloquine-resistance in P. 
falcipa rum.. Clones of this species selected in vitro for high mefloquine resistance 
showed evidence of amplification and over-expression of pf,ndrl (Cowman et al., 1994 
and Peel et al., 1994). Similarly, an increase in sensitivity to mefloquine was associated 
with de-amplification of pfmdrl when a highly chioroquine resistant mutant was 
selected by Barnes and colleagues (1992). However, pfmdrl amplification and/or 
increased expression of Pgh-1 do not invariably occur in parasites lines selected for 
increased mefloquine resistance (Lim et al., 1996; Ritchie et al., 1996; Rubio and 
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Cowman, 1996), or in P. falciparum mefloquiñe resistant isolates (Chaiyaroj et al., 
1999) suggesting that other mechanisms may mediate the resistance phenotype. 
Amplification of a gene whose product is the target of a chemotherapeutic agent is a 
well-established mechanism by which micro-organisms can develop resistance to the 
agent. For example, in studies on resistance to the antifolate drug pyrimethamine in P. 
chabaudi, the DHFR gene was found to have undergone a duplication event which 
involved a partial chromosome duplication, following continuous low-pressure of the 
drug on the parasites (Cowman and Lew, 1989). In this instance, the duplicated portion 
of the chromosome remained in the chromosome, and did not become translocated to 
another chromosome. Subsequent drug selection on the P. chabaudi line resulted in a 
point mutation in one copy of the gene and loss of the second copy Cowman, 1990). 
Similar results have been reported for two pyrimethamine-resistant lines selected from 
P. berghei (van Dijk, 1994 et at., 1984). In both these studies, it appeared that different 
methods of selection had given rise to different types of resistance mechanism. Thus, 
treatment of parasites with low drug doses had selected for parasites with gene 
duplication and consequent increased gene expression, whereas selection with higher 
drug doses had selected for parasites with functional gene mutations (Cowman and Lew, 
1990). Point mutations in DHFR appear to be the most common cause of resistance to 
higher levels of this drug in both P. chabaudi (Cowman and Lew, 1990, Cheng and Saul, 
1994) and in field populations of P. falciparum (Hyde, 1990, Nzila-Mounda et at., 
1998). 
There is good evidence for the involvement of pf,ndrl amplification in some forms of 
mefloquine-resistance in P. falcipa rum. This has been most studied in the W2 clone of 
this species. W2 was put under mefloquine selection to produce a line denoted W2mef 
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(Oduola et al., 1988) which possessed an increased copy number of pfindrl, an increase 
in the size of chromosome 5 containing the gene, and increased pf,ndrl expression 
(Wilson et al., 1989). The mefloquine-resistance of W2mef was increased further in two 
selection experiments (Cowman et al., 1994, Peel et al., 1994), and in both instances 
there were further increases in the copy number and expression of pf,ndrl. In related 
work, Barnes et al. (1992), showed that the mefloquine-resistance of the P. falciparum 
W2mef clone became lower following selection for chloroquine-resistance, and this was 
accompanied by a decrease in the size of chromosome 5 and of the copy number of 
pfmdrl. 
However, other genetic mechanisms of mefloquine-resistance must also exist in 
Plasmodium. No extra pflndrl amplification occurred when the mefloquine-resistant P. 
falciparum FAC8 clone, which already contained three copies of the pfmdrl gene, was 
selected for increased resistance to the drug (Lim et al., 1996). There is no clear 
relationship between pfmdrl copy number and mefloquine-resi stance in natural 
infections, although Wilson et al. (1993) found that some resistant Thai isolates 
contained more than one copy of the gene. 
There are also problems in interpreting such studies in view of the fact that most isolates 
contain a multiplicity of genetically distinct clones, which could differ in their drug-
response (Thaithong et al., 1984). In contrast, cloned parasite lines present ideal material 
to study both the phenomenon of cross-resistance and the genes responsible for this 
resistance. 
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6.1.2 Current work 
In order to clarify the role of the mdrl gene in mefloquine resistance, and to study the 
potential involvement of other genes, a stable mefloquine resistant clone of P. chabaudi, 
AS (15MF), was produced by using a continuous low-pressure and multi-step drug 
selection procedure. The copy number of pcmdrl, the P. chabaudi homologue of the 
pfmdr] gene of P. falcipa rum, was shown to have doubled, due to a duplicative 
transposition event which had transposed 400 kb of chromosome 12 to chromosome 4 
(section 4.1). mRNA levels of pcmdrl in AS( 1 5MF) were increased (section 4.1). These 
results thus support the hypothesis that amplification of an mdr gene of Plasmodium in 
both copy-number and expression may play a role in resistance to mefloquine. 
We have provided evidence that mefloquine-resi stance of the P. chabaudi AS (15MF) 
clone correlates with duplication and over-expression of the pcmdrl gene. We do not 
know whether the translocation event by which the duplicated portion of chromosome 
12 containing this gene became attached to chromosome 4 was important in establishing 
the resistance. The stable P. chabaudi AS( 1 5MF) clone retained the duplication in the 
absence of the drug. The translocation event may allow stable inheritance of the 
character by enabling the duplicated portion to replicate during mitosis along with the 
chromosome to which it became attached. 
We cannot rule out the possibility that other duplicated and translocated genes linked to 
Pcmdrl, or indeed genes elsewhere in the genome, are involved in the mechanism of 
mefloquine resistance in AS (1 5MF) 
To establish whether the duplication and/or over-expression of pcmdrl is an essential 
requirement for mefloquine resistance in P. chabaudi, we have performed a genetic 
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cross between AS (15MF) and a genetically distinct sensitive clone AJ. Untreated 
progeny of this cross were cloned directly, or treated with pyrimethamine and/or 
mefloquine prior to cloning (section 4.2). 
Sixteen independent recombinants were obtained from the P. chabaudi AJ x AS (15MF) 
genetic cross which were tested for mefloquine resistance and analysed for amplification 
and over-expression of the pcmdrl gene (sections 4.6.1 and 4.7). 
The in vivo tests for mefloquine sensitivity clearly allowed distinction between the 
sensitive parent P. chabaudi AJ and AS (1 5MF). The sensitivity of each progeny clone 
was assessed at least twice to ensure reproducibility. The results were consistent in most 
cases, but clones with exceptional responses were tested further for their mefloquine-
response. 
There was variation in mefloquine responses among the progeny clones. Six progeny 
proved to be sensitive, seven showed the same mefloquine response as the resistant 
parent AS (15MF) and three were resistant to mefloquine only to a low level of drug 
(section 4.6). As expected, there was a higher frequency of mefloquine-resistant clones 
among progeny which had been treated with pyrimethamine and/or mefloquine prior to 
cloning, presumably dueto drug selection of the AS-type resistant mutants. 
6.1.3 Interpretation 
The observation that no amplification of the pcmdrl gene was detected among the 
mefloquine-sensitive progeny clones (section 4.6.1), suggested that this is an important 
event in the manifestation of resistance, at least in some progeny. The majority of 
mefloquine-resistant progeny contained a duplication and over-expression of pcmdrl. 
However, the fact that the progeny clones displayed different levels of mefloquine-
sensitivity, is indicative that the mefloquine resistance phenotype depends on additional 
genetic changes, other than pcmdrl duplication alone. The results have shown a strong 
but incomplete correlation between mefloquine resistance and pcmdrl duplication and 
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over-expression (linkage 11/15) (sections 4.6.1 and 4.7), suggesting the involvement of 
at least one other gene in determining the mefloquine resistance phenotype. This 
consideration is supported by the following observations: 
. Two of the progeny clones, 396/11 and 441/11, carried a duplication of pcmdrl, but 
were mefloquine-resistant to a lower level than the resistant parent AS (15MF) 
• One progeny clone, 1016/11, was mefloquine-resistant to a low level but had only 
one copy of the pcmdr] gene. 
• Clone 440/5 was mefloquine-resistant at the same high level as the AS (15MF) 
parent, but had a single copy of the pcmdrl gene. No over-expression of pcmdrl 
could be detected in this clone. 
These results point to the involvement of genetic events other than pcmdrl duplication 
in determining the mefloquine resistance phenotype displayed by the parent clone P. 
chabaudi AS (15MF). The duplication of the pcmdrl gene is relatively easily perceived, 
since it results in a major karyotypic alteration that can be detected through PFGE and 
Southern blot analysis. However, it is clear that other genetic changes have also occurred 
during mefloquine selection, which did not produce detectable major chromosomal re-
arrangements. The next sections present different models as possible explanations for 
these findings. 
6.1.3.1 Model 1 - Are point mutations inpcmdrl involved in meflopuine resistance? 
There is evidence from field studies, genetic crossing work and transfection experiments 
that appear to indicate that point mutations in the P. falciparum mdrl gene (pfmdrl) 
may modulate mefloquine responses. Price and colleagues (1999), reported that a 
mutation at codon 86 (Asn86Tyr) was associated with increased mefloquine tolerance in 
P. falcipa rum from the western border of Thailand. Genetic crossing work has shown 
that polymorphisms at codon 184 (Phe to Tyr) and 1042 (Asn to Asp) in the Pghl 
protein can be associated with increaed sensitivity to both mefloquine and halofantrine 
(Duraisingh et al., 2000a). Recent transfection studies have also suggested strongly that 
point mutations in the pfmdrl nucleotide sequence which encode polymorphisms at 
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codons 1034 (Ser to Cys), 1042 (Asn to Asp) and 1246 (Asp to Tyr) in the Pgh-1 
peptide, may also cause P. falciparum parasites to accumulate more mefloquine and 
halofantrine, but less quinine (Reed et al., 2000). 
A possible explanation of the P. chabaudi work reported here is that additional genetic 
mutations in either copy of the pcmdrl gene had occurred in AS (15MF). The different 
levels of sensitivity observed among the progeny clones, could then be due to different 
segregation patterns of mutant and wild-type genes. Consequently, the pcmdrl gene 
nucleotide sequence was obtained in the present study (CHAPTER V), to determine if 
any mutations had occurred as result of mefloquine selection, which could account for 
the different levels of drug response observed among the cloned progeny. 
Pcmdrl gene nucleotide sequences were compared between the mefloquine-resistant P. 
chabaudi AS (15MF) and its direct sensitive precursor AS (15CQ). No differences were 
detected in the sequences between these two clones, indicating that mutations in this 
gene are not required for mefloquine resistance in P. chabaudi. However, it is possible 
that the levels of mefloquine resistance in these parasites do not require point mutations 
to be present in the pcmdrl gene. In P. falcipa rum, it has been observed that increased 
selection for mefloquine resistance from a mefloquine-resistant clone (W2mef) which 
contained an amplified pfmdrl, had resulted in a point mutation in aminoacid 86 
(tyrosine to phenylalanine), without further increases in copy numbers (Peel et al., 
1994). Similarly, point mutations in DHFR appear to be the most common cause of 
resistance to higher levels of pyrimethamine in both P. chabaudi (Cowman and Lew, 
1990, Cheng and Saul, 1994) and in field populations of P. falciparum (Hyde, 1990, 
Nzila-Mounda et al., 1998). 
CHAPTER VI - Discussion 	 127 
In view of the work of Peel and colleagues (1994) future studies in P. chabaudi could 
involve selecting for higher levels of chloroquine and mefloquine resistance to check if 
this will cause any sequence changes in the pcmdrl gene. 
Alternatively, it is possible that the pcmdrl's promoter has undergone mutation as a 
result of drug selection, rather than the gene itself. The nucleotide sequence of the 
gene's promoter was not obtained in the present study. However, subsequent studies 
should take this factor into consideration. 
6.1.3.2 Model 2 - Are mutations in a gene unlinked to pcmdrl involved in 
mefloguine resistance? 
Let us presume first that genetic mutations have occurred in a gene (gene I) during 
mefloquine selection, which is unlinked to pcmdr]. The chromosomal location of Gene I 
is irrelevant for the purpose of the model. We may assume that gene I is located on 
chromosome 1. Let us also assume that mutations in gene I can account for intermediate 
levels of mefloquine resistance when the gene has been inherited on its own among the 
progeny. However gene I does not confer the same level of mefloquine resistance of the 
AS (1 5MF) parent, and in the presence of two copies of the pcmdrl gene, gene I does 
not have an additive effect upon resistance. 
Figure 22 now considers the different possibilities on the inheritance of both gene I and 
pcmdr], and how this relates to mefloquine resistance. Some haplotypes display parental 
sensitive and mefloquine-resistant phenotypes, depending on the number of copies of the 
pcmdrl inherited, as expected. In addition, intermediate levels of mefloquine resistance 
can also be found among the progeny which carry gene I but have a single copy of the 
pcmdrl gene; clone 10 16/1 1 could be an example of such haplotype. However, the 
model fails to explain intermediate levels of mefloquine resistance in the presence of 
two copies of pcmdrl (clones 396/11 and 44 1/11), as well as progeny which are highly 
mefloquine-resistant but have only one copy of the gene (440/5). 
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Figure 22 - Possible haplotypes and phenotypes resulting from genetic crosses of 
AJ and AS (15MF) parasites containing pcmdrl and gene I. (numbers represent the 
chromosome number, i.e, 1, 12 or 4/12; S - sensitive; lowR - low resistant; R - 
resistant). 
I pcmdrl 	Gene I, wild-type • Gene I, mutated 
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6.1.3.3 Model 3- Is an enhancer involved in the different levels of mefloguine 
resistance among the cloned progeny? 
We will now consider the possibility that both pcmdrl duplication and mutations in a 
different gene (gene A) have been caused during mefloquine selection. Both genes A 
and pcmdrl have the capacity to cause a low level of mefloquine resistance 
independently, i.e., if gene A is found on its own, the parasites are low mefloquine-
resistant; if pcmdrl duplication is found on its own, the parasites are also low 
mefloquine-resistant. However, if both genes are found together, they do not have an 
additive effect on resistance, i.e., the parasites are still low mefloquine-resistant. For the 
purpose of the model we may consider that gene A is not linked to pcmdrl. 
We will now assume that a mutation occurred in a third gene during mefloquine 
selection (gene E) which encodes an enhancer or transcription factor that is epistatic to 
both pcmdr] and gene A., i.e. gene E has no effect on its own, but it has a positive 
regulation upon both genes together or independently. Gene E does not have to be 
closely linked to either gene A nor pcmdrl. In fact, unlike promoters, enhancers are not 
necessarily found in the proximity of the genes they act upon (Lewin, 1990). Let us now 
consider some possibilities on the inheritance of the three genes among the progeny and 
its relation to mefloquine resistance (Table 24). 
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Inheritance of pcmdrl, gene A and gene E Mefloquine Karyotype 
response [AJ/AS (15MF)J 
(example)  
Pcmdrl + a + e Sensitive AJ 
(AJ_or_388/12)  
Pcmdrl + a + e Low-resistant * AS (1 5MF) 
(396/11 or 441/11)  
Pcmdrl + A + e Lowresistant* AJ 
(1016/11)  
Pcmdrl + A + e Lowresistant * AS (1 5MF) 
(396/11 or 441/11)  
Pcmdrl + a +E Sensitive AJ 
(411/8 o4_440/9)  
Pcmdrl + a + E Resistant AS (1 5MF) 
(440/8 or442/9)  
Pcmdrl + A + E Resistant* AJ 
(440/5)  
Pcmdrl + A + E Resistant AS (1 5MF)  
[AS _15_(MF)]  
Table 24 - The relationship between the inheritance of genes A, F and pcmarl 
(pcmdrl - AJ pcmdrl on chromosome 12; a - wild type gene A; e - wild type gene E; 
pcmdrl - AS (1 5MF) pcmdrl; A - mutated gene A; E - mutated gene E) 
In summary, the model outlined above could account for the observations from the 
present cross. In particular, note those genotypes of those phenotypes marked with . 
However, the fact that genes A, E and pcmdrl have been considered to be unlinked, 
implies that clones with intermediate levels of mefloquine resistance should be found at 
similar frequencies of sensitive and resistant parasites among the progeny. It is possible 
however that some type of selective pressure acts on low-resistant parasite clones during 
mosquito transmission or in mice after sporozoite injection, which may account for the 
lower frequencies observed. 
The genetic model described in the next section is based on the hypothesis of genes A, E 
and pcmdrl described above. However, it assumes that the three genes are closely 
linked. 
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6.1.3.4 Model 4 - Are mutations in a gene linked to pcmdrl involved in mefloguine 
resistance? 
As above, let us consider first that a mutation in another gene (geneA) has been 
produced as result of mefloquine selection. Secondly, we will assume that either gene on 
its own may confer the same level of mefloquine resistance observed in AS (15MF). We 
shall also consider the existence of a third gene (gene E) that is epistatic to either gene A 
and pcmdrl; i.e. gene E has no effect on its own, but increases the level of mefloquine 
resistance when it is present with gene A, pcmdrl , or both. Alternatively, gene E may be 
a mutated promotor or enhancer that increases the expression of both gene A and 
pcmdrl. In contrast to model 3, let us also consider that gene E is closely linked to both 
gene A and pcmdrl. We will also consider that genes A, E and pcmdrl are located on 
chromosome 4/12 in P. chabaudi AS (15MF). However, only the pcmdrl gene lies 
inside the translocated portion of chromosome 12, whereas genes A and E are located in 
the section of chromosome 4/12 that originated from chromosome 4. 
We can now consider the different possibilities on the inheritance of the three genes 
among the progeny clones, and its possible relation to mefloquine resistance (see Figure 
23) 
Whilst similar to model 3, model 4 above may account for the atypical association of 
pcmdrl duplication with mefloquine responses observed among the progeny. If this 
model applies in the present cross, it would then be expected that both genes were 
inherited simultaneously at high frequencies among the mefloquine-resistant progeny 
clones, due to the fact that they are closely linked. However, in fewer cases, there may 
be breakage of linkage due to recombination occuring at a lower frequency. This could 
account for all of the results observed in the mefloquine drug tests of the progeny clones. 
The great majority of the mefloquine-resistant progeny clones carry a duplication of the 
pcmdrl gene, although it is not possible to ascertain whether or not the mutated gene A 
is present in these clones. On the other hand, clone 440/5 may represent a case whereby 
the duplicated pcmdrl was lost due to meiotic recombination and segregation of alleles 
CHAPTER VI - Discussion 	 132 
at each locus during the cross, but gene A was retained, resulting in the mefloquine-
resistant phenotype observed. In addition, this model also accounts for the phenotypes of 
clones P. chabaudi 396/11, 441/11 and 1016/11. 
Duplicated + translocated portion of 
chromosome 12 	 Pcmdrl 
GeneE
....................................................................................  F1 
 
Gene A 
AJ 	I 	 I I 	AS(15MF) I X 	i
(Chromosome 4) 	I (Chromosome 4/12) 
Meiotic Recombination 
Haplotypes = IN 
1 	2* 	3 	4 	5 	6 	7* 8 
S S lowR lowR R R lowR R 
eg AJ 	 eg 396/11 	eg 	eg 440/8 	eg 440/5 eg AS 
441/11 1016/11 (15MF) 
* haplotypes resulting from double crossovers 
Figure 23 - Haplotypes resulting from recombination between pcmdrl, gene A and 
gene E 
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6.1.3.5 How can these models be tested? 
In the last three sections I have considered genetic models to explain the distribution of 
the different mefloquine responses observed among the progeny of the present cross, 
which presuppose the involvement of at least two genes in the determination of 
mefloquine resistance. The possible existence or involvement of such genes or indeed 
others is yet to be determined. 
Future studies to identify these genes should involve genetic linkage analysis and fine 
chromosome mapping on the cloned progeny, which would involve a great number of 
genetic markers. More parasite clones should also be produced, in order to generate a 
sample size which decreases the probability of the atypical association of pcmdrl 
duplication with mefloquine responses being due to a casually biased distribution of 
phenotypes. In particular, other clones like 440/5 and 1016/11 should show inheritance 
of AS markers on chromosome 4 if model 4 is correct, whilst this requirement is not 
needed for model 3. 
Future studies could also involve making genetic crosses between P. chabaudi 440/5 and 
the mefloquine-sensitive parasite AJ, cloning the progeny of these crosses and 
performing genetic linkage analysis to determine the locus involved in the mefloquine-
resistant phenotype of clone 440/5. Particularly, presupposing that the genes responsible 
are located on chromosome 4 (see model 4, section 6.1.3.3), this work could be 
expressly directed towards genetic linkage analysis with chromosome 4-specific probes. 
Therefore, the production of suitable genetic markers for P. chabaudi requires some 
degree of urgency. 
The realisation of a P. chabaudi genome sequencing project would also help greatly not 
only in studies on the genetics of drug resistance, but also in identifying genes involved 
in protective immunity, virulence, mosquito transmission, etc. 
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6.2 quinine resistance 
6.2.1 Selection for quinine resistance - a reflection of quinine's success? 
An attempt was made to select a quinine resistant mutant from the drug sensitive clone 
AS (sens) by successively increasing drug doses with new mouse passages. After 6 
weeks the drug dose was increased from 25 to 100 mg/kg (section 3.5.1), suggesting an 
increase in tolerance of the parasites to the drug. However, when tested for quinine 
resistance, the drug treated lines did not appear to show signs of increased resistance 
(data not shown), and thus selection attempts using this clone were ceased at this stage. 
The initial dose used to treat parasites (25mg/kg) was known to be sub-curative and had 
little or no effect on parasite numbers. The increase in doses tolerated in subsequent 
passages was possibly not a true reflection of increasing resistance, but simply natural 
tolerance of the unselected clone AS (sens). Selection for quinine resistance from P. 
chabaudi AJ has also ultimately proved unsuccessful, as parasites did not show 
increased tolerance after six weeks under drug selective pressure (section 3.5.3). 
Rosario (1976a, 1976b) and Padua (1980), both failed to obtain resistance from AS 
(sens) to chloroquine and mefloquine, respectively. Rosario (1976a) was able to select 
for chloroquine resistance in P. chabaudi only if the starting parasite material was 
already pyrimethamine-resistant, P. chabaudi AS (pyr). The biological reasons for this 
are not understood, and this finding is unexpected in view of the likelihood that both the 
mechanisms of action and the genes determining resistance differ for both drugs. It has 
been shown that malaria parasites may have acquired the ability to develop resistance to 
structurally unrelated compounds, possibly by the selection of genetic traits that favour 
initiation of resistance (Rathod et al., 1997). Interestingly, several reports have been 
produced from field studies on P. falciparum, which describe concomitant resistance 
between chloroquine and pyrimethamine (reviewed in Peters, 1986). However, it is 
possible that the cross-resistance observed between these two drugs in field parasite 
isolates, is a result of the presence of a multi-clonal population in the isolate, in which 
the individual clones are either pyrimethamine or chloroquine-resistant. 
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Selection for high quinine resistance from the clone P. chabaudi AS (15CQ) was also 
attempted (section 3.5.2). These parasites were first treated with a higher dose of 
100mg/kg, since they already showed some degree of quinine resistance. However the 
parasites did not appear to respond well to increases in drug doses over the following 14 
weeks. Therefore, this experiment was ceased. 
It is possible that P. chabaudi is innately sensitive to quinine. In fact, selection for 
quinine resistance in P. chabaudi has never been reported previously, but in another 
rodent malaria model, P. berghei, Jacobs reported that resistance was achieved only after 
7 blood passages under continuous treatment, when 400mg/kg failed to stop parasite 
development (Jacobs, 1965). Similarly, Robinson and colleagues, 1986, claim to have 
selected for P. berghei parasites resistant to a high dose of 600mg/kg by single step 
selection. 
The results from the quinine selection experiments mentioned above show that quinine-
resistant parasites are extremely difficult or impossible to obtain in P. chabaudi. These 
results may reflect the situation observed in natural parasite populations of P. 
falciparum, where it is generally observed that quinine still retains surprisingly high 
levels of efficacy, despite having been in use for more than three centuries. The reasons 
for this are not fully understood, but it is possible that the relative apparent success of 
quinine may be due to a) inherent properties of the drug, b) its mode of action and 
mechanism of resistance, or a c) combination of a and b. 
Quinine is known to possess a short half-life elimination time in humans [approximately 
11 hours in healthy adult individuals (Krishna and White, 1996)]. In contrast to 
chloroquine and mefloquine, quinine is seldom used as a prophylactic agent, mainly due 
to its short elimination half-life and high toxicity. In the majority of cases, quinine is 
used only for the cure of severe malaria, a condition which requires hospitalisation. In 
these cases, very high drug doses are used, which should in theory eliminate even the 
drug resistant fraction of the patient's parasite population. Even assuming that some 
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quinine-resistant parasites may elude drug treatment, it is difficult to conceive that these 
would be transmitted to mosquitoes under hospitalisation. 
An attractive model to explain quinine resistance is that other structurally related drugs 
such as chloroquine or mefloquine act as the selective agent. This is supported by the 
observation that in natural parasite populations of P. falciparum, quinine-resistant 
malaria is normally associated with mefloquine and/or chloroquine resistance (Brasseur 
et al. 1988, 1992; Warsame et al., 1991; Subsaeng et al.; Basco et al., 1995; Knowles et 
al., 1984; Smrkovski et al., 1985; Warsame et al., 1991; Basco and Bras, 1992; Silveira 
et al., 1996). This hypothesis is favoured by the combination of two factors that have 
resulted from my studies 
• the problems faced in attempts for selection of resistance, suggesting that quinine-
resistant parasites are difficult to obtain through quinine pressure alone 
analysis of the results of the drug tests carried out (section 3.3), where it is shown 
that both chloroquine, AS (15CQ), AS (30CQ), and mefloquine resistant parasites, 
(AS 15MF), show signs of increased resistance to quinine when compared to drug 
sensitive clones, AJ, AS (sens), suggesting that quinine resistance may be selected 
through other chemically related drugs other than quinine itself. 
To conclude, it is possible that mutation(s) responsible for quinine resistance are very 
rare, occurring at extremely low rates, as suggested by Meshnick (1997) and/or quinine 
resistance results from a multigenic process, where the accumulation of all the mutations 
required for a resistant phenotype is very slow. 
Alternatively, the gene(s) required for quinine resistance may be selected through 
mefloquine and chloroquine, rather than quinine pressure. The accumulation of these 
mutations may ultimately render the parasites resistant to quinine. Unfortunately, our 
present knowledge of the genes determining quinine resistance does not allow us to 
conclude that one or more of these genes is shared between resistance to the three drugs. 
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It has been proposed that quinine is the selective pressure underlying mefloquine 
resistance (Rubio and Cowman, 1996), since mefloquine resistance has been detected in 
areas where the drug was yet to be introduced (Brasseur et al., 1992a, 1992b). This 
notion appears to be further supported by the fact that P. falcipa rum parasites which 
have been selected for increased mefloquine resistance, have resulted not only in the 
amplification and over-expression of the pfmdrl gene, but also in increased quinine 
resistance. The results of my genetic study do not allow us to conclude that pcmdrl 
amplification is the cause of quinine resistance. Although P. chabaudi mefloquine-
resistant parasites, AS (15MF), that carry a duplication of the pcmdrl gene also show 
increased quinine resistance, this appears to segregate inversely among the progeny 
clones of the AJ x AS (15MF) cross (see DISCUSSION, section 6.2.2). These results are 
discussed in the next section. 
6.2.2 Quinine resistance in the progeny clones of the AJ x AS (15MF) cross 
In the present study it was observed that the chloquine and mefloquine-resistant P. 
chabaudi AS (1 5MF) parasites presented some degree of quinine resistance (section 
3.3), suggesting that selection with these drugs had caused mutations responsible for 
quinine resistance. Consequently, AJ x AS (15MF) progeny were also tested for their 
sensitivity to quinine. The results were perplexing. 
The mefloquine sensitive parent of the cross, AJ, was sensitive to quinine, whereas the 
mefloquine-resistant parent AS (15MF) was quinine-resistant (section 3.3). If 
duplication of pcmdr] was the cause of both mefloquine and quinine resistance in AS 
(1 5MF), the majority of the quinine-resistant progeny clones would be expected to carry 
two copies of the gene. However, an opposite situation occurred, as the results from the 
quinine drug tests showed a strong inverse correlation between quinine resistance and 
the duplication of pcmdrl (section 4.9.2). 
It has been observed in the present cross that AS (15 MF) is very difficult to transmit 
through mosquitoes on its own, whereas AJ was easily transmitted. We do not 
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understand the reason for this observation but it may be related with a fitness-cost of 
drug resistance or it is possible that a gene exists in AJ, which encodes a transmission 
factor that facilitates the transmission of AJ parasites through mosquitoes, which has 
been mutated in AS (15MF) after mefloquine selection. It is possible that the 
incompatibility observed is caused by genes encoding transmission factors. 
The following model is presented in order to explain how most clones from the cross 
show an inverse relationship between quinine resistance and mefloquine resistance. It 
suggests that clones having quinine and mefloquine resistance do not transmit through 
mosquitoes efficiently and that there is an experimental bias against clones having 
sensitivity to both drugs. 
Let us assume that quinine resistance has arisen by mutation at a locus, Q, along with 
mefloquine resistance (duplication of pcmdrl). For simplicity we will consider that gene 
Q is located on chromosome 2. Secondly, let us assume that Q and pcmdrl are closely 
linked to two transmission factors tf 1 and tf2, respectively (see Figure 24) (for simplicity 
I assume that tf2AS is present on chromosome 12, but not in the duplicated portion on 
4/12). These two factors interact in an unspecified way during the transmission process 
between the appearance of oocysts and the production of asexual stages in the mouse 
upon which the mosquito feeds. In AS (15MF) the two allelic forms of these genes, 
tflAS and tf2AS, encode a non- or poorly-functional complex. In contrast, the allelic 
forms in the drug sensitive parent, AJ are tflAJ and tf2AJ and these produce 
transmissable parasites. Similarly the combinations tflAS - tf2AJ and tflAJ - tf2AS are 
assumed to yield transmissible parasites. Therefore after transmission of cross progeny 
sporozoites into new mouse hosts, parasites containing both alleles tflAS and tf2AS will 
be poorly represented or absent. Since these genes are linked to drug resistance genes, 
parasites resistant to both drugs will also be under-represented. Figure 24 shows the 
arrangement of the genes, the alleles present in the parental clones and the possible 
products and their transmissibility and drug responses after meiotic recombination. 
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Of course, progeny clones sensitive to both mefloquine and quinine should be expected 
to be present among the cloned progeny. The under-representation of this phenotype in 
the cross progeny may be due to the fact that much of the cloning was carried out after 
drug treatment, which decreases the probability of drug-sensitive phenotypes amongst 
the progeny clones. Also clones containing AJ markers only were rejected in the 
analysis as AJ parental types. It is possible that some of these may have been 
recombinants. Indeed, one recombinant clone, 453/6, is sensitive to both drugs. 
In summary, the unexpected findings of the quinine drug tests on the progeny clones of 
the AJ x AS (15MF) genetic cross require further analysis. The hypothesis above could 
be tested by cloning after treatment with both mefloquine and quinine. Alternatively, it 
would be of interest to select the quinine resistant clones for mefloquine resistance to 
determine whether the resulting parasites would lose their quinine-resistant phenotype, 
thus explaining the inverse relationship between resistance to each drug. 
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Figure 24 - Haplotypes resulting from recombination between genes Q, pcmdrl, 
tflAJ and tf2AS. (Q - gene Q from As (15MF); Q - AJ allele; pcmdrl - pcmdrl allele from AS 
(15MF); pcmdrl - AJ allele; tflAJ - transmission factor 1 from AJ; tflAS - AS (15MF allele; tf2AS - 
transmission factor 2 from AS (15MF); tf2AJ - AJ allele); 2 - chromosome 2; 12 - chromosome 12; for 
simplicity, this model ignores the chromosome 4/12 duplication) 
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6.3 Chioroguine resistance 
6.3.1 Chioropuine resistance in the A.! x AS (15MF) progeny 
The chloroquine resistance patterns of the progeny clones were assessed (section 4.10). 
The chloroquine responses of the cloned progeny were determined and compared with 
that of the sensitive and resistant parents of the cross, AJ and AS (15MF) respectively, 
which allowed to establish the degree of chloroquine sensitivity for each progeny clone. 
AS (15 MF) was selected from the intermediate chioroquine-resistant parasites AS 
(15CQ) (section 1.8.1). The fact that AS (15MF) retained the chloroquine-resistant 
phenotype indicates that the genetic mutation(s) accounting for chioroquine resistance 
had not been lost after mefloquine selection. 
Three levels of chloroquine-sensitivity were detected among the progeny clones (section 
4.10): sensitive (9 clones), very low resistance (4 clones) and low resistance (4 clones). 
None of the progeny clones was resistant to chloroquine at the same level as the parent 
AS (15MF). There are several possible reasons for this: 
. there may be a selective disadvantage resulting from the fitness-cost of higher levels 
of chloroquine resistance. There is no evidence to suggest that drug-sensitive clones 
of Plasmodium have a survival or growth advantage over low chioroquine- resistant 
ones, either in the mosquitoes or vertebrate hosts. In fact, low chloroquine-resistant 
P. chabaudi parasites have shown to possess a growth advantage over sensitive ones 
(Rosario, 1976a, 1976b). However, recent experiments have shown that the 
intermediate chloroquine-resistant parasites, AS (15CQ) may present a growth 
disadvantage over sensitive ones indicating that there maybe a fitness-cost when 
higher levels of resistance are present (Cravo et al., in prep.) 
. the absence of intermediate chloroquine resistance phenotypes among the cloned 
progeny may be due to the fact that this level of resistance requires several mutations 
at different loci, which are likely to segregate independently during meiotic 
recombination 
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• the progeny had not been selected with chloroquine prior to cloning. Therefore, 
future studies should involve treating the progeny with chloroquine and cloning 
subsequently, to check if clones are produced which present high chioroquine 
resistance. 
The fact that different levels of chloroquine-sensitivity were detected among the progeny 
clones suggests that chloroquine resistance in these parasites arose as the result of a 
multigenic event with at least two genes operating at different levels of resistance. 
Results from a previous P. chabaudi genetic cross between AJ and the chloroquine-
resistant parasite AS (3CQ) have shown two levels of resistance among the progeny-
low resistant and resistant (Canton et al., 1998). Carlton classified AS (3CQ) as 
chloroquine-resistant, as this was the resistant parent of the cross. In the case of the 
present study however, progeny clones displaying a chloroquine response similar to that 
of AS (3CQ), are classified as low chioroquine-resistant due to the relative difference in 
the chloroquine responses of the parents of both crosses (section 3.2). It is probable 
therefore that progeny clones exhibiting very low level of chloroquine resistance in the 
present study, correspond to those classified as low chioroquine-resistant in the work of 
Carlton and colleagues (Carlton et al., 1998). It was suggested that the levels of 
chloroquine resistance observed in AS (3CQ) were due to an additive effect of mutant 
genes at two loci, each conferring a low level of resistance (Canton et al., 1998). The 
clones exhibiting a low level of chloroquine resistance were suggested to contain only 
one gene due to meiotic recombination and segregation of alleles during the cross 
(Carlton et al., 1998). A similar phenomenon may also be occuring in the present cross, 
since the two levels of chloroquine resistance observed among the progeny, appear to be 
the same as those presented for the AJ x AS (3CQ) cross. 
A multi-locus genetic trait for chioroquine resistance has also been demonstrated before 
in high chloroquine-resistant parasites. Analysis of a cross between P. chabaudi AJ and 
AS (30CQ) showed that the high level of chlororoquine resistance in AS (30CQ) was 
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almost certainly due to several mutations at different loci, since both low and 
intermediate levels of resistance were found among the progeny clones (Padua, 1980). 
Finally, strong linkage was found between a chromosome li -specific probe, PCNA, and 
the low level of chioroquine resistance among the AJ x AS (15MF) progeny clones 
(section 4.12.3.2), confirming previous results obtained by Carlton and colleagues 
(Carlton et al., 1998). Consequently, my studies provide more evidence to support the 
hypothesis that a genetic locus on this chromosome is involved in chloroquine resistance 
in P. chabaudi. 
6.3.2 Are mutations in the pcmdrl gene involved in chloroguine resistance? 
Several alleles of pfmdrl encoding an aminoacid substitution at position 86 (Asn-86-
Tyr) have been suggested to confer the chloroquine-resistant phenotype displayed by the 
South-east Asian isolate P. falciparum K1 (Foote et al., 1990). In the same study, the P. 
falciparum 7G8 South-american chloroquine-resistant isolate, was characterised by four 
amino-acid substitutions: Tyr 1 84-Phe 184 , Ser 1 °34-Cys1 034,  Asn 1 °42-Asp1042 and 
Asp 1246-Tyr 1246 (Foote et al., 1990). Similarly, genetic transfection studies, have 
shown that some of these mutations may play a role in modulating the level of 
chloroquine-sensitivity in P. falciparum (Reed et al., 2000). However, exceptions have 
also been reported (Wellems et al., 1990), suggesting that other genetic mechanisms 
determine chloroquine sensitivity. In the P. chabaudi AJ x AS (3CQ) genetic cross, no 
association was found between the inheritance of chloroquine resistance and pcmdrl 
indicating that the pcmdrl gene was not the cause of resistance in the low chloroquine-
resistant parasites AS (3 CQ) (Carlton etal., 1998). 
In the present work, the pcmdrl nucleotide gene sequence was obtained from both 
chloroquine-sensitive ,AJ and AS (sens), and chloroquine-resistant parasites, AS (3CQ), 
AS (15CQ), AS (30CQ) and AS (15MF). The comparison between the different pcmdrl 
sequences has shown no nucleotide differences, indicating that chloroquine selection has 
not resulted in mutations in the gene (section 5.3.2). 
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6.4 Other results 
6.4.1 Pcmdrl sequence analysis - general considerations 
The pcmdrl and the pfindrl genes were compared both at the nucleotide and aminoacid 
level: A high degree of conservation was observed between the two genes - 75.2% and 
70.7% at the nucleotide and amino acid levels, respectively. In addition, protein 
structure predictions indicated that the pcmdrl encodes a membrane peptide that is 
structurally very similar to the P. falciparum P-glycoprotein homologue- 1 (Pgh 1) (data 
not shown). The ATP- binding sites of the pcmdrl-encoded peptide were compared to 
those of its P. falciparum homologue, pfindrl ( section ), as well as to other eukaryotic 
species (data not shown). Once more, a high degree of identity was observed, suggesting 
a conservation of function involving the active transport of substances across a 
membrane, which depends on energy being derived from nucleotide binding and 
hydrolysis. These observations support the notion that the pcmdrl may have the capacity 
of regulating the degree of accumulation of antimalarial drugs in the food vacuole by 
acting as a direct transporter of the drugs, or by behaving as a proton pump which is 
capable of modulating the pH in the food vacuole. 
Genetic transfection studies, crossing work, and field studies have shown that mutations 
in the pfmdrl may play a role in modulating the level of chloroquine, quinine or 
mefloquine responses in P. falciparum (see CHAPTER I, section 1.6.3). However, in the 
present work it was shown that no mutations had occurred in the pcmdrl gene after 
selection with chloroquine and mefloquine, indicating that these are not required for the 
resistance phenotypes observed in P. chabaudi. 
6.4.2 Relationships between chioroquine and meflopuine resistance 
There is evidence from P. falciparum studies that appears to indicate that the pfindrl-
encoded peptide, Pgh- 1, may play a role in chloroquine import, possibly by modulating 
the pH in the parasite's food vacuole (reviewed in section 1.6.3.1.3). 
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The transfection of Chinese Hamster Ovary (CHO) with wild-type pfmdrl, has resulted 
in cells expressing Pghl that exhibited increased sensitivity to chioroquine due to an 
increased drug uptake (Van Es et al., 1994a). In addition, the transfection of mutants of 
pJ'indrl into S. cerevisiae, resulted in increased sensitivity to chloroquine (Ruetz et al., 
1996), suggesting that Pgh-1 may play an important role in chloroquine-import in 
sensitive organisms. This is consistent with results obtained by in vitro selection for 
chioroquine resistance in P. falciparum, which resulted in de-amplification and reduced 
expression of the pfmdrl gene (Barnes et al., 1992). Conversely, in vitro selection for 
mefloquine, quinine and halofantrine resistance, which resulted in an increase in copy 
numbers and over-expression of pfmdrl, was associated with an increase in 
susceptibility to chioroquine (Cowman etal., 1994; Peel et al., 1994). 
These results may be indicative that increased expression of the pf,ndrl gene may result 
in greater accumulation of chloroquine. If this were the case, mefloquine resistance 
conferred through amplification and over-expression of pfmdrl would always be 
incompatible with chioroquine resistance. However, a similar phenomenon does not 
appear to occur in P. chabaudi. My work has shown that the P. chabaudi mefloquine-
resistant parasites, AS (1 5MF), which have been selected from the chloroquine-resistant 
parasites AS (1 5CQ), still retain the chloroquine resistance phenotype, even though the 
pcmdrl gene has been duplicated. Therefore, in this case, cross-resistance exists 
between chloroquine and mefloquine-resistant parasites, which is probably due to an 
accumulation of independent genetic mutations responsible for resistance to both drugs. 
This may signify that if the pfmdrl plays a role in chloroquine import into the food 
vacuole by being over-expressed, this is not a consistent phenomenon across all species 
of Plasmodium. These are difficult results to interpret, considering the high degree of 
conservation at the peptide level between the mdrl genes of both P. chabaudi and P. 
falciparum, suggesting a conservation of function. It may be possible that chloroquine 
has alternative sites of action in P. chabaudi, which do not involve chioroquine entering 
the food vacuole. In P. falciparum, it has been shown that a large proportion of the 
unpolymerised haem exits the food vacuole to be degraded by glutathione (see section 
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1.8.2.1). Perhaps the pcmdrl -encoded proton pump is highly efficient in exporting 
mefloquine from the food vacuole of P. chabaudi parasites, but much less efficient in 
importing chloroquine due to unknown reasons. If this were the case, it is feasible that 
the main way of chloroquine action in P. chabaudi is the inhibition of haem 
polymerisation in the parasite's cytosol rather than the food vacuole. In this case, the 
amplification of the pcmdrl gene would not be expected to result in increased 
chioroquine sensitivity. 
Alternatively, it is possible that a relationship exists in P. falciparum between the 
amplification of the pfindrl gene and the gene involved in chloroquine resistance, 
whereby one gene exerts negative regulation upon the other. However, this relationship 
may not apply in P. chabaudi due to the fact that the gene(s) determining chloroquine 
resistance may differ to those of P. falciparum. 
6.4.3 Why is P. chabaudi AS (15MF) difficult to transmit through mosciuitoes? 
In the current work, the mefloquine-resistant parent of the cross, AS (1 5MF) could not 
be transmitted through mosquitoes on its own and no clones of AS (15MF) genotypes 
were present among the progeny of the cross. 
It was observed that AS (15MF) parasites produced oocysts, indicating that fertilisation 
had occurred. However, no infections developed in mice after mosquito feeds, 
suggesting one of two possibilities. Firstly, it is possible that AS (15MF) oocysts had 
lost the capacity of producing sporozoites. Secondly, it is feasible that sporozoites are 
produced, but these are unviable and do not have the capacity to invade the salivary 
glands. Unfortunately, oocyst-infected mosquitoes were not analysed for the presence of 
sporozoites in the glands in this work. Thirdly, it is possible that sporozoites are injected 
into the bloodstream but lack a molecule that facilitates invasion of hepatocytes. 
Alternatively, it is possible that the genes determining drug resistance are closely linked 
to those involved in poor transmission through mosquitoes, although there is no 
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experimental evidence for this (see section 6.2.2). In contrast to P. chabaudi AS 
(1 5MF), AJ parasites were easily transmitted and seven progeny clones were obtained 
which were of the AJ parental type for the markers examined, most likely originating 
from selfing in mosquitoes. 
6.4.4 Number of unique progeny clones among the A.! x AS (15MF) progeny 
Sixty-one progeny clones were produced, and RFLP analysis on these clones allowed 
identification of 16 unique recombinant groups. The number of unique progeny classes 
appears to be relatively low, compared to the total number of clones. This is probably 
due to repeated sampling from a limited pool of clones during the cloning procedure 
and/or to preferential selection of particular recombinants after the cross in the mouse 
into which recombinant sporozoites were injected. Indeed, it has been suggested that 
clone-specific selection in the vertebrate host may have occurred in two P. falciparum 
crosses (Ranford-Cartwright et al, 1993). In another P. chabaudi genetic cross, a 
relatively similar proportion of recombinant clones was obtained; Carlton and 
colleagues, observed that out of a total 59 clones produced from the AJ x AS (3CQ) 
cross, only 20 proved to be independent recombinants (Carlton et al., 1998). 
6.5 Concluding remarks 
Our studies have shown that a P. chabaudi mefloquine resistant parasite, AS (1 5MF), 
which has been derived from a mefloquine-sensitive parasite AS (I5CQ), carries a 
duplication of the pcmdrl gene. Similar results have been obtained in P. falciparum, 
indicating that P. chabaudi is a good model for studies of drug resistance in malaria 
parasites. 
The analysis of a cross between the drug sensitive parasite P. chabaudi AJ and the 
mefloquine, chloroquine and quinine-resistant parasite AS (15MF), has shown complex 
relationships between resistance to these drugs. In addition, it was suggested that these 
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types of resistance are likely to be the result of intricate multi-genic events, which do not 
depend on the pcmdrl gene alone. The specific genes involved have not been identified 
in the present study, but future studies should involve linkage analysis and fine 
chromosome mapping, which should allow to locate and determine the role of such 
genes 
There is an urgent need for the production of suitable genetic markers for P. chabaudi, 
which will greatly enrich studies of the genetics of drug resistance, such as the present 
work. The realisation of a P. chabaudi genome project would be very useful in the 
identification and production of such markers. 
A question may arise with genuine foundations, which is: is it really worthwhile 
searching for genes implicated in mefloquine and chloroquine resistance in P. chabaudi 
when it appears that the pfcrt gene is a major factor in chioroquine resistance in P. 
falciparum and that pf,ndrl seems to be highly involved in mefloquine resistance? 
The answer is yes. Studies such as mine confirm the complexity of the genetic basis of 
drug resistance. Thus, even though it has been shown that pfcrt and pfmdrl may be 
heavily involved in drug resistance, there are ambiguities which are yet to be clarified. 
By way of illustration, the fact that several different levels of chioroquine or mefloquine 
responses are observed in natural parasite populations of P. falciparum, suggests that 
these phenomena are the result of multi-genic events. Rodent malaria models such as P. 
chabaudi, may help to identify other which influence levels of drug resistance and which 
may have homologues in P. falciparum involved in drug-resistance. 
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Strategies will hopefully be planned in the near or long future, which will allow us to 
circumvent the problems of drug resistance caused by genes such as pfcrt. However, the 
Plasmodium parasite is highly capable of activating other mechanisms if the external 
environment thus requires. The parasites will probably adapt rapidly to changes induced 
by the pressure of new drugs or structural changes in the drugs used at present. This has 
happened in the past. The identification of new genes involved in drug-resistance in P. 
chabaudi may help predict if their homologues will be selected for in P. falciparum in 
the future. Studies in P. chabaudi in the past have helped to uncover genes involved both 
in pyrimethamine and chioroquine resistance. 
Studies such as those described here may clarify the complex relationships between 
resistance to different drugs and the genes involved. This will deepen our understanding 
of drug resistance mechanisms, improve the identification of the parasites drug response, 
allow better use of antimalarial drugs and improve drug implementation policies. 
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APPENDIX I 
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APPENDIX II 
SOLUTIONS, BUFFERS AND MEDIA 
Citrate saline 0.9%(w/v) NaCI, 1 .5%(w/v) Na citrate 
Deep-freeze solution 	28%(v/v) glycerol, 3.0%(v/v) sorbitol, 0.65%(v/v) NaC1- 
sterilise by filtration. 
Mammalian ringer solution 27mM KC1, 27mM CaC1 21  0.1 5M NaCl 
PFG lysis solution 0.5M EDTA, 0.OlM Tris pH 9.5, l%(w/v) sarcosyl 
TBE buffer 0.09M Tris base, 0.09M boric acid, 0.002M EDTA 
TE buffer (TrIsIEDTA) 10mM Tris-HCI, 1mM EDTA 
DEPC treated water per litre: 0.1% DEPC in dH2O; stir overnight in fume hood; 
autoclave 
RNA sample buffer per 15.5 ml: lOmI deionised formamide: 3.5m1 37% 
Formaldehyde; 2m1 5xMOPS buffer. Divide into 0.5m1 aliquots and store at -20°C. 
RNA loading buffer 50% glycerol; 1mM EDTA; 0.4% bromophenol blue. Prepare in 
nuclease free water. Divide into 0.5m1 aliquots and store at -20°C. 
SSC (saline-sodium citrate) 3M NaCI, 0.3M sodium citrate 
Northern hybridisation solution 	per 20m1: lOmi deionised formamide; 5m1 
20xSSPE: ImI lOOx Denhardts reagent; 0.5m] 20%SDS; 3.5m1 DEPC treated sterile 
dH2O 
Heparinised PBS 13.7 mM NaCI, 2.7mM KC1, 4.3mM Na2HPO4 pH8.8, 1.4mM 
KH 7PO4 
DNA lysis solution 10mM Tris, 50mM EDTA, 0.1% SDS 
LB medium per litre: lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl- pH 
adjusted to 7.5 with NaOH 
LB - agar plates per litre: lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl- pH; 
1.5% agar. Adjusted to 7.5 with NaOH. Autoclave, allow to cool to 65°C and pour into 
Petri dishes. 
Southern hybridisation solution (for 1 litre) bOg Dextran sulphate, 100ml 10% SDS, 
589 NaCl, 846m1 dH2O; autoclave, divide into 20m1 aliquots and store at -20°C. 
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APPENDIX III 
COMMUNICATIONS AND PUBLICATIONS ARISING FROM THIS STUDY 
Communications 
Unravelling the mechanism of mefloquine resistance in Plasmodium. 
Jane Canton, Pedro Cravo and David Walliker 
8th Malaria meeting of the British Society for Parasitology, Glasgow, September 1996. 
The genetics of resistance to quinoline-containing antimalarials in Plasmodium 
chabaudi 
Pedro Cravo, Paul Hunt, Jane Canton and David Walliker 
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